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Abbreviations
AML Acute Myeloid Leukemia
ASO Allele Specific Oligonucleotide
BCRM B cells Clonally Related to the Malignant plasma cells
BM Bone Marrow
Bp Basepair
CDK Cyclin Dependent Kinase
CDR Complementarity Determining Region
CE Capillary Electrophoresis
CML Chronic Myeloid Leukemia
CSF Colony Stimulating Factor
Ct Threshold cycle
DGGE Denaturing Gradient Gel Electrophoresis
DNA Deoxyribonucleicacid
EBV Epstein Barr Virus
ELISA Enzyme Linked Immuno Sorbent Assay
EMBL European Molecular Biology Laboratory
FACS Fluorescence Activated Cell Sorting
FCM Flow Cytometry
FCS Fetal Calf Serum
FISH Fluorescent In Situ Hybridization
FITC FluoroesceinIsoThioCyanate
FR Framework Region
Id Immunoglobulin Idiotype
IgH Immunoglobulin Heavy Chain
IgL Immunoglobulin Light Chain
IMAC Immobilized Metal Affinity Chromatography
Kb Kilobase
KSHV Kaposi's Sarcoma associated Herpes Virus
MGG May-Grunwald-Giemsa
MGUS Monoclonal Gammopathy of Unknown Significance
MM Multiple Myeloma
mRNA messenger-RNA
NGSB Non-Gel Sieving Buffer
NHL Non-Hodgkin Lymphoma
NWBC Normal White Blood Cells
OD Optical Density
PAGE Polyacrylamide Gel Electrophoresis
PB Peripheral Blood
PBCA Peripheral Blood Cell Autografts
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PE Phycoerythrin
Rb Retinoblastoma susceptibility gene
scFV single chain Fv molecule
SSCP Single Stranded Conformation Polymorphism
T-ALL T cell Acute Lymphoblastic Leukemia
TBI Total Body Irradiation
UV Ultraviolet
VAD Vincristine-Adriamycin-Doxorubicin
VSV Viral Stomatitis Virus
wt wild-type
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Chapter
Multistep Ontogeny of Multiple Myeloma
'During a vacation M r McBean had vaulted out o f an underground cavern and 
instantly fe lt as i f  something had snapped or given way within the chest.' He was 
treated by the removal o f a pint o f blood and, subsequently, the application o f
leeches.
Dr William MacIntyre
from: Macintyre W.
Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter (1850).
Medical Chirurgical Transactions London 33: 211-232.
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1.1 Cancer is caused by oncogenic hits (reviewed in M ille r '80; Vogelstein '93)
Cancer is the second largest cause of death in western countries. A deregulated behaviour of the 
cancerous or malignant cells is responsible for tissue infiltration, the loss of organ function and finally 
the loss of organism integrity that is found in cancer. Distinct oncogenic events (e.g. mutations in 
essential genes or viral infections interfering with the normal function of essential proteins) are the 
driving force behind the changes in cellular behaviour and 3 to 7 of those events appear to be required 
to complete the transformation process. Cancer arises from the clonal outgrowth of a single cellular 
progenitor cell transformed by oncogenic events. Each event results in more clonal outgrowth and a 
higher risk of attaining additional mutations for the progenitor cell or its progeny. Most cancers occur 
in elderly. This may be explained by the time it takes to accumulate the mutations necessary for 
transformation. The decrease in immune regulation in elderly is an important factor in the development 
of cancer as well. Multiple myeloma is a cancer arising from a transformed hematopoietic cell and is 
particularly associated with old age.
1.2 M ultip le myeloma
The term 'multiple myeloma' was introduced by von Rustizky in 1873. During an autopsy he 
found eight separate tumors of the bone marrow (myelum), which he called myeloma's. In 1895 
Marschalko defined the essential characteristics of plasma cell morphology including the blocked 
chromatin, eccentric position of the nucleus, perinuclear opal area (hof) and the spherical or irregular 
cytoplasm. Five years later Wright described a 54 year old man with multiple myeloma and pointed 
out that the tumors consisted of such plasma cells. Nowadays the presence of malignant plasma cells 
in the bone marrow is an essential characteristic for the diagnosis of multiple myeloma. In most cases 
(~99%) these plasma cells secrete a monoclonal immunoglobulin and/or its constituent polypeptide 
subunits (heavy and light chains). This socalled paraprotein or M-component is generally detected in 
the serum (paraproteinaemie) and/or urine (Bence-Jones proteine) of patients (Kyle '75).
1.3 C lin ical phases in the ontogeny o f  multiple myeloma
The finding of an M-component in serum or urine (monoclonal gammopathy) is one of the first 
indications that a clonal expansion of B-lymphocytes or plasma cells is present. Serum M-components 
are found in ~1% of persons over age 25 (Cohen '66), ~3% of persons over age 70 (Haller '63; Kyle
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'89) and ~10% over age 80 (Crawford '87). Occasionally individuals with monoclonal gammopathies 
suffer from tissue damage (e.g. neuropathies) or organ dysfunction due to deposition of the M-protein 
(Ropper '98). For these individuals melphalan / prednisone or even autologous stem cell 
transplantation is frequently used to resolve symptoms (Ropper '98). Most individuals with 
monoclonal gammopathy however have no clinical symptoms. Longterm studies have shown that 
only 22-36% of apparently healthy individuals with monoclonal gammopathies subsequently 
developed plasma cell dyscrasias, hence the term monoclonal gammopathy of unknown significance 
(Bernett '86; Kyle '89). There is no evidence that persons with asymptomatic monoclonal 
gammopathy of unknown significance (MGUS) benefit from treatment. Since acute leukemia has been 
noted in 10 to 20% of long term surviving myeloma patients treated with chemotherapy, such therapy 
should be withheld until a symptomatic stage of multiple myeloma develops (Pankovich '72, 
Bergsagel '79, Cyzich '87, Ueki '91). For individuals with MGUS who progress towards plasma cell 
dyscrasias it may take many years. The median time between the diagnosis of MGUS and the 
development of myeloma was 9.6 years (Kyle '89). Inactive or smouldering myeloma may be 
diagnosed when patients show M-components and more than 10% plasma cells in bone marrow 
samples but no clinical symptoms related to myeloma and no more than three lytic bone lesions 
(Alexanian '80; Kyle '80). About 2% of patients with an asymptomatic M-component progress to 
develop neoplasms (mostly myeloma) each year.
The annual incidence of active myeloma is approximately 0.003% (Martin '61; Kyle '69; Hansen 
'89). The active phase can be distinguished from asymptomatic stages by a gradual rise in serum or 
urinary M-protein. Increased medullary proliferation of plasma cells results in painful osteolytic bone 
lesions, hypercalcemia and anemia (Kyle '75). Hypercalcemia and light chain deposition in turn may 
cause renal failure (Schubert '72; Durie '75). Once active disease has been diagnosed the median 
survival time is 17 months without treatment (Osgood '60). Local radiotherapy may be applied for 
painful bone lesions, with a risk of spinal cord compression, complex bone fractures or impaired 
function of vital organs (Holder '65; Heinrich '90), but systemic chemotherapy is the treatment of 
choice (Alexanian '80). Currently standard treatment of active myeloma is intermittent chemotherapy 
with combinations of alkylating agents (melphalan or cyclophosphamide) and prednisone (George 
'72; Costa '73; Alexanian '80). These kinds of regimens have good response rates (over 70%) and 
result in a median survival time of 30 months (Alexanian '80). At present there is no evidence that 
maintenance therapy is of any benefit to patients in remission. Relapses can be treated with the same 
chemotherapy regimens unless the disease no longer responds to repeated courses (Paccagnella '91). 
The introduction of high dose alkylating agents and total body irradiation combined with autologous 
stem cell transplantation induces complete remissions and prolongs survival (Barlogie '87; Gore '89;
9
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Jagannath '90). Since survival rates are good and the transplant related mortality is under 10% 
intensive therapy combined with autologous stem cell transplantation is frequently used for patients up 
to 70 years of age (Barlogie '91). Unfortunately the relapse rate is high with autologous 
transplantation (Attal '96; '97). Since these relapses may result from residual tumor cells in the graft 
(Gribben '91; Brenner '93; Deisseroth '94) attempts to purify the grafts may be important. To cure 
myeloma patients allogeneic bone marrow transplantation is the treatment of choice. Although 
transplant related mortality is high (30-40% within one year posttransplant), recent studies found an 
actual survival rate of 40% at 76 months (Gahrton '91). In addition infusions of donor lymphocytes 
can be effective in the treatment of myeloma relapses after allogeneic transplantations (Alyea '98). The 
graft versus myeloma reaction of the donor T-lymphocytes is held responsible for the eradication of 
the tumor clone.
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Figure 1: Disease stages in multiple myeloma as a result o f  accumulating oncogenic hits.
The acute or fulminant phase is marked by an increase in the growth rate of malignant plasma cells. 
Patients may develop pancytopenia due to extensive bone marrow infiltration and infections and fever 
are frequently encountered (Bergsagel '75). During the acute phase myeloma cells acquire the ability
10
Chapter four: A  Protocol to Quantitate M yeloma Cells in a Multicentre Study
to grow in cell culture (Takahashi '85) and may form extramedullary plasmacytoma's or invade the 
peripheral blood resulting in plasma cell leukemia. Aggressive treatment of these patients is difficult 
because of the pancytopenia and the presence of therapy resistant cells. Median survival is only 3 
months (Bergsagel '75).
1.4 Accumulation o f  oncogenic hits drives the progression o f  multiple myeloma
Clinical observations suggest that multiple myeloma starts as a benign clonal expansion of plasma 
cells (MGUS) that progresses towards an inactive phase where non-proliferating mature malignant 
plasma cells accumulate in the marrow. Serious clinical symptoms emerge in the active phase. Finally 
most patients enter a fulminant phase with many plasma cells and the frequent occurrence of 
extramedullary proliferation of these cells. The gradual evolution of plasma cell myeloma resembles 
the multistep progression of colon tumors. With colon tumors individual genetic mutations are 
associated with specific (morphologically discernible) disease stages (Fearon '90), suggesting that 
these mutations are the cause of tumor progression. For multiple myeloma several genetic mutations 
have also been associated with specific disease stages (Neri '89; Portier '92; Tanaka '92; Corradini 
'93). We hypothesize that the progression of multiple myeloma is driven by distinct oncogenic hits as 
is the case for colon tumors.
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Chapter
The Quest for Malignant Cells
'when boiled it becomes highly opake; on the addition o f nitric acid it effervesces, 
assumes a reddish hue, becomes quite clear, but, as it cools, assumes the consistence
and appearance which you see: heat reliquifies it. What is it?'
Dr William MacIntyre
from: Bence Jones H. Chemical pathology (1847). Lancet 2: 88-92.
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2.1 Defining malignant cells
Historically malignant cells are defined on the basis of morphology. Myeloma tumor cells 
morphologically resemble plasma cells or plasmablasts (Wright '00). The myeloma plasma cells are 
usually in close contact with bone marrow stromal cells. They normally secrete large amounts of 
immunoglobulins that are characteristic of cells that have undergone antigenic selection (Bakkus '92; 
Takeshita '94; Vescio '95; Sahota '96). The bulk of malignant myeloma cells therefore resemble long- 
lived plasma cells.
Figure 1: Ontogeny o f  multiple myeloma. The c ritica l h it discriminates between malignant cells and 
pre-malignant ancestors.
Malignant cells are clinically defined as all those cells directly responsible for disease. This 
criterium is probably met by several cell populations, differing in the number of oncogenic hits. Pre- 
malignant cells have acquired oncogenic hits as well but are nonetheless not directly responsible for 
disease. The essential or critical oncogenic hits transform these pre-malignant cells into fully 
transformed cells causing disease and are the only tumormarkers that are shared by all malignant cells 
(figure 1,2). Although many different oncogenic hits have been detected in myeloma, the critical hits 
have not yet been identified. Consequently suitable tumormarkers that define all malignant 
subpopulations in multiple myeloma are currently not available.
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2.2 Normal B-cell differentiation and the plasma cell
2.2.1 B-lymphocyte function
Lymphocytes are the primary directors of antigen-specific immune responses. They have the 
capacity to recognize and react with foreign or self molecules (antigens). B cells are defined as 
lymphocytes that bear membrane immunoglobulins. Immunoglobulins are composed of heavy and 
light chains and function as antigen sensitive receptors (Kunkel '63). B cell clones differ in their 
immunoglobulin structure and antigen specificity and the total B cell pool in an individual has the 
capacity to recognize a vast array of different antigens.
2.2.2 The immunoglobulin gene structure changes during B-cell differentiation
Most of the diversity between different immunoglobulins is concentrated in the variable part of the 
immunoglobulin. Three distinct gene segments: the variable V h , diversity D and joining Jh  encode the 
variable region of the heavy chain. An additional segment encodes the constant region (figure 2). Only 
two segments: the variable V k or VX and joining Jk or JX regions encode the variable region of the 
light chains. The fusion of these gene segments in pre-B cell stadia is highly diverse and is called 
immunoglobulin gene rearrangement (Early '80; Reth '86). In mice precursors of B cells are clearly 
demonstrated in bone marrow progenitors (Cumano '92). In these precursors all immunoglobulin loci 
are in germline conformation (figure 2) and the cells are not capable of forming immunoglobulin 
proteins (Melchers '94). In human pre B1 cells transcription of the immunoglobulin heavy chain locus 
on human chromosome 14q32 is activated and one of 25 functional D segments (Tomlinson '96) is 
fused to one of 6 Jh  segments (Ravetch '81; Rolink '91; '93b; Alt '92). Human pre B2 cells have 
undergone the V h  to D -Jh  fusion where one of 51 functional V h  segments (Tomlinson '92) is fused to 
the D -J h  product (Tonegawa '83; Alt '87; Decker '91). The fusions are mediated by recombinase 
proteins as RAG-1 and RAG-2 (Alt '92; Schatz '92) recognizing conserved heptamer-spacer-nonamer 
recombination recognition sequences flanking all functional V gene segments (Yancopoulos '86). The 
V h -D -J h  rearrangements (figure 2) are transcribed and spliced to the constant region segment ^  
(Seidman '78; Tonegawa '83) enabling the majority of pre B2 cells to produce cytoplasmic ^  heavy 
chain. After successful heavy chain gene rearrangement cytoplasmic ^  chain attaches to the 
endoplasmic reticulum in association with the immunoglobulin binding protein BiP (Haas '83). 
Binding of ^  chain to surrogate light chain proteins encoded by the Vpre-b and X5/14.1 genes allows 
translocation of this complex to the cell surface (Pillai '88; Rolink '91b; Bossy '91; Lassoued '93; 
Melchers '93), where it forms a functional B-cell antigen receptor complex in association with the Iga 
and IgP signalling molecules (van Noesel '93). Signalling of the B cell antigen receptor complex is 
necessary for further B cell maturation. Mice with defects in RAG-1 (Mombaerts '92) and RAG-2
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(Shinkai '92), mice with disrupted ^  heavy chain (Kitamura '91), mice with a disabled X5 gene 
(Rolink '93 a) and mice with signalling defect in the Iga and IgP proteins (Sanchez '93) all fail to 
develop significant amounts of mature peripheral B cells. Successful heavy chain rearrangement and 
signalling promotes the assembly of Ig light chains (Schatz '92). Light chain assembly in humans 
starts with transcriptional activation of the k  light chain locus on chromosome 2. One of 40 functional 
V k gene segment is then fused to one of 5 joining Jk gene segments (Lorenz '87; Tomlinson '92). If 
the k  light chain rearrangement is unsuccessful on both alleles, transcription of the X light chain locus 
on chromosome 22 is activated and one of 30 functional VX gene segment will recombine with one of 
4 joining JX segments (Tomlinson '92). Rearrangement stops when the B cells lose their recombinase 
activity in the bone marrow. B cells at this stage expressing membrane IgM are called virgin B cells. 
Short lived plasma cells that survive up to 3 days can develop from these virgin B cells upon 
triggering by antigen. Most of them secrete IgM, although switching to IgG, IgA, IgD and IgE 
isotypes sporadically occurs.
Most virgin B cells migrate from the bone marrow to secondary lymphoid organs. In these organs 
they become activated in T cell rich zones (e.g. the periarteriolar lymphatic sheath in the white pulp of 
the spleen). Some of the activated B cells, the socalled germinal center founder cells are capable of 
forming special textures in the lymphoid follicles called germinal centres. The germinal center founder 
cells downregulate their immunoglobulin receptors and undergo a phase of massive clonal expansion. 
These rapidly dividing cells are called centroblasts and they form the germinal center 'dark zone'. 
Under the influence of T-helper cells (Haire '93) the clonal progeny of these antigen-stimulated 
centroblasts are effected by a mechanism that causes somatic mutations (nucleotide substitutions) in 
the rearranged immunoglobulin genes (Rajewsky '87; Berek '87; Shlomchik '87; Kocks '88; Sharon 
'89). The mutations occur only in the coding region of the immunoglobulin genes (Kocks '88). 
Somatic hypermutation is active during a short period of lymphoid development and causes B cells to 
diverge in their affinities for different antigens (Shlomchik '87; Kocks '88; Sharon '89). Centroblasts 
at this stage migrate to the apical region or 'light zone' of the germinal center and differentiate into 
centrocytes that have upregulated their immunoglobulin receptors. The centrocytes are in constant 
interaction with follicular dendritic cells (FDC) and T-cells that present antigen. Centrocytes that have 
acquired immunoglobulin mutations resulting in an increased affinity for antigen survive. Centrocytes 
that cannot bind antigen (due to immunoglobulin mutations) die by apoptosis explaining the massive 
apoptotic figures seen in apical light zones. This process of selecting B cells with high affinity for 
antigen is called affinity maturation (Shlomchik '87; Kocks '88; Sharon '89). Surviving cells can 
undergo a switch of IgM or IgD to IgG, IgA or IgE isotypes. A recombination of switch sequences in 
the IgH locus, juxtaposing Cy, Ca or Ce near V-D-J sequences explains the change in Ig isotype
16
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produced (figure 2). Post-switch cells can either differentiate into memory B cells or antibody forming 
plasma cells. Upon triggering by antigen memory B cells or B cells subjected to antigenic selection 
can differentiate into plasmablasts. Plasmablasts migrate to the bone marrow, where they interact with 
stromal cells to differentiate into long-lived plasma cells, the effectors of the antigen-specific immune 
response, that can survive for several months.
2.2.3 B-lymphocytes selected by antigen show a clustering o f  replacement mutations in CDR's
The immunoglobulin heavy and light chains each contain three hypervariable (complementarity 
determining regions or CDR) segments and four conserved framework areas (van Dyk '92). The 
CDR's are the most diverse regions of the antibody molecule. All six CDR's associate to form the 
antigen-binding site (Alzari '88), whose conformation is maintained by the framework sequences 
(Foote '92). The CDR3 is in direct contact with antigen and is the most variable portion of the 
immunoglobulin. Its diversity is a result of several mechanisms. Since the CDR3 encompasses the 
fusion site of V, D en J segments, random recombination (Sanz '91; Clothia '92) contributes to CDR3 
hyperdiversity. During the fusion of the segments the enzyme terminal deoxytransferase (TdT) 
introduces a variable number of random nucleotides at the junctional sites. These so called N 
insertions are found in 68% of fetal B cells, 86% of neonatal B cells and between 90 and 100% of 
adult mature B cells (Sanz '91; Yamada '91; Wasserman '92). During the fusion nucleases can delete 
terminal nucleotides of the rearranging V, D en J segments. To add diversity to the CDR3 region the D 
segments can be transcribed in any of the three possible reading frames (Meek '90; Sanz '91). 
Because mutations in CDR's are the most likely to affect the antibody's binding site, a hallmark of an 
antigen-stimulated B-cell is the clustering of replacement mutations in the CDR's (Wysocki '86; 
Rajewsky '87; Berek '87; Shlomchik '87; Kocks '88; Sharon '89).
2.3 M onitoring the immunoglobulin heavy chain gene structure reveals B -cell types with a possible 
role in myeloma ontogeny and gives an indication o f  the tim ing o f  oncogenic events.
2.3.1 Plasma cells in Monoclonal Gammopathy o f  Unknown Significance
Plasma cell clones can persist for many years in individuals with MGUS. Persistant plasma cell 
clones may be explained by chronic infections, chronic inflammation, self reactive processes or 
transformed plasma cells c.q. transformed plasma cell precursors. Recently Sahota ('96) detected 
intraclonal heterogeneity in the IgH sequence of plasma cells in 4 out of 7 MGUS cases. The 
intraclonal diversity was consistent with ongoing somatic hypermutation and did not involve V gene 
variations. Identical Ig sequences or Ig sequences with minor differences are not consistent with
17
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chronic inflammation, chronic infections or self reactive processes and point towards (partially) 
transformed plasma cells. The type of intraclonal Ig sequence diversity found in MGUS is consistent 
with an oncogenic event that took place after Ig gene rearrangement but before or during somatic 
hypermutation (figure 2). In 1 of 4 cases Sahota ('96) found an Ig sequence linked to C^ that was 
clonally related to the Ig sequences of the plasma cells, suggesting that in this patient an oncogenic 
event took place in a B-cell that had not yet underwent isotype switching (figure 2). MGUS cases with 
no intraclonal Ig sequence diversity may develope from cases with diversity. This scenario may be 
explained by an additional oncogenic hit in B cell stages where somatic hypermutation is no longer 
active, resulting in a clonal expansion of one of the pre-malignant cells. Alternatively MGUS without 
intraclonal Ig sequence diversity may develop de novo. For de novo development the oncogenic event 
is pinpointed in B cell stages where somatic hypermutation is off (figure 2).
plasma cell
memory B 
IgM
centroblast/centrocyte
IgM
virgin B
IgM
pre B 
pre-pre B
hematopoietic stem cell
Ig heavy chain DNA Oncogenic events
V 4D 9J4 Cy 1 Ca1
somatic hypermutation
light chain rearrangment
IgH switch Translocation 
(common)
V 4D 9J4 Ca C  Cy3 Cy1 Ca1
V h 1-51 D h 1-25 Jh 1-6 Ca C9 Cy3 Q 1  
^  = switch region
critical hit
MGUS hit
JH Translocation 
(rare)
first hit
Figure 2: Lessons from  using the immunoglobulin as a clonality marker: Status o f  the Ig H  DNA 
during B  cell differentiation and the assignment o f  oncogenic events to specific B  cell differentiation 
stages.
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2.3.2 The myeloma plasma cell corresponds to a long-lived plasma cell
The malignant plasma cells in multiple myeloma are monoclonal as defined by their identical 
immunoglobulin heavy chain (IgH) gene rearrangement (Vescio '95; Takeshita '94). The Ig genes of 
myeloma plasma cells are highly mutated in a matter compatible with antigen selection (Bakkus '92; 
Vescio '93; Sahota '96; Kosmas '98) and do not acquire additional somatic mutations during disease 
progression (Vescio '93; Willems '96). We conclude that the malignant plasma cells in multiple 
myeloma correspond to long lived plasma cells that are usually found in close association with bone 
marrow stromal cells. The bulk of these plasma cells is clustered outside the marrow (extramedullary 
plasmacytoma) on rare occasions only. Since there is no heterogeneity of the VDJ rearrangement 
within myeloma tumors we conclude that the critical oncogenic events in MM must have taken place in 
B-cell stages that already underwent VDJ rearrangment and somatic hypermutation processes 
(memory B cells, plasmablasts or plasma cells). In fact these events must have taken place in the 
terminally differentiated plasma cell itself or do not interfere with most of the normal differentiation 
process (figure 2).
2.3.3 B-lymphocytes that are C lonally Related to the M alignan t plasma cells (BCRM) may be 
involved in myeloma ontogeny
Since all myeloma plasma cells have identical IgH sequences (Bakkus '92; Vescio '95) that are 
stable during disease progression (Vescio '93; Willems '96) the Ig protein and IgH sequence have 
been used to detect new candidate malignant or premalignant cells in myeloma patients. Using these 
markers B cells that are Clonally Related to the Malignant plasma cells (BCRM) have been detected. 
Using anti-idiotypic antibodies several authors have demonstrated idiotypic determinants that were 
shared between plasma cells and IgM B-lymphocytes (Kubagawa '79; Boccadoro '81; Bloem '88; 
Osteborg '91). Anti-idiotypic antibodies however frequently cross react with normal polyclonal B 
cells (Stevenson '86; Kiyotaki '87; Miller '89; Kampe '94). Recently B-lymphocytes with Ig 
rearrangements identical to that of the malignant plasma cells (BCRM) have been detected with 
sensitive PCR techniques (Billadeau '93; Bakkus '94; Corradini '93b; '95). Preswitch (IgM) BCRM 
have been found in the bone marrow of 54% of patients at diagnosis (Corradini '95). From PCR 
signals (Billadeau '93; Bakkus '94; Corradini '93b; '95) it is estimated that the frequency of these 
cells must be as low as 1 in 1,000 purified B-lymphocytes. The observation that the malignant 
subpopulations in biphenotypic myeloma (Schots '95) although having identical VDJ rearrangements, 
differ in Ig isotype suggest a role for IgM BCRM as tumor stem cells or premalignant ancestor cells. 
Some studies even suggest that these cells are the myeloma progenitor cells and differentiation of 
BCRM is responsible for replenishment of the malignant plasma cells (Palumbo '92). In 46% of 
myeloma patients IgM BCRM were undetectable (Corradini '95). In these patients IgM BCRM are
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either extremely rare (frequency < 0.001%) or absent. Recently pointmutated subclones were detected 
in IgM BCRM in 5 out of 17 (30%) MM patients (Szczepek '98). Therefore it seems likely that 
although post-switch tumor cells are antigen-dependent, pre-switch BCRM are still subject to antigen­
mediated clonal selection.
In early studies differentiation markers have been used to evaluate the involvement of early B 
lymphocyte stages in the ontogeny of active myeloma The co-expression of early B lineage or markers 
of other lineages with plasma cell markers has been observed on the malignant population (Grogan 
'87; Jensen '91; Omede '93) and the authors therefore concluded that transformation occurred in a 
pre-B cell stage or in hematopoietic stem cells. The conclusions from these studies however are 
controversial since multilineage markers have now been observed frequently on normal bone marrow 
plasma cells (Terstappen '90) and plasma cell lines (Zhang '94). Using sensitive PCR techniques 
(IgH-ASO PCR) BCRM have been detected in sorted CD38 dim, CD45 positive B cells (Billadeau 
'93), CD34 positive cells (Szczepek '97; Takeshita '94), CD19, CD20, CD21 and CD10 positive B 
cell stages (Takeshita '94). In many studies the contamination of plasma cells in sorted subfractions 
may account for positive PCR signals obscuring these results (Willems '96; Kimlinger '97). We 
conclude that sorting subpopulations followed by quantitation with IgH ASO-PCR is unsuitable for 
immunophenotyping of rare BCRM and there is no evidence for the involvement of hematopoietic 
stem cells in the ontogeny of multiple myeloma.
2.4. Aim  o f  this thesis
Plasma cells arise from the differentiation of B-lymphocyte progenitors. Since the consequences of 
oncogenic events are dependent on the cell type in which they take place, the key to understand 
myeloma ontogeny is to find the B cell stages where each individual event took place. We conclude 
that monitoring the immunoglobulin heavy chain gene structure of B-cell populations during myeloma 
progression indicates what cell types may be involved in myeloma ontogeny and provides important 
clues about the timing of oncogenic events that lead to disease manifestation.
In order to cure myeloma patients it is imperative to eradicate or control the malignant progenitors. 
The aim of this thesis is therefore to accurately define the malignant cells and their progenitors and 
acquire markers specific for the malignant clone in multiple myeloma patients. The only marker that 
discriminates normal B-lymphocytes and pre-malignant ancestors from malignant plasma cells and
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their progenitors is the essential or critical oncogenic hit that transforms pre-malignant cells into cells 
causing disease. Since p53 mutations have been detected in many different tumors (Baker '89; 
Mulligan '90; Varley '91; Hollstein '91) and have been shown to have oncogenic effects (Prosser '90; 
Michalovitz '91) we hypothesized that p53 might be the critical oncogenic hit in myeloma. We 
therefore tested myeloma tumor samples for mutations in the p53 gene (chapter 3). p53 mutations 
appeared not be the critical oncogenic hits in myeloma. The unavailability of ubiquitous myeloma 
tumormarkers prompted us to use the immunoglobulin heavy chain gene rearrangement of the 
malignant plasma cells as a clonality marker defining potentially malignant cells. We compared the 
reproducibility and accuracy of several methods to enable the quantitation of myeloma tumor cells and 
clonally related cells in a multicentre study in chapter 4 . Using these quantitation assays we found no 
evidence of malignant cells in CD34 positive subpopulations selected from myeloma peripheral blood 
autografts (chapter 5). Since cells with the IgH rearrangement of the malignant clone are not 
necessarily malignant we developed a strategy to differentiate between malignant subpopulations and 
non-malignant clonally related cells. This strategy involves the selection of all cells with the Ig 
idiotype of the malignant clone using anti-idiotype antibodies. In chapter 6 we proved that anti- 
idiotypic antibodies can be selected from phage display libraries with ease. In future experiments flow 
cytometric selection of idiotype positive cells should allow us to evaluate the extent of genetic 
mutations in these cells and more importantly their capacity to induce disease. These experiments will 
differentiate true malignant subpopulations from non-malignant clonally related cells. Finally chapter 7 
discusses the role that mutations found in myeloma plasma cells may have in the ontogeny of active 
myeloma.
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Chapter
Sporadic Mutations of the p53 Gene 
in Multiple Myeloma 
and No Evidence for Germline Mutations 
in Three Familial Multiple Myeloma Pedigrees
By: Peter M.W. Willems, Aldy W.H.M. Kuypers, Jules P.P. Meijerink, Rob S.G. Holdrinet and 
Ewald J.B.M. Mensink.
Leukemia 1993: 7(7): 986-991
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ABSTRACT
The recent finding that eight out of ten multiple myeloma cell lines have p53 gene mutations 
prompted us to examine the p53 tumour suppressor gene in 25 non-related multiple myeloma patients. 
None of 19 patient bone marrow samples available for Southern blot analysis showed rearrangements 
in the p53 gene and only one patient showed loss of the p53 locus. DNA encompassing exons 5, 7 
and 8, where p53 mutations commonly cluster, was amplified by PCR. Single strand conformation 
polymorphisms of the PCR-amplified exon 5 region were detected in two patients. Direct sequencing 
of the mutant band revealed that one patient had a C to T transition at codon 138 (Ala to Val) and one 
patient had a G to C transversion at codon 139 (Lys to Asn). P53 mutations in germline cells in 
hereditary cancer syndromes predispose the family members to the development of malignancies. 
Therefore we searched for p53 germline mutations in exons 5, 7 and 8 in the affected individuals from 
3 families with two multiple myeloma patients each (these patients include three individuals from the 
non-related group mentioned above). Using Southern blotting, PCR-SSCP analysis and direct 
sequencing no germline mutations were found. These results indicate that mutations in exons 5, 7 and
8 of the p53 gene are infrequent in multiple myeloma.
INTRODUCTIO N
Multiple myeloma (MM) is a malignant, clonal disorder characterized by infiltrations of plasma 
cells in the bone marrow accompanied by mild to extensive osteolytic lesions. The molecular 
mechanisms underlying the development (and evolution) of MM are largely unknown. There is 
evidence for the involvement of the c-myc gene as elevated myc mRNA expression has been detected 
in 25% of MM patients (Selvanayagam '88). In addition both the ras genes (Tsuchiya '88, Pacquette 
'90) and the pvt-like region (Bakkus '90) might be involved in progression of MM. The specific 
genetic alterations leading to the clonal expansion of plasma cells in MM however still have to be 
elucidated. A candidate genetic alteration involves the p53 locus that has been mapped on the short 
arm of chromosome 17 (17p13) (Isobe '86). It encodes the p53 protein that has been identified as a 
sequence-specific DNA binding factor (El-Deiry '92) and a potent transcription activator in v itro  
(Farmer '92).
Human malignancies commonly display mutations in the p53 gene (Baker '89; Iggo '90; Mulligan 
'90; Varley '91) and frequently the wt p53 product is lost all together (Prosser '90; Hollstein '91; 
Takahashi '91). In fact the functional loss or structural abnormality of only one of the p53 alleles in
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germline cells, as is the case in the hereditary Li-Fraumeni syndrome, predisposes the family members 
to the development of a variety of malignancies (Malkin '90; Srivastava '90). These findings are 
consistent with the idea that the wild type p53 protein functions as a suppressor of neoplastic growth 
and that inactivation is an important step in the genesis or progression of neoplasmata (Michalovitz
'91).
In the case of hematological malignancies, gross structural aberrations (20%) and point mutations 
(30%) of the p53 gene have been reported in patients with chronic myeloid leukemia (CML) in 
myeloid blast crisis, but exceptionally in chronic phase CML (Kelman '89; Mashal '90; Ahuja '91). In 
lymphoid neoplasms, p53 gene mutations are rare except in Burkitt's acute lymphoblastic leukemia 
and lymphoma, and in B cell chronic lymphocytic leukemia (Gaidano '91). In adult T-cell leukemia 
Sakashita and coworkers (Sakashita '92) showed that 5 out of 10 patients harbour point mutations that 
specifically occurred in the evolutionary conserved regions of the p53 gene. Six procent of the Li- 
Fraumeni patients (harbouring p53 mutations) develop leukemia (Marx '90) and both hereditary and 
acquired p53 mutations have been detected in cases of childhood acute lymphoblastic leukemia (Felix 
'92). Very recently Mazars and coworkers reported point mutations in eight out of ten myeloma cell 
lines suggesting an important role for p53 mutations in the development or progression of multiple 
myeloma (Mazars '92). These findings prompted us to investigate a possible role for the p53-gene 
product in the development of MM.
We present a screening of bone marrow samples of 25 non-related multiple myeloma patients for 
mutations in the p53 gene. Since p53 mutations tend to be clustered in four phylogenetically 
conserved regions of the gene (Caron de Fromentel '92), a PCR based strategy on genomic DNA was 
followed using single strand conformation polymorphism (SSCP) and direct sequencing. Since p53 
germline mutations in Li-Fraumeni patients predispose affected individuals to the development of 
malignancies (Marx '90), we tested peripheral blood samples from 5 patients belonging to three rare 
families with two MM cases for the presence of p53 germline mutations.
MATERIALS AND M ETHODS  
Patients
Classification and staging were according to Durie & Salmon (Durie '75). Relationship between 
MM patients from three pedigrees ('familial cases') was as follows: patients 23 and 24 were father and 
son, patients 25 and 26 were cousins and patient 27 has a father who also was diagnosed as having
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MM. Bone marrow samples were collected after informed consent. The number of plasma cells in 
each bone marrow sample was determined by light microscopy according to conventional methods.
DNA Isolation and Southern B lo t Analysis
DNA was isolated from blood and bone marrow cells as previously described by Miller and 
coworkers (Miller '88). To assess loss of the p53 locus or p53 locus rearrangements in a 
subpopulation of cells, 8 ^g of genomic bone marrow DNA of bone marrow cells was digested to 
completion with BamHI and separated by electrophoresis through a 0.7% agarose gel. DNA 
fragments were then transferred to nylon membranes (Hybond N+) and probed with a 1.8 kb p53 
cDNA probe (Harlow '85). After exposure and dehybridisation, the genomic blot was screened again 
with an a-globin probe to check for the amount of genomic DNA. The a-globin  probe was 
constructed by cloning of PCR-product (a1-globin sequence from position 148 to 642 (EMBL data 
library; accession number V00491).
Primers fo r  Polymerase Chain Reaction (PCR)
Oligonucleotide primers used in this study were synthesised on a 391A DNA synthesiser (Applied 
Biosystems, Warrington, UK). The nucleotide sequences of the primers used in this study are given 
below. Sense primers: p53-i3: 5'-TTT CTT TGC TGC CGT GTT CCA; p53-A5: 5'-TTC CTC TTC 
CTA CAG TAC TCC; p53-C5: 5'-CAG GTC TCC CCA AGG CGC ACT GGC C; p53-E7: 5'-GGC 
TCT GAC TGT ACC ACC ATC C; p53-E8: 5'-TAA TCT ACT GGG ACG GAA CA. Antisense 
primers: p53-AS1: 5'-ATA AGA TGC TGA GGA GGG GC; p53-E7A2: 5'-GTG ATG ATG GTG 
AGG ATG GGC C; p53-E8A: 5'-GGC TCC CCT TTC TTG CGG.
Table 1: Primers and conditions used fo r  amplification and sequencing o f  p53 gene-regions (EMBL 
X54156).
CR-amplified region Exon Fragment DNA amount 
Size
Primer Sequencing
Primer
[Mg2+] [dCTP] Annealing
Temperature
Sequencing
Temperature
egion I (nt 12.973-13.344) 5 372 bp 250ng p53-i3 p53-A5 2.5mM 30|lM 56°C 56°C
p53-AS1 p53-AS1 56°C
egion II (nt 13.948-14.093) 7 146 bp 500ng p53-C5 P53-E7 2.0mM 10|lM 71°C 65°C
p53-E7A2 p53-E7A2 71 °C
egion III (nt 14.455-14.553) 8 99 bp 500ng p53-E8 p53-E8 2.5mM 5|lM 56°C 56°C
p53-E8A p53-E8A 56°C
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Polymerase Chain Reaction
Genomic DNA isolated from bone marrow or blood cells was subjected to PCR in a 100 ^l PCR- 
solution containing 30 pmoles of each indicated primer, 250 ^M  dATP, dTTP and dGTP, 0.3^1 a - 
32P dCTP (Amersham International, Amersham, UK, 3000 Ci/mmol, 10 mCi/ml), 50 mM KCl, 10 
mM Tris-HCl (pH 8.4), 0.001% gelatine and 2.5 units Taq DNA polymerase (Life Technologies). 
Each separate amplification was optimised for detection of mutant forms (table 1). PCRs were 
performed for 35 cycles of 95 °C (1 minute), annealing temp (1 minute) and 72°C (1 minute) in a 
Perkin-Elmer Cetus thermocycler™. Figure 1 shows the strategy used for amplification of the p53 
gene.
i3 A5 C5 E7 E8
DNA
A B 1AS1 C E7A2 D E8A
Figure 1: p53 gene amplification strategy. d l  =exon H  =mutation cluster.
Genomic DNA Single Strand Conformation Polymorphism Analysis (SSCP)
Following amplification, 40 ^l of the reaction mixture was mixed with 210 ^l of 96% formamide, 
20 mM EDTA, 20 mM NaOH, 0.05% xylene cyanol, 0.05% bromophenol blue, heated at 85°C for 3 
minutes, snap cooled and kept on ice-water for 10 minutes before loading 2 ^l per lane onto 5.3% 0.4 
mm thick polyacrylamide gels (49:1 acrylamide: bisacrylamide) containing 45 mM Tris-borate pH 8.3, 
0.1 mM EDTA and variable amounts of glycerol. DNA-exon 8 amplifications were loaded onto 8.5% 
0.4 mm polyacrylamide gels (33.3:1 acrylamide: bisacrylamide). Electrophoresis was performed 
using three different conditions: at room temperature (2 Watts) with 5% glycerol, at 12°C (30 Watts) 
with 5% glycerol and at 12°C (30 Watts) without glycerol.
Elution from  Gel and Reamplification
A small area (approximately 25 mm2) of the gel corresponding to the position of the appropriate 
band was cut out. The gel piece was immersed in 100 ^l of a 20 mM Tris (pH 8.0), 1 mM EDTA 
solution and heated at 80°C for 15 minutes. The extract was briefly vortexed and incubated overnight 
at 4°C. After brief centrifugation 10 ^l of the supernatant was subjected to PCR reamplification for 40 
cycles. Amount and size of PCR-product generated was tested on a 2% agarose gel.
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Sequencing
For direct sequencing (Innis '88), a 35 cycle assymmetric PCR on 10 ng of template was 
performed using a 100 fold reduction of one of the primers. The resulting single stranded DNA was 
sequenced by the dideoxy chain termination method in a 10 cycle PCR using 1.2 pmol end-labeled 
primers (table 1 for sequencing primers and sequencing PCR annealing temperatures).
RESULTS
Table 2: SSCP and sequence findings in 27 multiple myeloma bone marrow samples.
Patient Diagnosis Stage Sex/Age Plasma Cell p53 deletion SSCP Exon Codon Nucleotide Amino Acid
Fraction analysis
1 Multiple Myeloma 3A M/64 65% not detectable region 1 abnormal 5 138 GCC —> GTC Ala —> Val
2 Multiple Myeloma 3A F/67 65% not detectable region 1 abnormal 5 139 AAG —> AAC Lys —> Asn
3 Multiple Myeloma 2A M/42 41% not detectable normal none detected
4 Multiple Myeloma 1A M/40 9% not detectable normal none detected
5 Multiple Myeloma * M/70 18% not detectable normal none detected
6 Multiple Myeloma 2A M/58 54% not detectable normal none detected
7 Multiple Myeloma 3A F/69 89% yes normal none detected
8 Multiple Myeloma 3B M/54 77% not detectable normal none detected
9 Multiple Myeloma 2A M/68 30% not detectable normal none detected
10 Multiple Myeloma 3A M/68 7% not done normal none detected
11 Multiple Myeloma 3B M/70 75% not detectable normal none detected
12 Multiple Myeloma 3A M/59 79% not detectable normal none detected
13 Multiple Myeloma 2A M/59 58% not detectable normal none detected
14 Multiple Myeloma 3A F/47 76% not done normal none detected
15 Multiple Myeloma 3A M/59 8% not detectable normal none detected
16 Multiple Myeloma 3B M/45 13% not detectable normal none detected
17 Multiple Myeloma 1A F/69 12% not detectable normal none detected
18 Multiple Myeloma * M/59 16% not detectable normal none detected
19 Multiple Myeloma 1A F/41 8% not done normal none detected
20 Multiple Myeloma * M/76 48% not done normal none detected
21 Multiple Myeloma 3A F/54 40% not done normal none detected
22 Multiple Myeloma 3A M/65 52% not done normal none detected
23 Multiple Myeloma 1A M/70 9% not done normal none detected
23 Blood sample - not detectable normal none detected
24 Multiple Myeloma 2A M/41 4% not done normal none detected
24 Blood sample - not detectable normal none detected
25 Multiple Myeloma 3A M/43 21% not detectable normal none detected
25 Blood sample - not detectable normal none detected
26 Multiple Myeloma 3A M/55 63% not detectable normal none detected
26 Blood sample - not detectable normal none detected
27 Multiple Myeloma 3A F/56 19% not detectable normal none detected
27 Blood sample - not detectable normal none detected
* staging was determined elsewhere
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Southern B lotting
Where possible, DNA of bone marrow and blood samples was analysed for gross structural 
abnormalities of the p53 locus by screening of a Southern blot with a p53 cDNA probe (Harlow '85). 
No DNA rearrangements were detected in 19 patient bone marrow samples nor in any of the 
peripheral blood samples of 5 familial cases of multiple myeloma (table 2). Subsequent use of an a- 
globin probe and densitometric scanning of bands enabled us to study p53 deletion. Loss of the p53 
locus was detected in only one bone marrow sample (patient 7). No loss of the p53 locus was detected 
in any of the 5 blood samples tested (table 2).
t t
Figure 2: PCR-SSCP analysis o f  the p53 gene region I  o f  bone marrow samples o f  14 multiple 
myeloma patients. Arrows indicate patients w ith abnormal m igrating bands. Norm al white blood cell 
(NWBC)-DNA is derived from  a poo l blood from  30 normals. Both NWBC and Jurkat do not carry  
p53 mutations in region I. CEM  is a heterozygous ce ll line w ith a p53-exon 5 mutation in one o f  its 
alleles, the other being n o rm a l. K562 is a celline homozygous fo r  a p53 gene mutation in region I  
(see figu re  3). Samples were separated on 5.3% polyacrylam ide gels containing 5% glycerol, 
5000Vh at 2 W (room temperature). X-ray f ilm  exposure was 24 hours (with intensifying screens).
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PCR-SSCP Analysis
We used SSCP mutation analysis, to detect p53 mutations in a small number of malignant plasma 
cells in a background of normal bone marrow cells (Orita '89). With SSCP analysis of amplified 
exons 5, 7 and 8 two out of 27 patients bone marrow samples (patients 1 and 2 in figure 2) showed 
abnormal migration patterns. In both patients, region I (table 1) encompassing mutation cluster A and 
B was involved (figure 2). In the case of patient 1, the abnormal pattern was also detectable in the 
peripheral blood sample (results not shown). We did not detect abnormal SSCP patterns for exons 5,
7 and 8 in peripheral blood DNA samples of the 5 familial MM cases.
D irect Sequencing o f  genomic DNA PCR products
Direct sequencing of amplified products from eluted abnormal migrating bands showed that point 
mutations in exon 5 were present. In both patients only one point mutation was found. In patient 1 
codon 138 (mutation cluster A) was changed from GCC to GTC (figure 3). Wild-type p53 protein 
consists of an alanine residue at position 138 encoded by the GCC triplet, the GTC triplet in the 
mutant encodes for the amino acid valine at this position. The G to C transversion in the terminal base 
of codon 139 (mutation cluster A) in patient 2 is also classified as a missense mutation, resulting in an 
AAC triplet encoding asparagine instead of lysine. The mutant p53 sequences of both patients 1 and 2 
were confirmed by directly sequencing bone marrow derived DNA (results not shown). No germline 
mutations could be detected after sequencing of the four mutation cluster regions in DNA derived from 
peripheral blood samples of familial MM patients 23, 25 and 26 (results not shown).
Figure 3: Sequence analysis o f  abnormal m igrating SSCP-bands. The arrows indicate the nucleotide 
mutations. K562 contains a cytidine insertion in codon 135/136 that causes a frameshift.
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DISCUSSION
In a search for the molecular mechanisms underlying the oncogenic events occurring in MM, we 
studied the structure of the p53 tumor suppressor gene. We found point mutations in the p53 gene in 
bone marrow samples of patients 1 and 2. A third patient with a plasmacel percentage of 89%, 
showed the loss of one p53 allele in these cells. These mutations in the p53 gene can have profound 
effects on normal cell development. In the tumor suppressor model absence of the p53 wt protein 
causes malignant cell growth. The mere presence of a mutant p53 protein was also shown to be 
involved in tumour progression in several models through a dominant negative effect (Baker '89; 
Eliyaho '89). This effect may be explained by the formation of heterodimers of the wt and mutant p53 
proteins resulting in an inactive oligomeric p53 complex (Milner '91). The recent finding that 80% of 
the tested myeloma cell lines showed point mutations located in the four previously identified mutation 
clusters in the p53 gene (Mazars '92) strongly implicated a role for p53 in the development of MM. 
None the less we observed mutations in the p53 gene in only 3 out of 25 non-related patients (12%). 
This may be an underestimation of the actual mutation frequency for several reasons. First, only the 
regions were screened where mutations were shown to cluster in other tumours. Detection of point 
mutations outside these regions is very rare (Caron de Fromentel '92). Second, point mutations in the 
amplified mutation clusters can be overlooked when using the SSCP technique. The percentage of 
cells bearing p53 mutations can be below the detection-limit. In literature a detection limit of less than 
3% mutant DNA was reported (Suzuki '91). We determined the detection limit of the PCR-SSCP 
technique by amplifying p53-region I in dilutions of DNA of cell line CEM that is point mutated in this 
region (Cheng '90) into normal DNA. As little as 2% mutant DNA could be detected in a background 
of wild-type DNA with PCR-SSCP (results not shown). All the bone marrow samples we 
investigated contained 4% plasma cells or more, and therefore we should have been able to detect 
these p53 mutations. Point mutations can also be missed when there is little difference between the 
mobilities of mutant and wt DNA. We minimized any potential false negative results by using at least 
three different electrophoretic conditions and checked several negative SSCP results by direct 
sequencing of bands that appeared to migrate normally (results not shown).
The relatively low frequency of p53 mutations we detected in MM bone marrow samples is in 
accordance with the results of a recently published MM study by Preudhomme et al. (Preudhomme 
'92). In MM-related disorders only one out of 27 mouse plasmacytomas was shown to contain p53 
mutations (Gutierrez '92) and no mutant or wt protein was detected immunohistochemically in 3 
human plasmacytomas (Villuendas '92). It is not uncommon in haematological malignancies to find a 
higher frequency of p53 mutation in cell lines than in tumour samples. In human T-cell acute
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lymphoblastic leukemia (T-ALL) the p53 gene was found to be mutated in at least 60% of cell lines 
with two cytogenetically normal copies of chromosome 17 (Cheng '90). P53 mutations in human T­
ALL tumour samples are however very rare (Felix '92; Jonveaux '91). An analogous situation has 
been reported for non-Hodgkin lymphoma (Gaidano '91). Because many cell lines are established 
from leukemic cells at relapse this may account for the differences in p53 mutation frequency in 
primary tumour samples compared to cell lines. In matched primary tumours and cell lines in vivo and 
in v itro  data are often identical (Cheng '90). It is also possible that mutations detected in cell lines 
were generated in vitro.
That p53 mutations are involved in the development of malignancies is now broadly accepted. The 
etiology of full-blown malignancies is regarded as a multistep process. In many models, mutations in 
p53 occur late in carcinogenesis (Fearon '90). Loss of the functional wt p53 for example correlates 
with the progression of several tumours such as adenomas to carcinomas in colorectal tumorigenesis 
(Baker '90), differentiated to undifferentiated carcinomas in thyroid tumorigenesis (Ito '92), 
astrocytomas to glioblastomas in the brain (Sidransky '92) and chronic phase to accelerated phase and 
blast crisis in CML (Ahuja '91; Foti '91). Patient 1 and patient 2, harboring p53 mutations, survived 
respectively 3 weeks and 6 weeks after sampling suggesting that these mutations are associated with a 
short survival. In patient 1 65% of the circulating white blood cells were plasma cells. This is not an 
unusual occurrence in terminal stage MM and it might explain the presence of the p53 mutation in the 
peripheral blood sample. Longitudinal studies of single patients are however necessary to address the 
question whether p53 mutations correlate with the clinical progression of MM.
We were inspired to look for germline mutations in the p53 gene in related MM patients since 
inherited p53 mutations as in Li-Fraumeni syndrome predispose family members to the development 
of a variety of malignancies (Malkin '90; Srivastava '90). Furthermore, germline mutations in the p53 
gene seem not to be restricted to Li-Fraumeni patients (Toguchida '92; Prosser '92). A p53 germline 
mutation was also found in 1 out of 4 patients with multifocal osteogenic sarcoma (Iavarone '92). In a 
large scale study of children and young adults with a second malignant neoplasm, 6.8% of the patients 
carried p53 germline mutations (Malkin '92). However we did not find these mutations in the 
mutation clusters A to D in families with two MM cases each suggesting that these p53 germline 
mutations have no critical role in the etiology of MM.
We conclude that p53 gene mutations in exons 5,7 and 8 are rare in MM. Gene mutation is 
however only one of the mechanisms by which a cell can become deprived of functionally active wt 
protein. In recent literature it has become increasingly clear that the level and phosphorylation of
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functional p53 protein are essential parameters involved in restraining cell-transformation (Takahashi 
'92). This urges for complementary studies evaluating these parameters.
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ABSTRACT
Recently the Belgium-Dutch Hematology-Oncology group initiated a multicentre study to evaluate 
if  myeloma patients treated with intensive chemotherapy benefit from additional peripheral stem cell 
transplantation. In order to accurately determine treatment response we decided to quantitate malignant 
cells. To test a consensus quantitation strategy five centres independently determined the 
immunoglobulin heavy chain sequences o f patient tumor cells, developed allele specific 
oligonucleotides (ASO) and ASO-PCRs. We compared the reproducibility of real-time quantitation 
with quantitation using limiting dilutions. We distributed DNA samples with a 4 log range of tumor 
cell concentrations and found average quantitation values deviating 74% and 42% from the input 
values with real-time PCR (1 centre) and limiting dilutions (4 centres) respectively. Within single 
centres we found an average variation coefficient of 0.74 with limiting dilutions not significantly 
different from the average 0.82 centre to centre variation coefficient. Within a single centre real-time 
quantitation proved more reproducible (average variation coefficient of 0.36). This report shows that 
real-time PCR or limiting dilution assays result in accurate quantitation values and that both assays can 
be used for quantitation in a single multicentre trial. We present a consensus strategy that allows an 
accurate comparison of quantitation data generated in independent centres.
INTRODUCTION:
Multiple myeloma is a malignant disease characterized by an increased number of clonal plasma 
cells in the bone marrow. Intensive treatment of multiple myeloma (MM) patients results in more 
complete remissions, event-free and overall survival than treatment with conventional doses of 
chemotherapy. Recently updated results from the French 'IMF' group showed a 43% (median: 57 
months) 6-year post diagnosis probability of survival in the myeloma group treated with high dose 
chemotherapy versus 21% (median: 42 months) in the group treated with conventional doses. In 
multivariate analysis the most important prognostic factor was response to treatment (Attal '96, '97). 
Based on these results the Belgium-Dutch Hematology-Oncology group (HOVON) initiated a 
multicentre study (HOVON-24) to evaluate the additional effect of peripheral stem cell transplantation 
(PSCT) on treatment outcome. In this study myeloma patients receive 3 to 4 courses of VAD followed 
by cyclofosfamide, stem cell mobilization and 2 courses of i.v. intermediate dose melphalan (70 
mg/m2). Subsequently patients are randomized receiving either interferon-a alone or Cy/TBI and 
PSCT followed by interferon-a maintenance. Treatment response is measured using bone marrow 
plasma cell percentage, plasma cell monoclonality (k/X ratio) and serum or urine M-protein
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concentration as parameters. A reliable assessment of tumor cell fractions below 1% however is not 
possible with morphological or flow-cytometric examinations. The serum or urine M-protein 
concentration reflects the secreting capability of monoclonal plasma cells rather than the absolute 
number of tumor cells and is therefore of limited value as a parameter for treatment response as well. 
Data generated by Corradini et al. ('98) strongly suggest a correlation between the PCR detection of 
posttransplant tumor cells and treatment outcome. Ninety-two percent of myeloma patients subjected 
to autologous stem cell transplantation were found PCR positive and most of these patients relapsed. 
With patients subjected to allogeneic bone marrow transplantation 45% became PCR negative. Only 1 
out of 4 PCR negative patients relapsed. In order to define treatment response more accurately we 
decided to quantitate malignant cells using PCR.
For logistic reasons quantitation data were generated in the individual participating HOVON 
centres. Other multicentre studies reporting large centre to centre variations in quantitation data 
(Preudhomme '96) clearly indicate that an accurate comparison of data generated in individual centres 
is dependent on standardization of a reproducible method. The HOVON 24 group therefore developed 
a consensus strategy for quantitation of malignant cells in myeloma patients. The quantitation was 
based on amplification of the unique immunoglobulin heavy chain sequence of the malignant clone 
using allele specific oligonucleotides (IgH ASO-PCR). In this report we tested a consensus strategy 
using a limiting dilution assay (Cremer '97) in a multicentre setting and compared these data with 
quantitation results using a recently developed integrated system for thermal cycling, real-time 
fluorescent detection and subsequent calculation of PCR product (Perkin Elmer ABI-PRISM™ 7700 
SDS).
METHODS
Patients
All Patients had stage III MM according to Durie and Salmon ('75). Bone marrow cells were 
obtained by aspiration from the sternum or iliac crest of the patients after informed consent. Cytospin 
preparations of BM were stained with May Grünwald Giemsa (MGG) and morphology of 200 
nucleated cells was quantitated by two independent investigators. Cells were layered over Ficoll 
Hypaque and the mononuclear layer was collected after density centrifugation and washed in 
phosphate buffered saline (PBS). These cells were cryopreserved at -196°C in small aliquots.
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Nucleic acid extraction
Over 10.106 cryopreserved cells were thawed, washed in PBS and counted using a Coulter 
Counter. Five million cells were used for DNA extraction using the QIAamp™ Blood (Qiagen) kit. 
The remaining 5.106 cells were used for RNA extraction using the RNAzol™ B isolation (CAMPRO- 
Scientific) kit. For quantitation of samples containing less then 1.106 cells after thawing whole cell 
lysates were used (Willems '96).
cDNA synthesis
One ^g of RNA (5 ^l) was reversed transcribed in a total volume of 20 ^l, containing 50 mM Tris- 
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 625 |iM  dNTPs, 5 |iM  random hexamers 
(Pharmacia, Uppsala, Sweden) 20 U RNAsin (Promega, Madison, Wi, USA) and 200 U Mo-MuLV 
reverse transcriptase (Life Technologies, Gaithersburg, Md, USA). Reverse transcription was 
performed at 42°C for 45 minutes.
Vh  fam ily specific amplification o f  IgH using consensus primers
Six independent IgH-PCR were performed using leader region Vh family specific sense primers 
(table 1) and a constant region antisense primer (ca  for IgA producing tumor clones, cy for IgG 
producing tumor clones). 1 ^l of cDNA was subjected to IgH-PCR in a 100 ^l PCR solution 
containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 250 |iM  dNTPs, 2.5 Units Taq 
DNA polymerase (Life Technologies, Gaithersburg, Md, USA) and 30 pmol of each primer 
(Eurogentec). The PCR was performed for 35 cycles of 1 min 94°C, 1 min 60°C and 1 min 72°C, and 
a final 10 min extension at 72°C in a Perkin-Elmer Cetus™ thermocycler. Products were separated on 
a 2% agarose gel. As an alternative Fr1 region Vh family specific sense primers or Jh antisense 
primers were used.
Direct sequencing
Double stranded IgH PCR product was sequenced in two directions by the dideoxy chain 
termination method (Innis '88) in a 15-cycle PCR using 5 pmol of one of the end-labelled sequencing 
primers (table 1) and 1 ^l (10 ng) template. The sequences were probed for homology with published 
functional Vh, D h and Jh gene segments (Vbase downloaded from internet site http://www.mrc- 
cpe.cam.ac.uk/imt-doc/public/INTRO.html) using DNAPLOT or fasta software.
38
Chapter four: A Protocol to Quantitate Myeloma Cells in a Multicentre Study
Table 1: Primers used fo r  PCR and sequencing.
amplification
A ) IgH  rearrangm ent tumor clone
Primers.
sense
VH1-leader
VH3-leader
VH4-leader
VH5-leader
VH6-leader
5'-A TG G A C TG G A C CTG G A G G -3'
5 '-G A G TTTG G G CTG A G CTG G -3'
5'-CTG G TG G CA G C TCC CA G A -3'
5 '-C TCG CC CTCC TCC TG G CT-3'
5'-A TG TCTG TCTCCTTCCTC-3'
CY
C a
5'-G GG TCT A G A CA G G CA G CC CA G G G CCG CTG TG C -3'
5 '-G G C TCA G C G G G A A G A CCT TG G -3'
antisense
B) sequencing or alternative set VH1/7 5'-TCTG G G G CT G A G G TG A A G A A -3'
VH2 5 '-A CCTTGA AG GA GTCTGG TCCT-3'
VH3 5 '-G G G G G TCC CTG A G A CTC TC-3'
VH4 5'-G CC CA G G A CTG G TG A A G C -3'
VH5 5 '-C TG G TG CA G TCTG G A G C A G -3'
VH6 5 '-G TA CAG CTG CA GCA GTCAG GT-3'
Jh-cons
Jh21
5'-G GTCACCG TCTCCTCAGG T-3'
5 '-A CCTGA GG AGA CG GTG ACC-3'
C) beta-actin reference PCR
D ) beta-globin reference PCR
p-actin  forw 5'-TCACCCACACTGTGCCCATCTACGA-3'
PCO5
GH21
5'-CAACCTCAAACAGACACCATG-3'
5'-GGAAAATAGACCAATAGGCAG-3'
p-actin  rev 5'-CAG CG GAA CCGCTCATTGCCAA TGG -3' 
PCO3 5'-ACACAACTGTGTTCACTAGC-3'
Design o f  allele specific oligonucleotides (ASO)
Allele specific oligonucleotides complementary to the CDRI (sense) and CDRIII (antisense) region 
were designed using the Primer Express software program (Perkin-Elmer, Foster City CA, Demo 
version 1.0 ppd). Design criteria for ASOs were: Tm between 59°C and 64°C (nearest neighbour 
method), no secondary structures with Tm more than 50°C, no primer dimer formation with AG less 
than -10 kcal/mol, no stretches of four or more G's, the ultimate 3' base of the sense primer 
preferentially complementary to a point mutation in the CDRI region and the 3 penultimate 3' bases of 
the antisense primer in the CDRIII region preferentially in the N region between VH and D segments.
Tumor clone specific PCR
An ASO-PCR was performed on 1 ^l patient cDNA essentially as described for IgH consensus 
PCR except for the use of 30 pmol 5' and 3' ASO primers instead of Vh  and constant region 
consensus primers. PCR products were separated on 2% agarose gel. A PCR-product of the correct 
length justifies further use of the tested ASOs. The specificity of the ASO-PCR (essentially performed 
as described for IgH consensus PCR) was tested using 0.5 ^g patient or 1 ^g control DNAs (normal 
bone marrow cells (NBMC), normal white blood cells (NWBC) and normal tonsillar cells (NTC)). 
Three independent allele-specific dilution series were generated by diluting patient marrow DNA in 
10-fold decrements into NWBC DNA to yield a concentration of 0.1 ^g per ^l and 160.000 cells per 
PCR. Sensitivity of the ASO-PCR was tested using these dilution series as templates. PCR products 
were separated on 2% agarose gel, transferred to nylon membranes (Hybond N+) and probed with
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end-labelled Vh  family specific Fr2 or Fr3 probes under stringent conditions. Radioactive signals 
were visualized on X-ray film (Kodak). Sensitivity of the ASO-PCR was considered satisfactory 
when PCR product was detectable up to 0.1% tumor cells on agarose gel or 0.01% tumor cells on X- 
ray film. To increase sensitivity ASO-PCR annealing temperature may be optimized testing 58- 62°C.
1 Quantitation using limiting dilutions (Sykes '92; Cremer '97)
Patient DNA samples were serially diluted (using V10 decrements) in dH2 O. Dilutions were 
amplified using a two step PCR procedure. The initial amplifications were performed using 30 pmol 
of Fr1 region or leader region V h  family specific sense primer and the Jh21 antisense primer. 10 ^l of 
DNA-template was subjected to IgH-PCR essentially performed as in the VH family specific 
consensus IgH-PCR except for the use of 2 mM MgCl2 . Two ^ l of the first PCR was used as 
template in a nested PCR-procedure performed with 30 pmol of patient specific ASOs and 2.5 mM 
MgCl2 . PCR products were separated on 2 % agarose gel. The most diluted sample that was positive 
in the above procedure and its neighbouring dilutions (two lower, two higher) were subjected to this 
limiting dilution assay in nine-fold. Results were corrected for input of amplifyable DNA. V108 to 
V101 1  dilutions were subjected in ten-fold to a two step beta-globin reference PCR (Saiki '88). Five 
^l of DNA-template was subjected to reference PCR performed essentially as the tumor specific ASO- 
PCR except for the use of 30 pmol PCO3 and GH21 primers. Two ^l of the first PCR was used as 
template in a semi-nested PCR procedure performed with 30 pmol of PCO5 and GH21 primers. 
Precautions necessary to avoid cross-contaminations were as described by Kwok and Higuchi ('89). 
The number of tumor cells in a sample was calculated using a program based upon Poisson 
distribution statistics of positive and negative reactions of the PCR at each dilution level (Strijbosch 
'88). As starting value for Newton's method of iterative approximation the weighted mean estimation 
was used. The likelihood maximization and the %2 minimization were calculated as described by 
Taswell ('81).
2 Quantitation o f  tumor cells using a calibration curve
A s calibrator-samples we used serial dilutions of patient bone marrow at diagnosis containing over 
10% plasma cells in NWBC. The relation between the fraction of tumor cells and the amount of ASO- 
PCR product in calibration samples is expressed in a regression equation used to translate ASO-PCR 
product (densitometrical units, relative reporter group fluorescence or threshold cycle) in tumor cell 
fraction of patient samples. Deviations in the logarithmic relation between tumor cell fraction and 
amount of PCR product measured using individual calibrator samples are expressed in the correlation 
coefficient of the regression equation. Consequently this correlation coefficient expresses the accuracy 
of the quantitation.
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2a Real-time quantitation o f  PCR product using the Taqman™ assay
Calibrator and unknown samples were subjected to real-time quantitation (Lee '93; Livak '95; Heid 
'96; Gelmini '97) using the 5’ nuclease assay (Holland '91) and the ABI/Prism™ 7700 sequence 
detector (Perkin-Elmer, Fostercity, CA, USA) (Heid '96). In this system the tumor specific PCR 
products are quantified using a non-extendible dual labeled fluorogenic probe that is situated nested 
from the PCR-primers. This Taqman™probe (PE/ABI, Warrington, UK) synthesized according to 
Lee ('93) contains a 5' fluorogenic reporter group (e.g. TET or JOE) and a 3' fluorogenic quenching 
group (TAMRA). During laser-induced excitation of the intact Taqman™ probe, the 5’ fluorescent 
reporter dye is quenched by the 3’ quencher dye through Förster-type energy transfer (Förster '48; 
Lankowicz '89). During specific amplification, the hybridized Taqman™probe is hydrolyzed by the 5’ 
secondary structure dependent exonuclease activity of Taq polymerase (Livak '95; Holland '91, '92). 
The reporter group fluorescence (ARn) due to hydrolysis of the probe is proportional to the amount of 
PCR product and is normalized to a passive internal reference signal (i.e. the rhodamine derivative 
ROX). Sample positivity is measured at the cycle number at which emitted fluorescence exceeds the 
10 times standard deviation of base-line emissions during cycle 3 through 15, i.e. the threshold cycle 
(Ct). Ct is proportional to the initial number of target molecules (Higuchi '93). One ^g of patient DNA 
was used as template. Each sample was amplified in triplicate in the presence of 15 pmol of each 
specific ASO, 10 pmol of Taqman™probe, 200 ^M  dNTPs, 60 nM of passive reference ROX, 1.25 
U of AmpliTaqGold™ DNA polymerase (Perkin-Elmer), 4 mM MgCl2 , 50 mM KCl, 10 mM Tris- 
HCl (pH 8.3), 10 mM EDTA in a volume of 50 ^l. Samples were heated for 10’ at 95°C and 
amplified for 50 cycles of 0.5’ at 95°C, 1,5’ at 60°, followed by a final extension of 10' at 72°C. The 
amount of ASO-PCR product formed is quantitated using the relative reporter group fluorescence 
(delta Rn) at a given cycle or using the Ct. The ABI/Prism™ 7700 Sequence Detector System 
computed the fraction of tumor cells in patient samples using the patient specific linear regression 
equation as a calibrator.
The amount of tumor cells as determined by PCR is dependent on the amount of DNA used in a 
PCR reaction and the presence of factors affecting amplification fidelity and efficiency. Normalizing 
the tumor cell specific ASO-PCR for the input of amplifyable DNA in each sample is therefore 
requisite. PCR amplification of a reference locus was used for normalization. With real-time PCR the 
beta-actin reference locus was amplified using 15 pmol of beta-actin forward and reverse primer and 
10 pmol of beta-actin Taqman™probe (Perkin-Elmer, Fostercity, CA, USA) using Taqman buffers 
and cycling parameters as for the ASO-PCR. The amount of amplifyable DNA was computed relative 
to a dilution curve of 1 ^g of NWBC DNA in dH2 O (5 fold decrements). For each patient sample, the 
ASO-PCR signal was normalized to the beta-actin signal. Figure 1 shows that ASO-PCRs for patients
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and PCR amplification of the beta-actin locus have equal amplification efficiencies over a dynamic 
range of at least 2  log template concentrations (input 800-80.000 cells).
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Figure 1: Quantitating dilution series o f  tumor cells o f  patient H  in dH2 O using real-time ASO-PCR. 
Squares and triangles show the average Ct (± SD) o f  3 quantitation experiments with the VH3-Fr2 and 
VH3-Fr3 Taqman™ probe respectively. Quantitation o f  the absolute number o f  cells was done using a 
beta-actin real-time PCR (diamonds).
2b Conventional quantitation o f  PCR product using densitometrical scanning
Calibrator and unknown samples were used as templates in ASO-PCRs. ASO-PCRs were 
performed for 35 cycles on 1 ^g of DNA essentially as described for IgH consensus PCR except for 
the use of 30 pmol 5' and 3' ASO primers instead of Vh  and constant region consensus primers. 
Quantitation was performed as in Willems ('96).
RESULTS
Development o f  a consensus strategy fo r  quantitation o f  myeloma tumor cells
The unique immunoglobulin heavy chain gene rearrangement (IgH) is generally used as a marker 
for the malignant B clone. IgH PCR approaches to quantitate myeloma tumor cells either probe IgH 
PCR products with a tumor specific probe (Bjorkstrand '95; Mariette '94; Bird '94) or use
♦ beta-actin y = -1.47Ln(x) + 34 .02 R2 = 0.97
■ Fr2-probe ASO-h y = -1.44Ln(x) + 42.46 R2 = 0.99
▲ Fr3-probe ASO-h y = -1.47Ln(x) + 42 .79 R2 = 0.98
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Figure 2: Real-time PCR quantitation o f  patient S and H  tumor cells. Tumor cells were quantitated 
with IgH ASO-PCR using consensus sense primers (table 1) and tumor specific antisense primers (for 
patient S) or vice versa (for patient H). Both strategies resulted in false positivity in control NWBC 
populations fo r  these patients.
tumorspecific IgH primers (Billadeau '91; '92; Bakkus '92; Vescio '94; Schiller '95). Preliminary 
experiments showed occasional false positivity of control samples in IgH ASO-PCR using only one 
tumor specific primer (figure 2). In addition we observed that mismatched probes were able to 
hybridize and function in quantitation strategies (figure 6). To avoid false positivity and the necessity 
of developing expensive patient specific fluorogenic Taqman™ probes for real-time PCR, we tested a 
consensus strategy using two tumor specific IgH primers and confirmation of amplified IgH 
sequences with consensus probes. Using Clustal W -big 'n 'FAT version 1.4 (Thompson '94) we 
aligned functional V h sequences (Tomlinson '92; '96). We were unable to find probe sequences 
complementary to all V h germline sequences and initiated probe design for the Vh3 family 
(approximately 50% of patient sequences). Using the consensus Vh3 germline sequence we plotted 
the deviations we found in a panel of 24 myeloma tumor sequences (figure 3). Using the Primer 
Express software program (Perkin-Elmer, Foster City CA, Demo version 1.0 ppd), we designed Vh 
family-specific Fr2 and Fr3 probes suitable for real-time PCR. Design criteria's for probes were: Tm 
between 66°C and 70°C (nearest neighbour method), ultimate 5' base A,T or C, more C than G bases, 
no secondary structures with Tm more than 50°C and no probe dimer formation with AG less than -10 
kcal/mol. The VH3-Fr2 and VH3-Fr3 probes matched 53% and 43% of myeloma tumor IgH 
sequences with a Vh3 rearrangement respectively. Eighty percent of all tumor Vh3 sequences matched 
with at least one of these probes. The remaining 20% of myeloma tumor Vh3 sequences showed 
single mismatches with either the VH3-Fr2 or VH3-Fr3 probe.
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Figure 3: Deviations from  the consensus Vh 3 germline sequence found in a panel o f  24 myeloma 
tumor sequences obtained in the HOVON-24 study.
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Validating the quantitation strategy in a multicentre setting
To test our consensus strategy for the quantitation of myeloma tumor cells we distributed bone 
marrow samples of patient H (70% tumor cells) and patient 6 (30% tumor cells) among 5 participating 
centres. We compared the immunoglobulin heavy chain sequence of the malignant clone obtained by 
the individual centres (figure 4). No sequence heterogeneity was observed. Within well defined 
restrictions (methods) each centre chose allele specific oligonucleotides (figure 4) and developed its 
own ASO-PCR. Upon analysis using agarose electrophoresis the individual ASO-PCRs detected <1 
malignant cell in a background of 1000 NWBC. A blotting procedure and probing the PCR samples 
with a Fr3 consensus probe (Willems '96) enhanced the sensitivity of the assay with a factor 10
patient 6: DP4 9-d6-25-Jh4a (CDR1,2,3)
5'U-tcaccttcaatatctatgctctac
5'E-ctggattcaccttcaatatctatgctc
5'C-ttcaatatctatgctctacattgg
5'G-caccttcaatatctatgctcta
5'A-caccttcaatatctatgctctacat
gcagcctctggattcaccttcaatatctatgctctacattgggtccgccaggctccaggcaaggggct
ggagtgggtggctgttatg tcatatgatttaagtcac^aatattatgcagactccgtgaagggccgat
tcaccatctccagagacgattccaagaatactctatatctgcaaatgaataacctgcgacctgaagac
acggctgtctattactgtgcgagagatcgcttcatagtcctgccagcgc ctatgccggcgggaccctttgactacttgggc
cttcatagtcctgccagcg-3'A
atagtcctgccagcgcctat-3'G
gaccctttgactacttgggc-3'C
gcttcatagtcctgccagc-3'E
cgggaccctttgactacttg-3'U
patient H: DP47-D2-15-Jh4b (CDR1,2,3)
5'U-ttagcagcaatgccatgagttg
5'E-tttagcagcaatgccatgagt
5'C-tttagcagcattgccatgatgtg
5'G-ggattcacctttagcagca
5'A-ttagcagcaatgccatgagt
gcagcctctggattcacctttagcagcâatgccatgagttgggtccgccaggctccagggaaggggct
ggagtgggtctcagHtattagtggtagtggtggtaS-^ acaâactacgcagactccgtgaagggccggt
tcaccatctccagagacaaatccaagaaaatggtgtatctgcaaatgacagcctgagagacggggaca
gagaggtggttgctgctaca-3'A
tattggagaggtggttgctg-3'G
ctacaggatttgactcctgg-3'C
ggtggttgctgctacagga-3'E
gttgctgctacaggatttgactc-3'U
Figure 4: Immunoglobulin heavy chain sequences o f  the malignant clone in patients 6  and H  and the 
allele specific oligonucleotides developed in five  independent centres to quantitate malignant cells. 
Deviations from germline sequences are given in superscript. CDR sequences are underlined.
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(results not shown). For validation of the consensus strategy dilutions of patient H and 6 DNA were 
distributed and the quantitation results of 5 participating centres (4 using a limiting dilution assay and
1 using real-time PCR) were compared (table 2). The average values found with limiting dilution 
assay deviated 42% of the input value. Using a normalized real-time PCR we calculated values that on 
average deviated 74% of the input value. There was no significant difference from the average 
quantitation values found using limiting dilutions. Variation coefficients with the limiting dilution 
assay ranged from 0.36 to 1.06 (average 0.74) within single centres. We found an average 0.82 
centre to centre variation coefficient that was not significantly different from the average variation 
coefficient found within single centres (table 2). Centre to centre variation reduced significantly and 
dropped from 0.82 with the single limiting dilution assay to 0.59 when each centre used the average 
of three independent limiting dilution assays as a quantitation value. Variation coefficients with real­
time quantitation ranged from 0.29 to 0.48 (average 0.36) and were significantly lower than with the 
limiting dilution assay.
Table 2: Day to day and multicentre reproducibility o f  quantitating malignant myeloma cells using real­
time IgH  ASO-PCR or a limiting dilution assay. The factor-range expresses the quotient o f  actual 
maximal and minimal values found in the quantitation assays.
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p a tien t cen te r  q uan tita tion  #  analyses ty p e  o f  v a ria tio n  i n p u t  c a l c u l a t e d  A S O -P C R  co n tro l P C R  to ta l av erag e  av erage
m eth o d t u m o r  ce lls t u m o r  ce lls v a ria tio n v a ria tio n v a ria tio n p e r  p a tie n t to ta l
# # V aria tio n  C o ëffic ien t /  Factor- ran g e
6 E lim iting  d ilu tio n 3 day  to  day 9 . 6 1 0 . 1 0 .24  /  1.6 0 .56  /  2.3 0.61 /  3.8
6 C lim iting  d ilu tio n 3 day  to  day 9 . 6 1 3 . 7 0 .32  /  1.9 0.92  /  10.6 0 .97  /  20.3
6 A rea l tim e  P C R 4 d ay  to  day 9 . 6 1 2 . 6 0.15 /  1.5 0 .26  /  1.6 0 .30  /  2 .4
6 E ,C ,G ,U lim itin g  d ilu tion single m u lti-cen tre  (4) 9 . 6 11 0 .24  /  2.0 0.72  /  14.1 0 .76  /  27 .7
6 E ,C ,G ,U lim itin g  d ilu tio n trip lo  5 m u lti-cen tre  (4) 9 . 6 1 0 . 7 0.11 /  1.3 0 .44  /  1.9 0.45 /  3.5
6 E lim iting  d ilu tio n 3 day  to  day 1 6 0 0 2 3 0 6 0 .09  /  1.2 1.04 /  6.6 1.04 /  7 .9 0.83 /  5.9
6 C lim iting  d ilu tio n 3 day  to  day 1 6 0 0 6 9 5 0.65 /  3.9 0 .84  /  6.8 1.06 /  26.5 1.02 /  23 .4
6 A rea l tim e  P C R 4 d ay  to  day 1 6 0 0 1 8 9 0 0 .32  /  2.5 0 .14  /  1.3 0.35 /  2 .9 0.33 /  2 .7
6 E ,C ,G ,U lim itin g  d ilu tion single m u lti-cen tre  (4) 1 6 0 0 1 2 8 7 0 .50  /  7.2 0.89  /  15.1 1.02 /  107.6 0.89  /  67 .7
6 E ,C ,G ,U lim itin g  d ilu tio n trip lo  5 m u lti-cen tre  (4) 1 6 0 0 1 7 0 1 0.45 /  3.1 0 .49  /  2.1 0 .67  /  6.5 0 .56  /  5.0
H E lim iting  d ilu tio n 3 day  to  day 5 6 5 4 0 .64  /  3.5 0 .49  /  2 .7 0.81 /  9 .0
H C lim iting  d ilu tio n 3 day  to  day 5 6 2 6 0.28 /  1.6 0 .22  /  1.6 0 .36  /  2 .4
H A rea l tim e  P C R 4 d ay  to  day 5 6 3 3 0 .46  /  2.0 0 .14  /  1.3 0.48 /  2 .7
H E ,C ,G ,U lim itin g  d ilu tion single m u lti-cen tre  (4) 5 6 4 5 0.73 /  9.0 0 .50  /  4 .2 0 .89  /  36.0
H E ,C ,G ,U lim itin g  d ilu tio n trip lo  5 m u lti-cen tre  (4) 5 6 4 5 0.55 /  4 .4 0 .3 7  /  2.1 0 .66  /  9 .2
H E lim iting  d ilu tio n 3 day  to  day 5 6 0 8 6 6 0 .40  /  2 .4 0.33 /1 .9 0 .52  /  4 .6 0 .67  /  6.8 0.75 /  6 .4
H C lim iting  d ilu tio n 3 day  to  day 5 6 0 9 5 6 0 .56  /  3.0 0 .04  /  1.1 0 .56  /  3.3 0 .46  /  2.9 0 .74  /  13.2
H A real tim e  P C R 4 d ay  to  day 5 6 0 1 7 0 2 0 .27  /  1.7 0 .10  /  1.2 0 .29  /  2 .0 0 .39  /  2 .4 0 .36  /  2.6
H E ,C ,G ,U lim itin g  d ilu tion single m u lti-cen tre  (4) 5 6 0 9 9 3 0.43 /  4 .6 0 .44  /  2 .4 0 .62  /  10.9 0.76  /  23.5 0.83 /  45 .6
H E ,C ,G ,U lim itin g  d ilu tio n trip lo  5 m u lti-cen tre  (4) 5 6 0 9 9 0 0 .34  /  2.1 0 .44  /  1.9 0 .56  /  4 .0 0.61 /  6.6 0 .59  /  5.8
Performance o f  the IgH consensus probes in real-time quantitation.
A ccuracy: Using a 5 log range of tumor cell concentrations in real-time PCR (figure 5a) we 
measured the increase in fluorescence (delta Rn) after 35 cycles and 50 cycles reflecting the amount of 
ASO-PCR product generated at 35 or 50 cycles of real-time PCR. We found regression equations 
(relating the delta Rn to tumor cell concentrations) with correlation coefficients of 0.97-0.99 and 0.95­
0.97 for 35 and 50 cycles respectively (figure 5c). Using the threshold cycle (Ct) as a parameter for 
the amount of PCR product we consistently found regression equations with correlation coefficients 
above 0.99 (figure 5b). In contrast detection of blotted ASO-PCR product with labeled probes and 
densitometrical scanning of PCR product results in regression equations with correlation coefficients 
of 0.91 for patient H and 0.93 for patient 6 (figure 5d). We conclude that using calibration curve 
equations describing the logarithmic relation between Ct and starting quantity (i.e. fraction of tumor 
cells) produces quantitation data with the highest accuracy.
Sensitivity: Using dilution series of patient H and patient 6 bone marrow we compared the 
performance of the VH3-Fr2 Taqman™probe with the VH3-Fr3 Taqman™probe in real-time IgH 
ASO-PCR. Patient 6 dilution series were amplified with an amplification efficiency of 97% 
irrespective of the probe used. Patient H dilution series were amplified with an amplification efficiency
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of 100% or 96% with the use of Fr2 or Fr 3 probes respectively (figure 6).We conclude that real-time 
ASO-PCR (figure 5,6) is able to detect 1 DNA target or 1 tumor cells in a background of 80.000 
normal cells (sensitivity 1.25. 10-5). To achieve this sensitivity a minimum of 38 amplification cycles 
is required. Conventional detection of blotted ASO-PCR product with labeled probes and 
densitometrical scanning (figure 5d) is able to detect 10 DNA targets (sensitivity 1.25. 10-4).
Reproducibility: With conventional ASO-PCR and densitometrical quantitation (table 2) variation 
coefficients ranged from 0.68 to 0.88 (average 0.77). Using a 5 log range of template concentrations 
in real-time PCR variation coefficients within a single PCR ranged from 0.04 to 0.37 (average 0.21) 
(table 3). We assessed day to day variation of real-time quantitation using identical calibration samples 
as PCR templates on 5 consecutive days (table 3). Variation coefficients ranged from 0.23 to 0.57 
(average 0.38). Real-time ASO-PCR performed with the Vn3-Fr3 probe or the Vn3-Fr2 probe 
showed no significant differences in reproducibility (table 3). Alignment of the Vn3-Fr3 probe with 
the tumor VDJ sequence of patient H showed a mismatch on the 3' position 18 of the probe. We 
conclude that this mismatch has no consequences for reproducibility and sensitivity of the real-time 
PCR and single mismatched probes may be used in real-time quantitation.
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Figure 5: Quantitation o f  malignant cells in myeloma patients H  and 6  samples using real-time IgH  
ASO-PCR (figure a-c) or conventional ASO-PCR and densitometrical scanning (figure d). Calibration 
curves were constructed plotting the initial number o f  tumor cells against the Ct (figure b), the amount 
o f  emitted fluorescence (PCR product) at 35 and 50 cycles (figure c) or the density (figure d).
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Figure 6 : Comparing the performance o f  the VH3-Fr2 and VH3-Fr3 probe in real-time quantitation. 
Dilution series o f  patients H  and 6  bone marrow were subjected to real-time IgH ASO-PCR in five  
fold. Using these results calibration curves were constructed plotting the initial number o f  tumor cells 
against the threshold cycle (± SD).
Table 3: Quantitation reproducibility using real-time ASO-PCR or conventional ASO-PCR and  
densitometrical scanning. The factor-range expresses the quotient o f  actual maximal and minimal 
values found in the quantitation assays.
patient quantitation probe type o f variation inpu t calculated variation quantity Factor- variation
method tum or cells quan tity  coefficient interval (95%) range average-variations coefficient
H Real- time PCR Fr2 intra PCR 1425 1422 0.2 1141-170S 1.5
day to day 1425 1634 0.23 1252-2016 1.6
intra PCR 1.4 0.8 0.14 0.7-0.9 1.3 real-lime PCR intra PCR 0.17
day to day 1.4 1.7 0.41 1.0-2.4 2.4 real-lime PCR inter PCR 0.32
H Real- time PCR FrS intra PCR 1425 2026 0.1 1BS0-2222 1.2
day to day 1425 1493 0.36 95B-202B 2.1
intra PCR 1.4 1.2 0.37 0.8-1.6 2 real-time PCR intra PCR 0.24
day to day 1.4 1.6 0.47 0.8-2.4 3 real-time PCR inter PCR 0.42
H Real-time PCR Fr2 and FrS real-time PCR intra PCR 0.21
real-time PCR inter PCR 0.37
6 Real- time PCR Fr2 intra PCR 2250 2601 0.04 2491-2711 1.1
day to day 2250 1677 0.57 715-26S9 3.7
intra PCR 22 21.3 0.36 B.7-2B.9 2.1 real-time PCR intra PCR 0.2
day to day 22 18.4 0.37 11.6-25.2 2.2 real-time PCR inter PCR 0.47
6 Real- time PCR FrS intra PCR 2250 3543 0.17 2990-41S6 1.4
day to day 2250 3010 0.34 1994-4026 2
intra PCR 22 18 0.24 B .7-22.2 1.6 real-time PCR intra PCR 0.21
day to day 22 18.7 0.28 B.5-2S.9 1.8 real-time PCR inter PCR 0.31
6 Real-time PCR Fr2 and FrS real-time PCR intra PCR 0.21
real-time PCR inter PCR 0.39
H densitometric al Fr2 intra PCR 1425 5065 0.68 1609-B521 5.3
intra PCR 14 6.5 0.72 1.8-11.2 6.2 densitometric al patie nt H 0.7
6 densitometric al Fr2 intra PCR 2250 11004 0.88 1S1B-20690 15.7
intra PCR 22 16.5 0.78 S.6-29.4 8.2 densitometrical patient 6 0.83
all
densitometrical 0.77
real-time PCR intra PCR 0.21
real-time PCR inter PCR 0.38
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DISCUSSION
Recently the Belgium-Dutch Hematology-Oncology group (HOVON) initiated a multicentre study 
to evaluate if myeloma patients treated with intensive chemotherapy benefit from additional peripheral 
stem cell transplantation. Treatment outcome was measured using the bone marrow plasma cell 
percentage, plasma cell monoclonality (k/X ratio) and serum or urine M-protein concentration as 
parameters. For follicular non-Hodgkin lymphoma patients a significantly reduced disease-free 
survival rate correlated with the presence of PCR detectable lymphoma cells after therapy (Gribben 
'91; '93). The sustained PCR detection of a bcr-abl gene rearrangement in patients suffering from 
chronic myeloid leukemia correlated with a higher probability of relapse (Delage '91). Although it is 
not proven yet that treatment response is correlated with a decrease in the number of myeloma tumor 
cells, data generated by Corradini et a l. ('98) strongly suggest a correlation between the PCR detection 
of myeloma tumor cells after therapy and treatment outcome. Longitudinal PCR quantitation of 
myeloma cells in HOVON-24 might confirm that rises in tumor cell numbers predict clinical relapse. 
For these reasons we decided to quantitate the fraction of malignant cells as an additional parameter to 
monitor treatment response.
In this report we compared the reproducibility of several PCR methods to quantitate myeloma 
tumor cells. With the construction of a tumor specific PCR, the amplification target of choice is a well 
described marker restricted to and ubiquitously present in all malignant cells. Since such markers are 
unavailable for most multiple myeloma patients the unique immunoglobulin heavy chain (IgH) 
rearrangement is generally used as a marker for the malignant clone. IgH PCR approaches to 
quantitate myeloma tumor cells either probe IgH PCR products with a tumor specific probe 
(Bjorkstrand '95; Mariette '94; Bird '94) or use tumor specific IgH primers (Billadeau '91; '92; 
Bakkus '92; Vescio '94; Schiller '95). Since quantitation of myeloma tumor cells with consensus IgH 
primers and a tumor specific probe is generally less sensitive than the use of allele specific 
oligonucleotides (Mariette '94; Bird '94; Billadeau '91; '92; Bakkus '92; Vescio '94; Schiller '95) and 
we occasionally observed false positivity while using consensus IgH primers we chose for the use of 
two IgH ASOs and sequence confirmation with consensus IgH probes. Early reports describe 
quantitation methods using calibration curve equations that relate the amount of ASO-PCR product 
found in patient samples (with unknown fraction of tumor cells) with the amount of ASO-PCR 
product found in dilution series (with known fraction of tumor cells). Measuring the amount of PCR 
product was labour intensive involving Southern blotting, screening with labeled probes and 
densitometrical analysis (Billadeau '91; Bakkus '92; Vescio '94). We found that with this method 
accurate measurements are limited to a 3 log range of templates (Willems '96; this study). In this
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report we tested real-time IgH ASO-PCR and a limiting dilution assay (Cremer '97) as alternatives for 
quantitation of tumor cells.
With real-time IgH ASO-PCR the amount of PCR product is proportional to the amount of emitted 
fluorescence (delta Rn) due to probe hydrolysis. In addition the initial number of PCR target 
molecules is proportional to the threshold cycle (Ct) where a fixed amount of emitted fluorescence (10 
times base fluorescence) is detected (Higuchi '93; Heid '96). This report shows that calibration curve 
equations relating the amount of tumor cells with delta Rn or Ct allow an accurate quantitation of a 5 
log range of myeloma tumor cells (1.10-5 to 1.100). We suggest the use of Ct as a parameter reflecting 
the amount of PCR product formed in real-time PCR since relating the starting quantity (tumor cells) 
with the threshold cycle resulted in calibration curve equations with the highest correlation coefficients 
(consistently above 0.99). Reproducibility within a single real-time PCR was high (average variation 
coefficient 0.21). Even day to day measurements resulted in good reproducibility (average variation 
coefficient 0.38). In contrast reproducibility within a single ASO-PCR that was quantitated using 
blotting, probing and densitometrical analysis was much lower (average variation coefficient 0.77). 
We conclude that real-time IgH ASO-PCR is a highly reproducible, accurate and sensitive method to 
quantitate myeloma tumor cells. We recommend the use of real-time PCR in multicentre trials for a 
number of additional reasons. Closed tube analysis with real-time PCR results in a reduced 
contamination risk and less false positives. Standardization (a major concern in multicentre studies) is 
warranted with real-time PCR since standardized equipment, PCR buffers and strict PCR guidelines 
and quantitation statistics are available. Recently we concluded that real-time PCR master mixes with 
all ingredients (without template) can be stored at -80°C for long periods of time without mentionable 
loss of PCR efficiency (Smetsers '98). Distributing ready to use master mixtures to individual centres 
will enhance reaction reproducibility, facilitate standardization and reduce PCR contamination risk 
even more.
We tried to develop consensus in stead of patient specific fluorogenic probes to facilitate the 
standardized quantitation of myeloma tumor cells. Alignment studies of functional Vh  germline genes 
showed that a minimum of two consensus probes per Vh  family were required to develop a consensus 
strategy for quantitation myeloma tumor cells. In this report we initiated probe design for tumor cell 
IgH rearrangements involving the Vh 3 family. Alignment of 24 myeloma tumor cell IgH Vh 3 
rearrangements obtained in the HOVON study with a VH3-Fr2 and VH3-Fr3 probe suitable for real­
time PCR showed that 80% of tumor Vh 3 sequences were complementary to one of both probes. 
Alignment of the VH3-Fr3 probe with the tumor IgH sequence of patient H showed a mismatch on 
position 3' position of the probe. This mismatch had no consequences for sensitivity, accuracy or
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reproducibility of the real-time quantitation. In preliminary experiments we observed identical results 
for the quantitation of tumor Vh4 sequences using VH4-Fr2 and VH4-Fr3 consensus probes (results 
not shown). Assuming that all single mismatches are of no consequence for real-time quantitation two 
probes would be sufficient to quantitate all tumor Vh3 sequences. The consensus real-time IgH ASO- 
PCR strategy presented here circumvents the need to develop a new expensive fluorogenic probe for 
each patient. In addition it is a useful strategy for the quantitation of tumor cells in other B cell 
malignancies. For many non-Hodgkin lymphoma (NHL) patients the best available marker to 
quantitate malignant cells is the IgH rearrangement. For these patients the consensus real-time IgH 
ASO-PCR strategy is recommended, although ongoing somatic hypermutation of the malignant clone 
in the majority of follicular NHL patients (Levy '87) might interfere with accurate tumor cell counts. 
With ALL patients the frequent occurence of Vh replacements during a patients history might obstruct 
real-time quantitation of acute lymphoblastic leukemic cells with consensus fluorogenic probes (Bird 
'88; Wasserman '92b). Quantitation of these cells probably requires the use of consensus IgH sense 
primers and a patient specific CDR3 fluorogenic probe to avoid false positivity.
The equipment to perform real-time PCR was not available to all participating HOVON centres. We 
therefore distributed patient samples and compared the use of real-time PCR (1 centre) and a limiting 
dilution assay (4 centres) for quantitation of myeloma tumor cells in a multicentre setting. Limiting 
dilution assays use statistics to translate the highest dilution of patient sample were tumor cells are 
ASO-PCR detectable into the number of tumor cells in this sample (Cremer '97; Sykes '92). A 
prerequisite for the statistical procedures with limiting dilution assay is that a single copy of the CDR3 
region of the malignant clone can be detected. By diluting patient bone marrow of 2 patients with over 
10% plasma cells in NWBC the individual centres were able to demonstrate that this requirement was 
met (results not shown). Using the limiting dilution assay we calculated values that on average 
deviated 13% of the input value and we found an average variation coefficient of 0.37 (without 
corrections using a reference PCR). Comparable results with a limiting dilution assay were obtained 
by Cremer ('97). They calculated values that on average deviated 32% of the input value and an 
average variation coefficient of 0.32. We tested the real-time PCR and the limiting dilution assay in a 
multicentre setting. The average values found with real-time quantitative PCR were not significantly 
different from the averages found with the normalized limiting dilution assay. Reproducibility of the 
real-time quantitation was higher (average variation coefficient 0.36) than with the limiting dilution 
quantitation (average variation coefficient 0.74). In addition the average variation coefficient inside 
centres (0.74) was not significantly different from the average centre to centre variation coefficient 
(0.82) indicating that standardization of the limiting dilution assay was successful. To reduce centre to 
centre variations we tested the use of three independent limiting dilution assays to quantitate each
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sample. The reproducibility of the triple limiting dilution assay (average variation coefficient of 0.59) 
approached that of the real-time quantitative PCR (average variation coefficient of 0.36). We conclude 
that both quantitation methods result in accurate quantitation values and both methods can be used in a 
single multicentre trial.
We present a strategy to quantitate malignant cells in myeloma patients using IgH ASO-PCR. 
Using the consensus strategy an accurate comparison of quantitation data generated in independent 
centres is possible. This strategy can be adapted for the quantitation of tumor cells in other B-cell 
malignancies and may serve as a template for the construction of consensus protocols for multicentre 
quantitation studies in general.
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due to Impurity, not to CD34+ Myeloma Cells
By: Peter M.W. Willems, Sandra Croockewit, Reinier A.P. Raymakers, Rob S.G. Holdrinet, Gerard 
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SUM M ARY
Malignant cells in hematopoietic autografts can contribute to posttransplant relapse. Engraftment of 
myeloma patients with CD34+ peripheral blood progenitors selected from total autografts reduces the 
number of tumour cells infused with 2.7 to 4.5 logs. Residual tumour cells detected in CD34+ 
selected cells may be due to selection impurity or the existence of malignant CD34+ progenitors. In 
three patients we evaluated the CD34 purity and tumour load of total autografts, CD34+ progenitors 
selected with immunomagnetic beads and highly purified CD34+ progenitors obtained in 2 rounds of 
selection (combining magnetic- with flow cytometry activated cell sorting) to determine the cause of 
residual tumour cells in CD34 selections.
Using Allele Specific Oligonucleotides (ASO) complementary to the unique Ig heavy chain 
sequence (CDRIII region) of the malignant clone, semi-quantitative ASO-PCR was capable of 
detecting one malignant cell in 104 to 105 normal white blood cells. Selection of CD34+ cells from 
bone marrow (BM) with approximately 20% malignant plasma cells resulted in a 1.4 log reduction of 
tumour burden. Using two colour flow-cytometry we observed CD34-, BB4+ malignant plasma cells 
contaminating this CD34 selection. Prior to sorting, peripheral blood cell autografts (PBCA) contained 
approximately 0.1% malignant cells. Selection of >99% pure CD34+ cells using immunomagnetic 
beads (Dynal) resulted in an approximately 2 log reduction of malignant cells, but residual tumour 
cells were still detectable. ASO-PCR detected no malignant cells in >99.9% pure CD34+ peripheral 
blood progenitors obtained with 2  rounds of selection (combining magnetic- with flow cytometry 
activated cell sorting). We conclude that CD34+ malignant cells are not detectable in myeloma PBCA 
and that residual tumour cells in CD34 selections are due to contaminating CD34 negative cells.
INTRODUCTION
Autologous bone marrow transplantation as a treatment for multiple myeloma patients frequently 
results in early relapse (Barlogie '87; Gore '89; Jagannath '90). These relapses can result from 
residual tumour cells in the autologous graft as was shown for AML (Brenner '93), follicular 
lymphomas (Gribben '91) and CML (Deisseroth '94). Using selected CD34+ peripheral blood 
progenitors rather than total peripheral blood cell autografts (PBCA) reduces the number of tumour 
cells infused with 2.7 to 4.5 logs (Schiller '95). In myeloma some residual tumour cells have been 
detected in selections of CD34+ cells (Takishita '94; Belch '94; Bersagel '94; Schiller '95), 
suggesting either the existence of malignant CD34+ progenitors or impurity of the CD34 selection. If
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malignant CD34+ progenitors contributing to posttransplant relapse exist in myeloma, CD34 selection 
would be inadequate as a purging strategy for myeloma autografts. On the other hand if  residual 
tumour cells are due to impurity of the CD34 selection, better CD34 selection methods are needed. To 
determine the cause of residual tumour cells in selections of CD34+ cells we quantitated the tumour 
load and evaluated CD34 purity of total autografts, CD34+ progenitors selected with immunomagnetic 
beads and CD34+ progenitors purified with 2 rounds of selection (combining magnetic- and flow 
cytometry activated cell sorting).
Using oligonucleotide primers complementary to the unique immunoglobulin heavy chain CDRIII 
sequence of the malignant clone we developed tumour specific PCRs capable of detecting one tumour 
cell in a background of 100.000 normal cells. Using these sensitive PCRs we show that multiple 
myeloma PBCA contain about 0.1% tumour cells and that immunomagnetic bead selection of CD34+ 
cells results in an approximately 2 log depletion of tumour cells. Residual tumour cells in CD34 
selections were due to contaminating CD34 negative cells.
MATERIAL and METHODS 
Patients
All 3 patients (K, S and T) included in this study had stage III multiple myeloma according to Durie 
and Salmon ('75) and were previously treated with alkylating agents and prednisone. Patients S and K 
subsequently received repeated courses of steroids with vincristine and doxorubicin administered by 
continous infusion (VAD). Patients T and S achieved partial remission whereas patient K was 
refractory to prior treatment. For all three patients peripheral blood stem cells were harvested after 
high dose cyclophosphamide (7 g/m2). and G- or GM-CSF (patient T & K). Stem cells were re­
infused after high dose melphalan (140 mg/m2) and TBI (9 Gy).
Cell isolations
Bone marrow cells were obtained by aspiration from the sternum of the patients after informed 
consent. PBCA were collected in 4 to 6 aphereses procedures with a continuous flow cell separator 
(Fenwal CS 3000, Baxter Healthcare, Deerfield, USA (Areman '90)). Cytospin preparations of BM 
and PBCA were stained with May Grunwald Giemsa (MGG) and differential morphology of 200 
nucleated cells was scored by two independent investigators. Cells were layered over Ficoll Hypaque 
and the mononuclear layer was collected after density centrifugation and washed in phosphate 
buffered saline (PBS). These cells were cryopreserved at -196°C in small aliquots.
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Cell sortings
The cryopreserved cells were thawed, washed and resuspended in RPMI 1640 supplemented with 
10% FCS. More than 40.106 thawed cells were washed and resuspended in PBS with 1% BSA 
(PBSB) to a concentration of 100.106 cells/ml. CD34+ cells were selected according to the 
manufacturer's protocol with M450 beads directly coated with '561' antibody (Dynal). Bead to cell 
ratio was 1:2. After 30 minute incubation at 4°C with CD34-beads, a magnetic separation was 
performed. Selected cells were concentrated in 150 ^l PBSB and detachment of beads was performed 
by adding 50 ^l CD34 Detach-a-Bead (Dynal). After a one hour incubation at room temperature beads 
were magnetically separated from detached cells. Purity of CD34 selection was flow-cytometrically 
monitored. In brief, detached cells were washed twice and concentrated in 100 ^l PBSB and 
incubated with a mixture of phycoerythrin (PE)-conjugated CD34 (HPCA-2, Becton Dickinson) and 
fluorescein isothyocyanate (FITC)-conjugated BB4 (Immuno Quality Products). As a control cells 
were labelled with IgG1-FITC/IgG1-PE. Flow cytometric analysis and FACS was performed with an 
Epics Elite flow-cytometer (Coulter Corporation, Hialeah, USA) equipped with a 15 mW argon laser 
(488nm). Cells were flow-cytometrically sorted with a data rate of between 1000 and 2000 cells per 
second into a PBSB foam layer on top of 100 ^l PBSB in 1 ml eppendorf vials. An aliquot of each 
sorted fraction was re-analysed on the flow-cytometer to assess the purity. Fifty ^l of each sorted 
fraction was cytocentrifuged and stained with MGG to assess morphology of sorted cells.
DNA extraction
DNA was extracted by making whole cell lysates. If present, erythrocytes were lysed with NH4CL 
The NH4O  was washed away with PBS. Cells in PBS were transferred to eppendorf tubes and 
pelleted in an eppendorf centrifuge (5 min, 400 g at 4°C). The supernatant was removed and the pellet 
loosened by vigorous rasping. The pellet of > 105 cells was resuspended in PCR buffer supplemented 
with 0.5% NP40 and 0.5% Tween20 to a concentration of 10.000 cells/^l. One ^l of proteinase K 
(10mg/ml) was added for every 100 ^l cell lysate. The cell lysate was incubated at 55°C for 1 hour 
after which the proteinase K was inactivated by a 10 minute incubation at 95°C. When < 104 cells 
were available, pelleted cells were resuspended to a concentration of 10 cells/^l. In those cases 1 ^l of 
proteinase K (0.1 mg/ml) was added for every 100 ^l. Whole cell lysates were frozen at -70°C until 
10 ^l of cell lysate was used in each PCR.
Amplification o f  CDRIII using consensus primers
Whole cell lysates were subjected to PCR in a 100 ^l PCR solution containing: 31 ^M  dNTP, 
0.2^1 [a-32P]dCTP (Amersham International, Amersham, UK, 3000 Ci/mmol, 10 mCi/ml), 50 mM
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KCl, 10 mM Tris-HCl pH 8.4, 0.0001% gelatine, 2.5 Units Taq  DNA polymerase (Life 
Technologies) and 30 pmol of each consensus primer (figure 2). Primers were synthesised on a 391A 
DNA synthesiser (Applied biosystems, Warrington, UK). PCR was performed for 35 cycles of 1 min 
95°C, 1 min 55°C and 1 min 72°C, supplemented with a final 10 min extension at 72°C in a Perkin- 
Elmer Cetus™ thermocycler. Radioactive products were separated on a 6% non-denaturing 
polyacrylamide gel.
Analysis o f  CDRIII sequence
For direct sequencing double stranded DNA was sequenced by the dideoxy chain termination 
method (Innis '88) in a 10-cycle PCR using 5 pmol of one of the end-labelled CDRIII consensus 
primers (figure 2) and 1 ^l (10 ng) template. CDRIII sequences were searched for homology (Yamada 
'91) with published DIR (DH gene containing irregular spacer signals), D gene segments (Ichihara 
'88; Matsuda '90; Buluwela '88) and JH gene segments (Ravetch '81).
Tumour specific PCR o f  patient samples
To achieve highest PCR specificity allele specific oligonucleotides (ASOs) were designed 
complementary to the CDRIII region with the highest variability amongst different B cell clones 
(figure 2). A non radioactive amplification was performed essentially as described for CDRIII 
consensus PCR except for the use of 30 pmol 5'ASO primer instead of Vconsensus primer (figure 2) 
and a dNTP concentration of 250 ^M. PCR products were separated on 2% agarose gel, transferred 
to nylon membranes (Hybond N+) and probed with end-labelled ASO probes under stringent 
conditions. Radioactive signals were visualized on X-ray film (Kodak) and quantified by 
densitometrical scanning on a LKB laser densitometer. Allele-specific calibration curves were 
generated after serially diluting patient marrow DNA into PCR lysate buffer in 10-fold decrements, 
supplemented with normal white blood cell (NWBC) lysate to yield a concentration of 10.000 cells 
per ^l PCR lysate buffer and 105 cells per PCR.
Statistical estimation o f  tumour load
Quantified PCR product is given in OD (optical density, arbitrary units). Least squares was used to 
fit a linear regression equation for ln (OD) as a function of ln (tumour fraction) for each patient. The 
number of tumour cells in patient samples and its 95% Scheffe's confidence interval was computed 
using this patient specific linear regression equation (Billadeau '91; Billadeau '92).
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(52m control PCR
PCR amplification was performed as for the ASO-PCR except for the use of 30 pmol 52m sense: 
5 ’ -C T C G C G C T A C T C T C T C T T T C T  and  30 pm ol 5 2m an tisen se : 5 ’- 
CTAAACTTGTCCCGACCCTC primers. Size of the 52m PCR product was estimated on 2% 
agarose gels using a 100 bp ladder (Pharmacia) as a reference.
RESULTS
Vcon
V n D n J
a nti Jhcon
C D R 3PC R
Vcon
D
anti Jhcon
Sequence predominate clone & generate allele specific oligonucleotide (ASO). 
PSD
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anti Jhcon or Jh5i
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ASO -PC R
T" 1 D n n
anti Jhcon
Southern blotting
Screening with radiolabeled ASOi
A30 ^
1 f11 D n n
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Figure 1a: Outline o f  the method used to develop ASO-PCR. Schematic representation o f  the 
rearranged heavy chain locus amplified by CDR3 primers.
60
Chapter five: Residual Myeloma Cells in CD34 Selection due to Impurity
CDRIII sequencing
To determine the Ig heavy chain CDRIII sequence of the malignant clone we performed radioactive 
PCR using the consensus primers aJhcon and Vcon flanking the Ig CDRIII region (figure 1a). 
Performing this PCR with DNA template isolated from polyclonal B cell compartments (NWBC) 
resulted in multiple PCR products differing in length and sequence. The use of DNA template isolated 
from multiple myeloma bone marrow samples (containing over 10% plasma cells) resulted in just one 
PCR product (figure 1b). Direct sequencing of these PCR products consistently revealed only one 
CDRIII sequence at different time points (before and after high dose chemotherapy) in a patient's 
disease.
Figure 1b: IgH CDR3 PCR products generated  
using consensus primers. The radioactive products 
are se p a ra te d  on a 6 % non-denaturing  
polyacrylamide gel.
Sensitivity o f  ASO-PCR to specifically detect 
malignant cells
For each patien t tw o allele specific 
oligonucleotides (ASO) were synthesised (figure 
2). Using a 5' ASO and the a  Jhcon or a  Jh5i 
primer a PCR was developed that was specific for 
the malignant clone. ASO-PCR products were 
blotted and hybridised with a radiolabeled internal 
A SO -probe (figure 1a). Q uantitation by 
densitometrical scanning shows that each tumour 
specific PCR detects only malignant cells in one of 
the multiple myeloma patients but not in several
NWBC preparations. Also ASO-probes specifically designed for each patient never hybridised with 
ASO-PCR products of other multiple myeloma patients. By serially diluting the DNA derived from 
myeloma bone marrow samples (containing over 30% plasma cells) in DNA derived from NWBC we 
were able to show that sensitivity of the ASO-PCRs ranged from detection of one tumour cell in 104 
to 105 normal white blood cells (figure 3,4).
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FR3 CDR3 FR4
Vcon ASO
■ ASO-probe
CTGTCGACACGGCCGTGTATTACTG TGCGAGACGGCCTAGGTATATCCAATGGCTGGGCCCCAGGA TTTGACTACTGGGGCCAAGGGAACCCT-JH4b
patient S 1 DM1/DM2/DN1 DIR 1
ASO
CTGTCGACACGGCCGTGTATTACTG TGTCGCCGGGGCAGTGGGTATTGCGGG
patient K ' D21/9
ASO ---------- ASO-pro be
CTGTCGACACGGCCGTGTATTACTG CGCGAGAGATGACGCTGTGCTGATGGAGGGGGGG
patient T DXP4
ASO-probe
T CACTATT GGGGCCAAGGGAACCCT-JH4b
AACTGGTTCGACCCCTGGGGCCAAGGGAACCCT-JH5b
GGTCACCGTCTCCTCAGGT- aJhcon
TTTTGGAGGTCAGGAAAGAAAG- aJh5i
Figure 2: DNA sequences o f  IgH  VDJ junctions from  predom inant clones in myeloma BM  and  
location o f  prim ers used in ASO-PCR strategy. The 3' end o f  the third-framework region (FR3) and  
5' end o f  the fourth fram ework region (FR4) are indicated according to K abat ('91). The boxed 
regions designate putative D  and DIR sequences (Ichihara '8 8). The Jh  gene used, the amount o f  
trimming, and possib le somatic mutations (bold capitals) are indicated based upon published  
sequences (Ravetch '81).
Quantitation o f  malignant cells in myeloma autografts
As a control we performed PCR with B2m primers on all samples tested in the tumour-specific 
PCRs. Only minor differences in signal intensity of the B2m PCR products were observed (figure 
3,4). We conclude that the DNA preparation was of sufficient quality to allow PCR amplification of 
each sample with comparable efficiency. ASO-PCR detected between 0.07 and 0.17% malignant cells 
in PBCA in 3 patients in duplicate PCR experiments (figure 5). Plasma cells were never detected in 
cytospin preparations of PBCA whereas in cytospins of bone marrow aspirates 2-5% plasma cells 
were found (results not shown).
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(a)
(b)
Figure 3: (a) ASO-PCR analysis o f  tumor cells in PBCA fractions o f  patient S. The dilutions o f  BM  
DNA samples used to obtain the calibration curve are shown on the left. C D 34pos columns represent 
duplicate PCRs o f  the same selection o f  CD34+ cells with immunomagnetic beads. An aliquot o f  this 
CD34+ selection was then subdivided by flow  sorting. The columns CD34 pos, BB4 neg and CD34 
pos, BB4 pos represent ASO-PCR results perform ed with DNA isolated from  flow  sorted CD34+, 
BB4- and CD34+, BB4+ cells (b) Ethidium bromide stained 2% agarose ge l showing /52m control 
products o f  patient S DNA samples used in ASO-PCR.
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Figure 4: (a) ASO-PCR analysis o f  myeloma tumor in BM  fractions ofpatient S. The dilutions o f  BM  
DNA samples used to obtain the calibration curve are shown on the left. Sample description is as in 
figure 3. The CD34 neg column represent ASO-PCR results perform ed with DNA isolated from  bone 
marrow samples that were depleted o f  CD 34positive cells. (b) Ethidium bromide stained 2% agarose 
gel showing /52m control products ofpatient S DNA samples used in ASO-PCR.
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Figure 5: Percentage tumor burden in peripheral blood cell autografts (a) and BM  samples (b) o f  
myeloma patients as detected by ASO-PCR. Values are given with statistically generated confidence 
intervals (see material & methods) and < 0 .0 0 1 % tumor cells indicates that the number o f  tumor cells 
in the sample is below the detection limit o f  ASO-PCR. CD34+ samples were selected with CD34 
immunomagnetic beads and the CD34 depleted fraction was called CD34-; CD34+, BB4- samples are 
cells sorted with CD34 immunomagnetic beads and subsequent flow  cytometry. CD34- are samples 
depleted o f  CD34+ cells. Aliquots o f  these CD34+ selection were then subdivided by flow  sorting 
into CD34+ BB4+ cells and CD34+ BB4- cells and tumour burden herein was also assessed.
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Isolation o f  CD34+ progenitors using immunomagnetic beads
CD34+ cells were selected from PBCA and BM using CD34+-immunomagnetic beads (Dynal). 
Flow-cytometrical analysis of detached cells, stained with CD34-Phycoerythrin showed that purity of 
CD34+ peripheral blood progenitor cells was always higher than 99% (figure 6c). Using this 
procedure PBCA or BM were depleted of 99% of the CD34+ cells and we consequently called these 
fractions CD34-. Tumour specific ASO-PCR detected fewer than 0.002% malignant cells in CD34+ 
immunomagnetic bead preparations and 0.03-0.1% malignant cells in CD34- PBCA fractions (figure 
3,5a). Thus the majority of malignant cells were not selected with CD34 immunomagnetic beads and 
CD34 selection from PBCA using immunomagnetic beads (Dynal) reduced malignant cells with 
approximately 2 logs. Selection of CD34+ cells from bone marrow of patient T resulted in a 2.6 log 
reduction in tumour cells (figure 5b). We used BM of patient S (who had progressed to plasma cell 
leukaemia) to test if  in bone marrow heavily infiltrated with malignant cells the same reduction of 
tumour cells could be accomplished with CD34 selection. Flow-cytometrical analysis of this BM 
sample stained with the plasma cell (PC) marker BB4-FITC (Pellat-Deceunynck '94) revealed 20.7% 
PC. In MGG stained cytospins 22% PC were detected (results not shown). When the selected CD34+ 
cells were stained with BB4 and CD34, purity was higher than 75%. BB4+ PC (1%) were however 
contaminating this selection (figure 6b). Tumour specific ASO-PCR detected 22.2% malignant cells in 
this BM aspirate of patient S and 25.7% in the CD34- fraction. In the CD34+ fraction 0.8% malignant 
cells were detected (fig 4,5b). We conclude that selection of CD34+ cells from highly contaminated 
BM results in a 1.4 log reduction of tumour cells.
Isolation o f  CD34+ progenitors using immunomagnetic beads fo llow ed  by flow  cytom etrically 
activated cell sorting (FACS)
The selection of CD34+ progenitors from BM of patient S was contaminated with BB4+ PC (figure 
6b). Using FACS we sorted 103 BB4+ PC (figure 6b, gate D) from CD34 immunomagnetic bead 
fractions.
Figure 6 : Flow cytometrical analysis o f  cells obtained with CD34 immunomagnetic bead selection 
from  bone marrow (a,b) and PBCA (c,d) o f  patien t S. Analysis o f  forw ard  and side scatter (a) and  
CD34 (PE) and BB4 (FITC) expression (b). For bone marrow as w ell as PBCA m aterial CD34+, 
BB4- cells in gate F  and CD34+, BB4+ cells in gate D  were further purified by FACS. Purity o f  the 
CD34+, BB4- cellsort was monitored by flow  cytometrical analysis o f  CD34 (PE) and BB4 (FITC) 
expression (d).The quadrant B indicates green and red  fluorescence o f  IgG-PE/IgG-FITC control 
antibodies.
66
Chapter six: Detection of Myeloma Plasma Cells with Anti-idiotypic Single Chain Fv's
67
Myeloma Plasma Cells and Clonally Related B-lymphocytes
Cytospin preparations of sorted BB4+ cells showed only cells with typical plasma cell morphology 
(results not shown). ASO-PCR showed that BB4+ PC belong to the malignant clone (figure 4). Over 
90% of the BB4+ cells were CD34 negative suggesting that most plasma cells contaminate the CD34 
selections in a non specific manner. If  this were true it would mean that increasing the purity of 
CD34+ cells could further reduce the contamination of malignant cells. Highly purified CD34+ BM 
progenitors were obtained in 2  rounds of selection combining magnetic- with flow cytometry activated 
cell sorting (figure 6b, gate F). Purity of these flow sorted CD34+ cells was higher than 99.9%. 
ASO-PCR showed that a second round of purification with FACS results in a 2.3 log reduction of 
malignant cells (figure 4,5b). Flow-cytometrical analysis of CD34+ immunomagnetic bead selections 
from PBCA of patients S and T showed 0.1% CD34+, BB4+ cells but no CD34-, BB4+ PC. Using 
FACS we sorted 105 CD34+, BB4+ and 105 CD34+, BB4- cells. Purity of flow sorted CD34+ 
peripheral blood progenitors was higher than 99,9% (fig 6d). ASO-PCR could not detect tumour cells 
in either of these fractions (fig 3,5a). Consequently malignant cells with a CD34+ progenitor 
phenotype were not detectable in PBCA of 3 patients and residual tumour cells detected in CD34 
selections were due to contaminating CD34 negative myeloma cells.
DISCUSSION
In this study we showed that residual tumour cells in CD34 selections of myeloma autografts are 
due to impurity. We used tumour specific PCR, capable of detecting one malignant cell in a 
background of 105 normal white blood cells. In accordance with other studies (Mariette '94; Bird '94) 
we found between 0.07 and 0.17% malignant cells in PBCA. CD34 selection using immunomagnetic 
beads resulted in an approximately 2 log depletion of malignant cells in myeloma PBCA of 3 patients. 
Even when highly contaminated BM (22% PC) was used for CD34 selection, a 1.4 log reduction in 
tumour cells was achieved. Assuming that most tumour cells do not express the CD34 marker, a 2 log 
reduction in malignant cells is in agreement with the 2 log increase of CD34+ cells achieved by CD34 
selection. An additional advantage of autologous CD34+ transplants over total peripheral blood cell 
transplants is that fewer cells are needed, resulting in a 2.7-4.5 log reduction of malignant cells in 
clinical trials (Schiller '95).
Since the CD34 selection was not 100% pure we reasoned that positive ASO-PCR signals might 
result from contamination with CD34 negative cells. Starting with BM heavily infiltrated with plasma 
cells we showed that contaminating malignant plasma cells were the major cause of impurity in CD34 
immunomagnetic beads selections. In those cases the purging of BB4+ PC in combination with CD34
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selection using immunomagnetic beads should provide further tumour cell reduction. A 
contamination-phenomenon was also reported by Vescio ('94). They found positive ASO-PCR 
signals when CD34 cells were collected from BM with one round o f selection using a 
immunoadsorption column, whereas a second round of CD34 selection with FACS resulted in a 
negative ASO-PCR. Others have suggested that residual tumour cells in selections of CD34+ cells are 
malignant CD34+ progenitors (Takishita '94; Belch '94; Bersagel '94). Since no PCR data of 
preselected material are shown it cannot be excluded that the positive ASO-PCR signals Takashita et 
al. ('94) report after having selected CD34 or CD20 cells from PB of myeloma patients with FACS 
arise from contamination. To prove that positive ASO-PCR signals in CD34 selections arise from 
contamination with CD34 negative tumour cells not from malignant CD34+ progenitors we performed 
a second round of CD34 selection with FACS resulting in > 99.9% pure CD34+ cells. We found a 
clearcut reduction of malignant cells with ASO-PCR when we compared 105 CD34 immunomagnetic 
bead selected cells with 105 highly purified CD34+ cells (isolated with 2 rounds of CD34 selection) in 
patients S and T. In 105 highly purified CD34+ cells from PBCA we were not able to detect malignant 
cells with ASO-PCR. These experiments show that ASO-PCR signals in CD34 selections arise from 
contamination with CD34 negative tumour cells.
Our results argue against the presence of malignant CD34+ precursors. One could reason however 
that malignant CD34+ stem cells that have yet to undergo Ig gene rearrangement or malignant pre B 
cells that could still undergo Vh replacements and somatic hypermutation could exist and escape 
detection by ASO-PCR. If such precursor cells would exist, the plasma cell progeny should have an 
extremely diverse Ig gene sequence. However after sequencing multiple clones in each patient Bakkus 
et al. ('92) and Vescio et al. ('93) found no evidence of intraclonal diversity. They concluded there 
was no ongoing somatic hypermutation. In addition others found no evidence for ongoing Vh 
replacements (Takishita '94). Therefore the scenario of a malignant pre-B-lymphocyte or stem cell as a 
precursor for malignant plasma cells is unlikely. It has been suggested that a change in the 
predominant tumour clone may occasionally occur in multiple myeloma (Bird '94) resulting in tumour 
cells that are not detected by ASO-PCR. We detected the same monoclonal tumour population before 
and after peripheral blood cell transplantation without major additional clones appearing. We conclude 
that there was no clonal evolution in our patients and tumour cells are thus adequately quantified.
In summary residual tumour cells detected in CD34 selections are due to impurity. Removal of all 
tumour cells from the graft is not possible with CD34 selection protocols that are currently applied in 
clinical trials (Schiller '95). We and others (Vescio '94) however consistently achieved negative ASO- 
PCR signals with 2 rounds of CD34 selection, or a combination of counterflow elutriation, treatment
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with phenylalanine methylester and flow sorting of CD34+, Lin-, Thy+ stem cells (Gazitt '95). Since 
purity of CD34 selection seems the most essential parameter in obtaining tumour free autografts we 
are currently evaluating the purity of different CD34+ isolation methods and their applicability in the 
clinical setting of autologous transplantation.
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ABSTRACT
Bone marrow plasma cells constitute the bulk of malignant cells in multiple myeloma patients. B- 
lymphocytes having immunoglobulin heavy chain gene rearrangments identical to those of the 
malignant clone (clonally related B-lymphocytes) may function as malignant plasma cell precursors. 
We and others proposed the use of anti-idiotypic antibodies to isolate and study clonally related B- 
lymphocytes. This strategy failed up to now because anti-idiotypic antibodies raised by conventional 
hybridoma techniques proved to react frequently with epitopes shared by different idiotypes. Recently 
we succeeded to select specific single chain Fv antibodies from phage libraries. To select single chain 
Fv bearing phages specifically directed against the immunoglobulin idiotype expressed by myeloma 
tumor cells we panned a semisynthetic phage library against purified myeloma paraprotein Fab 
fragments. The selection was performed in the presence of soluble polyclonal immunoglobulin as a 
competitor. Three independent selections for three myeloma patients yielded 10-26 clones. Between 
two and seven of the selected clones were reactive with patient Fab and not with polyclonal 
immunoglobulin in enzyme linked immunosorbent assays. Five out of six anti-idiotypic single chain 
Fv's were able to specifically stain fixed monoclonal plasma cells in myeloma bone marrow. Idiotype 
specificity of these single chain Fv's was confirmed by flow cytometry since they did not react with 
monoclonal plasma cells of other patients, a panel of 9 myeloma cell lines, isolated polyclonal bone 
marrow plasma cells and cultured B-lymphocytes. Using these anti-idiotypic reagents we were able to 
detect 25 myeloma plasma cells in a background of 50.000 immunoglobulin-isotype matched cells of 
the myeloma cell line UM-1 or 50.000 donor bone marrow cells (sensitivity 0.05%). This paper 
shows that highly specific anti-idiotypic single chain Fv antibody fragments selected from a phage 
display library can be used to detect rare idiotypic cells in patient samples.
INTRODUCTION
In myeloma patients the predominant cell type of the malignant clone is the bone marrow plasma 
cell. Recently B-lymphocytes with immunoglobulin heavy chain gene rearrangments identical to those 
of the malignant plasma cells (clonally related B-lymphocytes) have been detected with sensitive PCR 
techniques. It was suggested that these cells may be precursors of malignant plasma cells (Billadeau 
'93; Bakkus '94; Corradini '95; Willems '96). The immunophenotype of clonally related B- 
lymphocytes is still obscure and this obstructs their isolation and studies concerning their role in 
myeloma.
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Immunoglobulin molecules are composed of heavy and light chains, that in combination form the 
unique antigen-recognition structure or idiotype. The use of anti-idiotypic antibodies (anti-Ids) that 
specifically detect membrane idiotype expressing B cells is an appealing strategy to isolate clonally 
related B-lymphocytes. Unfortunately monoclonal anti-Ids raised by conventional hybridoma 
techniques frequently cross-react with other idiotypes (Kubagawa '79; Stevenson '86; Kiyotaki '87; 
Miller '89; Kampe '94).
Recently new techniques to obtain immunological reagents have been developed that bypass 
laborious hybridoma techniques and immunization. The human B cell pool was mimicked by 
harvesting V gene repertoires from human lymphocytes and cloning them into a vector encoding the 
major coat protein (glIIp) from filamentous M13 phages. Phages constructed with immunoglobulin- 
glIIp fusion proteins display the immunoglobulin like domains on their coat (Winter '94). Phage 
libraries displaying up to 1012  different single chain antibody fragments (scFv) on their coats are used 
for in vitro selection of phages reactive with antigens (Waterhouse '93; Griffiths '94; Nissem '94; 
Winter '94; de Kruif '95; de Wildt '96). This paper shows the feasibility of selecting anti-idiotypic 
scFv bearing phages with high specificity and sensitivity for the monoclonal immunoglobulin 
produced by myeloma plasma cells.
MATERIALS AND METHODS
Myeloma cell lines and patient material
Myeloma cell lines IM-9, ARH-77, RPMI 8226, U-266, MC-CAR, HS-Sultan (American Type 
Culture Collection, Rockville, MD), Fravel, UM-1, OPM-1 (gifts of Dr W. Vooijs, AZU, Utrecht, 
The Netherlands) were cultured in RPMI 1640 (GIBCO, Paisley, Scotland) supplemented with 2 mM 
L-glutamine, 100 U/ml penicillin, 100 ^g/ml streptomycin (Flow Laboratories, Irvine, U.K.) and 
10% heat inactivated FCS (GIBCO) in a fully humidified 5% CO2  atmosphere at 37°C. The bone 
marrow (BM) mononuclear fraction of 3 newly diagnosed myeloma patients with stage 3 disease was 
isolated by Ficoll Hypaque density centrifugation and cryopreserved at -196°C.
Purification o f  donor polyclonal plasma cells or peripheral blood B-lymphocytes
Plasma cells were isolated from donor BM (obtained after informed consent). Interphase cells were 
collected from Ficoll Hypaque density gradients and resuspended in PBS (4.108 cells/ml) and 
incubated with 1/10 volume of B-B4 Ab (IQP, Groningen, The Netherlands) at 4°C for 30 minutes.
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Cells were then washed and incubated (1.108 cells/ml) with goat-anti-mouse immunomagnetic beads 
(Dynal, Oslo, Norway) at a 1:2 bead to cell ratio. After 30 minutes incubation at 4°C cells were 
selected by magnetic separation and concentrated in 150 ^l of PBS. Detachment of beads and B-B4 
Ab was performed using CD19 Detach-a-Bead (Dynal), a polyclonal anti-Fab serum according to the 
manufacturer's protocol. The detached cells were washed and labelled with B-B4-phycoerythrin (IQP) 
and CD38-FITC (Caltag, San Francisco, CA). As a control cells were labelled with IgG1-FITC/IgG1- 
PE. Flow cytometric analysis and cell sorting was performed with an Epics Elite flow cytometer 
(Coulter Cooperation, Hialeah, Fl), equipped with a 15 mW argon laser. CD38, B-B4 double positive 
cells were sorted and flow cytometrically re-analyzed to assess the purity. 5000 sorted cells were 
cytocentrifuged and staining with May-Grunwald-Giemsa confirmed plasma cell morphology.
Isolation of B-lymphocytes was essentially identical to the plasma cell isolations. CD19+ cells were 
isolated from donor buffy coat mononuclear fractions using 'M450' beads directly coated with 
'CD19' antibody (Dynal) added in a 1:2 bead to cell ratio. Flow cytometry (FCM) of selected cells 
incubated with CD19-PE (DAKOPATTS, Glostrup, Denmark) revealed >95% purity.
In vitro culturing ofperipheral blood B-lymphocytes
Ltk mouse fibroblast cells transfected with the human FcyII receptor (CD32L cells, obtained from 
the American Type Culture System) were cultured in RPMI 1640 supplemented with 5% FCS and 2% 
HAT. After irradiation (70 Gy) CD32L cells were seeded 2.105 per well in 24 wells flat bottom 
culture plates (Costar, Cambridge, MA) and incubated overnight in a fully humidified 5% CO2 
atmosphere at 37°C. B cells were resuspended in culture medium consisting of IMDM (Gibco, Grand 
Island, NY) supplemented with 5% heat inactivated FCS, 50 |lg/ml human transferrin (Behringwerke, 
Mannheim, Germany), 5 ^g/ml bovine insulin (Sigma chemical, St Louis, MO), 0.5% human serum 
albumin (CLB, Amsterdam, The Netherlands), 0.01 mM beta-mercapto-ethanol (Sigma) and human 
recombinant IL-4 (a gift from Dr J. Banchereau, Schering Plough, Dardilly, France) at a final 
concentration of 50 ng/ml. 75.104 B-lymphocytes in 1 ml culture medium were seeded upon the 
CD32L cells. Anti-CD40 MoAb 89 (a gift from Dr J. Banchereau) was added at a final concentration 
of 0.5 ^g/ml. Cells were collected and cryopreserved after a 4 day culture period.
Expression o f  IgH and IgL chains
Patient plasma cells, myeloma cell lines, donor plasma cells, donor B cells and cultured donor B 
cells were assayed for Ig expression using FCM. For cytoplasmic expression cells were fixed with 
Ortho permeafix (Ortho Diagnostic Systems, Raritan, NJ) for 45 minutes at room temperature and 
then incubated with anti kappa, anti lambda, anti IgM, anti IgG and anti IgA F(ab')2 FITC polyclonal
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Ab (Kallestadt, Amiter, TA) at 4°C for 30 minutes. For surface expression cells were directly 
incubated with the FITC labelled Ab.
Preparation and isolation o f  paraprotein Fab and polyclonal donor Ig
Ig was isolated from five ml patient serum (IgG concentration 18-62 mg/ml) or 50 ml donor serum 
using separate equilibrated immobilized protein G (Pierce, Rockford, IL) columns and paraprotein 
Fab's were prepared using the Fab preparation kit (immobilized papain) according to the 
manufacturer's (Pierce) protocol. Undigested Ig and Fc fragments were removed by affinity 
chromatography with protein A-sepharose (Pierce). Immunoblotting with polyclonal rabbit antibodies 
against human IgG/A/M (DAKOPATTS) or polyclonal rabbit antibodies against human kappa or 
lambda light chains (DAKOPATTS) revealed less than 0.1% Fc or intact Ig contamination in the Fab 
preparations.
Phage libraries and selection procedures
For selection of anti-idiotypic reagents we used the 'single pot' Nissim phage library (13) 
containing over 108 clones expressing different single chain (V h -V ^ 3 ) Fv chains. This phage
repertoire was incubated for one hour at room temperature with 2 mg polyclonal donor Ig in 2ml 
incubation-volume. The total mixture was then panned for binders using maxisorp immunotubes 
(Nunc, Kamstrup, Denmark) coated with 10 ^g/ml patient Fab in PBS overnight at room temperature. 
The library was subjected to 4 rounds of this selection-procedure.
Screening o f selected clones
Ninety-five individual ampicillin-resistant colonies of E.coli TG-1 were analyzed for phagemid 
p resence  by PC R  using  pH EN SEQ : C TA TG C G G C C C C A TTC A  and L M B 3 : 
CAGGAAACAGCTATGAC primers. PCR products were digested with BstN1 to generate restriction 
patterns that are insert specific. These 96 colonies were grown and soluble scFv fragments were 
induced with 1mM isopropyl b-D-thiogalactoside (IPTG; Gibco) as described in Marks et al. ('91). 
The presence of soluble myc tagged scFv in culture medium was detected with a mouse anti-myc 
MoAb 9E10 (Munro '86) in a dot blot assay. The binding of soluble scFv to patient Fab's, polyclonal 
donor Ig or BSA coated in maxisorp plates (Nunc) was detected with 9E10 (Munro '86) MoAb in an 
ELISA procedure.
Purification o f  scFv
Phagemid was isolated from 5 ml cultures of bacteria expressing scFv. The scFv insert was 
released from the phagem id vector using Nco I and N ot I restriction  enzymes.
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pUC119Sfi/NotmycHis6 and pUC119Sfi/NotHis6vsv were digested with NcoI and NotI. Inserts 
were gel-purified and ligated into gel-purified digested vectors (G riffiths '94). The 
pUC119Sfi/NotmycHis6 and pUC119Sfi/NotHis6vsv clones encoding anti-Id and control scFv were 
grown in 0.5 litre cultures. Expression of scFv was induced with IPTG as described by De Bellis and 
Schwartz ('90). ScFv were purified from bacterial periplasmic fractions using immobilized metal 
chelate affinity chromatography (Hochuyli '88; Hoffmann '91). The purification of scFv was 
monitored using SDS-PAGE under nonreducing conditions and silver staining of separated proteins. 
Concentrations of purified scFv were determined by measuring absorption at 280nm in a 
spectrofotometer and comparison with molecular weight marker concentrations using SDS-PAGE.
FCM  with anti-Id scFv
Cryopreserved BM samples containing plasma cells were thawed and fixed for 45 minutes room 
temperature using Ortho permeafix (Ortho). ScFv in PBS or crude bacterial supernatant were added 
and the mixture was incubated for 30 min at 4°C. ScFv were detected through a 30 min incubation at 
4°C with 0.02 mg/ml anti-myc antibody (9E10) or 0.02 mg/ml anti-vsv antibody (clone P5D4; 
Boehringer, Mannheim, Germany). Bound scFv's were detected using 1:50 diluted goat-anti-mouse 
(Fab')2-FITC (American Qualex, San Clemente, CA) and FCM. Background fluorescence was 
measured using irrelevant scFv's and PBS.
RESULTS
Selection and characterization o f  anti-Id scFv directed against the M-protein idiotype
To obtain tumor clone specific reagents we first isolated and purified M-protein Fab fragments 
from 3 myeloma patients. These Fab fragments were coated in tubes. To select for specific anti- 
idiotypic single chain Fv bearing phages directed against the myeloma M-protein we panned the 
Nissim phage library (Nissem '94) against the coated M-protein Fab fragments in the presence of 
soluble polyclonal immunoglobulin as a competitor. After 4 rounds of this panning procedure we 
screened 95 individual (phage producing) bacterial clones using phagemid primers. We detected full 
length Vh -Vl  in 91-94 clones indicating that the majority of phages selected carried complete single 
chain Fv structures. BstN1 restriction enzyme digestion of the full length Vh -Vl  inserts (i.e. 
fingerprinting) revealed 10-26 clones differing in Vh  insert (table 1). The selected bacterial clones 
were induced to produce soluble scFv and dot blotting showed that all culture supernatants contained 
significant amounts of scFv (results not shown). We found that 2-7 different soluble scFv bound
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specifically to patient Fab preparations and not to polyclonal donor Ig in an ELISA (table 1). The 6 
clones (T3, T7, T13, T15, V19 and V22) that specifically reacted with Fab fragments of patient 1 or 2 
were further characterized.
Table 1: Number o f  selected phage clones and reactivity o f  monoclonal single chain Fv's with patient 
Fab or polyclonal Ig in ELISA per 96 clones tested. Anti-idiotypic clones are defined as reactive with 
patient Fab, not with polyclonal Ig  or control monoclonal Ig. The analysis o f  clones selected from the 
phage library and reactivity o f  these clones was done after 4 rounds o f  panning against patient Fab 
fragments.
number of phage clones selected
patient total reactive with reactive with anti-idiotypic
patient Fab polyclonal Ig
1 10 6 2 4
2 26 3 1 2
3 15 8 1 7
Detection ofpatient plasma cells using anti-Id scFv's
We tested the reactivity of the selected anti-Id scFv's with patient myelomatous plasma cells. Using 
fixed patient BM samples we were able to show that crude bacterial culture supernatants containing 
low amounts of soluble scFv specifically stained lambda positive plasma cells (results not shown). 
We tried to enhance specific staining intensity using higher scFv concentrations or detection tags with 
lower background staining. Therefore we subcloned the selected anti-Id and control scFv's in vectors 
encoding myc/his6 tags and his6/vsv tags. The his6 tags enable bulk purification of scFv from 
bacterial periplasmic fractions using Immobilized Metal chelate Affinity Chromatography (Hoffman 
'91). Figure 1 shows that scFv can be purified to over 99% purity from a complex mixture of bacterial 
periplasmic proteins with IMAC. We incubated BM of patient 1 and 2 with scFv (concentrations 
ranging from 0.07 ^g/ml to 35 ^g/ml). Maximal staining of myelomatous plasma cells with minimal 
background staining of other BM cells was found at approximately 0.8 ^g/ml for 5 out of 6 scFv. At 
the highest concentration tested (35 ^g/ml) incubation of patient bone marrow with anti-idiotypic scFv 
T15 or control scFv T1 showed no detectable staining of plasma cells over background (results not 
shown). Staining intensity of patient myelomatous plasma cells with anti-idiotypic scFv T3, T7, T13 
(for patient 1 bone marrow samples) and V19 and V22 (for patient 2 bone marrow samples) was 
comparable to commercially available polyclonal light chain antibodies (figure 2 , table 2 ).
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Figure 1: SDS-PAGE (4-12% gradient) analysis 
o f  single chain Fv's purified from  crude bacterial 
periplasm ic fractions using im mobilized metale 
chelate affinity chromatography. Proteins were 
silver stained and protein size (indicated on the 
left) and concentration was estim ated using  
molecular weight protein markers.
Comparison o f myc tag with viral stomatitis virus tag fo r  the detection o f  scFv binding
Since myc is an endogenous protein that is highly expressed in myeloma plasma cells using part of 
the myc protein as a scFv tag might result in high background staining of cells. We compared the 
detection of scFv binding and background staining of fixed patient bone marrows using anti-myc tag 
antibodies (for T1-, T7- and V19-myc/his6) and anti viral stomatitis virus (vsv) tag antibodies (for T1- 
, T7- and V19-his6/vsv). Vsv and myc anti-idiotypic scFv showed comparable binding to patient Fab 
in ELISA (results not shown). Although overall background reactivity as determined with irrelevant 
control scFv T1 was higher with myc-tagged scFv, discrimination of plasma cells in patient bone 
marrow samples was not improved using vsv-tagged scFv (figure 3).
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Figure 2: Flow-cytometric detection o f  plasm a cells in myeloma bone marrow using anti-idiotypic 
single chain Fv's directed against patient M-proteins. Bone marrow ofpatient 1T (a-c; e-g) containing 
approximately 37% plasm a cells was fix ed  (Ortho) and stained with anti-kappa-FITC (a) or anti- 
lambda-FITC (e). Anti-idiotypic single chain Fv's binding to M-protein Fab fragments o f  patient 1T  
(T3, T7) reacted with patient 1 plasm a cells (f,g) not with patient 2 plasm a cells (h). ScFv's binding to 
M-protein Fab fragments ofpatient 2V  (V19) reacted with patient 2 plasma cells (d) not with patient 1 
plasm a cells (c). For determination o f  background reactivity bone marrow was incubated with PBS 
(not shown) or irrelevant control scFv (b). ScFv binding was detected with anti-myc antibodies 9E10 
and goat-anti-mouse FITC.
Specificity o f  anti-idiotypic scFv's
We tested the anti-Id scFv that showed strong reactivity with patient myelomatous plasma cells for 
cross-reactivity with other Ig idiotypes. Figure 2 and table 2 show that scFv (T3, T7 and T13) 
selected for binding to Fab fragments from serum of patient 1 and reactive with myelomatous plasma 
cells of patient 1 did not cross react with myelomatous plasma cells of patient 2 and scFv (V19 and 
V22) selected for binding to Fab fragments isolated from serum of patient 2 reacted with myelomatous 
plasma cells of patient 2  not with myelomatous plasma cells of patient 1 although the myelomatous 
plasma cells of both patients expressed identical Ig isotypes and comparable Ig levels. Binding of the
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anti-Id scFv with myeloma cell lines was comparable to background binding of control scFv's (T1), 
although 6 out of 9 cell lines expressed both IgH- and IgL-chains and Ig levels of 2 of those cell lines 
were comparable with Ig levels in patient myelomatous plasma cells (table 2).
OUePLAY:SINGLE PARArMTCA
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Figure 3: Comparison o f viral stomatitis virus and myc tagged anti-idiotypic scFv (T7) in the detection 
o f  myeloma plasm a cells. Fixed bone marrow cells o f  patient 1 were stained with anti-idiotypic scFv 
T7 using either anti-myc antibodies 9E10 fo r  T7myc/his (solid line) or anti-vsv antibodies P5D 4 fo r  
V7his/vsv (dotted line) to detect the binding o f  scFv. Labeling o f  scFv tagged cells with goat-anti- 
mouse FITC and FCM  allows the detection offluorescent plasma cells (indicated with an arrow).
As a control we tested the reactivity of the anti-Id scFv with polyclonal donor plasma cells and 
polyclonal cultured donor B-lymphocytes. Polyclonal plasma cells were selected from donor BM 
containing 0.5% plasma cells (figure 4a). We enriched for normal plasma cells using a mouse MoAb 
B-B4 (reactive with syndecan 1), specifically recognizing plasma cells among hematopoietic cells 
(Wijdenes '96). B-B4 labelled cells were selected with goat-anti-mouse magnetic beads (figure 4c). 
As a second purification step we flow sorted cells with high expression of CD38 and B-B4 from the 
B-B4 enriched fraction resulting in a 98% pure plasma cell fraction (figure 4d) confirmed by 
morphological evaluation of cytospin preparations. The majority of these plasma cells were of IgG
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Table 2: Staining o f  myeloma cell lines, myeloma bone marrow samples, donor plasm a cells, donor B 
lymphocytes and cultured B lymphocytes with anti-idiotypic scFv's and anti-heavy and light chain 
polyclonal F(ab)'s. Cells were fixed  (Ortho) and stained with FITC coupled anti heavy or light chain 
polyclonal F(ab)'s or incubated with purified scFv's. M aximal background fluorescence (10) was 
defined as the maximum fluorescence o f  non plasm a cells in patien t samples incubated with anti- 
idiotypic scFv. As a control cells were incubated with PBS (no scFv) or irrelevant control scFv (T1). 
Binding is given as mean fluorescence and the percentage ofpositive cells is given in brackets.
kappa lambda IgG IgM IgA no scFv T1 T3 T7 T13 T15 V19 V22
Fravel 5.2 0.3 8 90 7 1.0 (0.2) 1.0 (0.3) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1)
ARH77 9 0.2 23 3 5 0.6 (0.05) 0.8 (0.05) 0.8 (0.07) 0.6 (0.01) 0.7 (0.07) 0.5 (0.07) 0.5 (0.07) 0.7 (0.07)
IM9 6.1 0.2 13 2 4 0.7 (0.05) 0.9 (0.1) 0.9 (0.1) 0.9 (0.07) 0.7 (0.05) 0.8 (0.05) 0.8 (0.06) 0.7 (0.1)
UM1 41 0.8 120 10 10 3.8 (0.2) 4.0 (0.2) 3.8 (0.1) 3.6 (0.05) 3.8 (0.1) 3.8 (0.2) 3.7 (0.05) 3.8 (0.05)
U266 1.7 8 9 10 10 1.6 (0.4) 1.7 (0.6) 1.7 (0.4) 1.7 (0.4) 1.7 (0.4) 1.7 (0.4) 1.7 (0.4) 1.7 (0.4)
RPMI8226 0.7 7.5 9 7 9 5.0 (1.8) 5.6 (4.4) 5.6 (3.3) 5.5 (3.3) 5.9 (6.1) 5.6 (4.8) 5.5 (3.0) 5.7 (3.3)
HS-Sultan 2.3 0.2 26 4 3 1.0 (0.2) 1.8 (0.3) 1.2 (0.2) 1.2 (0.2) 1.3 (0.1) 1.4 (0.2) 1.5 (0.2) 1.5 (0.2)
MC-CAR 0.9 3 11 3 4 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.6 (0.2) 0.7 (0.3) 0.7 (0.2) 0.7 (0.3) 0.7 (0.2)
OPM1 2 11 10 6 10 1.8 (0.4) 2.3 (0.5) 2.0 (0.6) 1.9 (0.2) 2.3 (1.0) 2.2 (0.6) 1.9 (0.3) 2.2 (0.5)
patient 1 plasma cells (35-39%) 10 250 270 10 20 3 (0.05) 3 (0.02) 65 (39) 59 (39) 50 (35) 3 (0.02) 3 (0.02) 3 (0.02)
patient 2 plasma cells (14-19%) 20 0.4 44 1 4 3 (1.0) 4 (1.5) 1.6 (0.0) 1.6 (0.0) 0.7 (0.2) 3 (0.0) 41 (19) 39 (14)
patient 1 non plasma cells 4 10 15 3 4 1 0.8 1 1 1 0.7 0.8 0.
patient 2 non plasma cells 0.3 0.3 1 0.5 3 0.5 0.5 0.3 0.4 0.5 0.6 0.5 0.
donor plasm a cells 48 (40) 54 (56) 190 (54) 410 (5) 44 (44) 1 (0.1) 1 (0.2) 1 (0.2) 1 (0.1) 1 (0.2) 1 (0.2) 1 (0.1) 1 (0.1)
donor B lymphocytes 4 (34) 5 (55) 20 (1.0) 27 (70) 20 (0.5)
CD40 cultured donor B lymphocytes 4.7 (30) 3.6 (59) 8 (22) 10 (31) 17 (10) 1 (0.3) 1 (0.5) 1 (0.3) 1 (0.2) 1 (0.1) 1 (0.1) 1 (0.1) 1 (0.1)
(54%) or IgA (44%) isotype (figure 5d, table 2). Immunomagnetic beads were used to isolate CD19 
expressing B-lymphocytes from peripheral blood of donors. Culturing of these B-lymphocytes with 
CD32L cells in the presence of anti CD40 and IL4 induced proliferation and an isotype switch towards 
IgG (22%) and IgA (10%) expressing B-cells (table 2). KA ratio's of both plasma cells and cultured 
B-lymphocytes (table 2) suggested polyclonality. We amplified the hypervariable region of the Ig 
heavy chain gene rearrangements by CDR3-PCR and subsequent analysis by denaturing PAGE 
proved polyclonality of the isolated donor plasma cells and cultured B-lymphocytes (results not 
shown). Reactivity of polyclonal plasma cells and polyclonal cultured B cells with anti-idiotypic scFv 
was comparable with the background reactivity of cells with irrelevant control scFv's (figure 5, table 
2). These experiments prove the anti-idiotypic nature of our selected scFv's.
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Figure 4: Flow cytometric analysis o f  donor bone marrow fractions enriched fo r  plasm a cells. Cells 
were stained with CD38-FITC and B-B4-PE to identify plasm a cells (double positives) in donor bone 
marrow mononuclear cells (a), donor bone marrow depleted fo r  B-B4 positive cells (b) and donor 
bone marrow fractions enriched fo r  plasm a cells using B-B4 and goat-anti-mouse magnetic beads (c). 
The plasm a cell enriched fraction (c) was further purified by flow  sorting o f  CD38, B-B4 double 
positive cells and the sorted fraction was re-analysed on the flow  cytometer (d).
® b c d
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Figure 5: Reactivity o f  anti-idiotypic scFv with polyclonal donor plasm a cells. Donor plasm a cells 
were fixed  (Ortho) and incubated with FITC coupled anti-IgG polyclonal F(ab)'s (d) or incubated  
with pu rified  anti-idiotypic (b,c) or control (a) scFv's. Quadrants indicate the background  
fluorescence defined as the maximum fluorescence o f  non plasm a cells in patien t samples incubated 
with anti-idiotypic scFv.
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Sensitivity o f  anti-idiotypic scFv's
To test if  anti-Id scFv can be used to detect low percentages of clonal tumor cells in a background 
of normal cells we diluted patient 2 BM containing 30% of myelomatous plasma cells in normal donor 
BM or in the myeloma cell line UM1 expressing high levels of IgG kappa. Figure 6 shows that we 
were able to detect 0.05% clonotypic plasma cells in a background of other bone marrow cells (6a) or 
UM1 (6b) using flow-cytometry.
Figure 6 : Sensitivity o f  plasm a cell detection using an anti-idiotypic scFv (V19). Bone marrow o f  
patient 2V  containing 30% plasma cells (ab1) was diluted in donor bone marrow (a6)  or myeloma cell 
line UM1 (b6). The dilutions were fixed  (Ortho) and incubated with anti-idiotypic scFv V19. ScFv 
binding was detected with anti-myc antibodies 9E10 and goat-anti-mouse FITC and analysed using 
flow-cytom etry.
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DISCUSSION
Anti-idiotypic antibodies that discriminate immunoglobulin idiotype expressing B cells from normal 
cells can be used to purge malignant B cells from autologous grafts and to treat B-lymphoma patients 
(Brown '80; Meeker '85; Brown '89; White '96). Low specificity of 'anti-idiotypic' antibodies 
developed by immunizing rabbits or mice with antigen hampers their use in the study and eradication 
of idiotype positive B cells in B-cell malignancies. In a large scale study Kiyotaki et al. ('87) showed 
that 36 out of 39 conventional anti-Id Ab reacted with more than 0.1% of plasma cells isolated from 
tonsils of healthy persons. In this study we selected single chain Fv bearing phages specifically 
directed against the M-protein idiotype of myeloma patients from a 'single pot' phage display library. 
To obtain reagents capable of specific detection of malignant cells we panned the phage library against 
purified myeloma M-protein Fab fragments in the presence of soluble polyclonal immunoglobulin as a 
competitor. Competitive selection procedures have been used successfully for selection of phages 
capable of discriminating between two highly homologous homeobox proteins (de Kruyf '95b). The 
isolation of phages reactive with a defined difference between two otherwise identical protein mixtures 
(Stausbol-Gron '96) illustrates the potential of these competitive selection procedures. We selected 2-7 
anti-Id single chain Fv bearing phage clones per selection. Using flow cytometry we have found that 5 
out of 6 soluble anti-Id scFv specifically stained myelomatous plasma cells of one patient, not with the 
plasma cells of other myeloma patients, nor with myeloma cell lines expressing high levels of isotype 
matched Ig. ScFv's were incubated with donor plasma cells and cultured B-lymphocytes to assess the 
scFv reactivity with cell populations containing multiple idiotypes. We showed with PCR analysis that 
these populations were polyclonal for one of the regions (CDR3) encoding the immunoglobulin 
idiotype. Anti-idiotypic scFv stained <0.3% of the cells and staining was always less than with 
control scFv, proving the anti-idiotypic nature of the selected scFv reagents.
In dilution experiments we were able to detect 0.05% of patient plasma cells in a background of 
donor BM cells or UM1 cells expressing high levels of immunoglobulin. The detection limit of this 
technique is dependent on the background reactivity with irrelevant scFv. In our experiments the 
background reactivity was generally between 0.5 and 0.01%. Lowering background reactivity might 
permit a more sensitive detection of myelomatous plasma cells. In initial experiments scFv were 
tagged with small stretches of the c-myc protein (Nissem '94: de Wildt '96) enabling their detection. 
Since expression of endogenous c-myc protein resulted in high background staining and obscured the 
detection of intracellular myc-tagged scFv we reasoned that using a viral tag might enable a more 
sensitive detection of scFv. Therefore we subcloned our reactive anti-Id scFv in vectors with viral 
stomatitis virus (vsv) tags (Kreis '86; Soldati '91). Although overall background reactivity of vsv-
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tagged scFv was lower than myc-tagged scFv, discrimination of plasma cells in patient bone marrow 
samples was not improved using vsv-tagged scFv. This might be caused by variations in endogenous 
c-myc levels in hematopoietic subpopulations. High levels of c-myc protein and mRNA have been 
detected in activated malignant plasma cells (Nobuyoshi '91; Paulin '96) and might aid in the 
discrimination between myc-scFv positive plasma cells and myc-scFv negative non plasma cells. Our 
observation that plasma cells have more background myc fluorescence (determined in controls without 
scFv) than other BM cells supports this hypothesis. Current efforts to lower background activity are 
concentrated on the construction and use of directly labelled scFv.
To study the role of clonally related B-lymphocytes in the pathogenesis of multiple myeloma their 
isolation is imperative. PCR assays using allele specific oligonucleotides (ASO) complementary to the 
unique IgH CDRIII sequence of the malignant clone are currently the most sensitive and specific 
assays for detection of malignant B- or plasma cells. Therefore ASO-PCRs that are capable of 
detecting one malignant or clonally related cell in a background of 100.000 other cells have been used 
to evaluate minimal residual disease (Bakkus '92; Corradini '93b). Recently Cao et al. ('95) and 
Brown et al. ('95) showed that malignant plasma cells can be identified with in situ hybridization 
using fluorescent or enzyme labelled ASO-probes reactive with the IgH CDRIII region. Since fixation 
is a prerequisite for these techniques none of them allows the functional study of clonally related B 
cells. This study shows that anti-Id scFv can be used to detect one idiotype expressing plasma cell in a 
background of two thousand normal cells. The challenge ahead is the isolation of viable clonally 
related B-cells using these anti-Ids.
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Chapter
Oncogenic Events in Multiple Myeloma
'de tijd heelt alle wonden, maar slaat er nog veel meer'
H. Dorrestijn
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7.1 Oncogenic events resulting in the clinical manifestation o f  multiple myeloma
Specific DNA damage can cause deregulation of cells with the risk of tumor formation. To avoid 
the accumulation of DNA damage most normal cells have a limited life span. In healthy individuals 
dying cells are generally replaced by new ones to maintain cell numbers at a constant level. Essential 
processes in this basic scheme are cell death, proliferation and differentiation of cells. Abnormalities 
enhancing the proliferative capacity of cells, preventing differentiation, abnormalities preventing cell 
death and resulting in DNA or chromosomal abnormalities cooperate allowing the abnormal 
accumulation of clonal cells and the development of tumors.
7.2 Gross structural and numerical DNA abnormalities associated with multiple myeloma: clues fo r  
oncogenic events
Using conventional cytogenetic analysis karyotypic abnormalities are found in 30 to 50% of 
myeloma patients. Karyotypic abnormalities were found in 20% of stage 1 patients, 60% in stage 3 
patients and over 80% of patients with extramedullary tumors. The extent of the mutations increased 
with progressive stages of myeloma (Dewald '85; Gould '88; Jonveaux '92; Weh '93; Zandecki '94; 
Lai '95; Sawyer '95; Taniwaki '95; Taberno '96). Karyotypic analysis depends on obtaining reliable 
metaphases. Metaphase availability is poor with stage 1 patients having tumor cells with poor 
proliferative capacities. The correlation between frequency of karyotypic abnormalities and disease 
stage is therefore (at least in part) due to a difference in proliferative capacity of the plasma cells at 
different disease stages. That karyotypic analysis underestimates the true frequency of DNA 
alterations was proven by the detection of aneuploidia in 82% of myeloma patients using flow- 
cytometry and the detection of chromosome abnormalities in 89 to 96% of myeloma patients using 
interphase fluorescence in situ hybridization (Drach '95; Flactif '95). Although karyotypic data are 
unavailable for MGUS cases, aneuploidia was detected in 43 to 53% of patients using FISH or image 
analysis (Drach '95; Zandecki '95). Despite the limited availability of karyotypic data for MGUS, it 
appears that processes leading to karyotypic instability begin in MGUS, are accelerated in MM and 
continue to progress throughout the entire course of MM (figl).
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1: Classical Cytogenetics 2: Flow Cytometric 3: Flow Cytometric and 4: Interphase FISH
DNA Content Classical Cytogenetics
Figure 1: Frequency o f  myeloma patients with DNA abnormalities
The characteristic numerical abnormalities in multiple myeloma are monosomy 13 and trisomies of 
chromosome 3, 5, 7, 9, 11, 15 and 19. Nonrandom structural abnormalities most frequently involve 
deletions of chromosome 1 (especially del 1p11-q11 and del 1p32-p36) and 13q14 interstitial deletion 
(15% cases). Chromosomal translocations are characteristic oncogenic structural alterations associated 
with haematological malignancies (Korsmeyer '92). In myeloma the IgH locus on chromosome 14q32 
(20-40% cases), the bcl1 locus on chromosome 11q13 (up to 20% cases) and the c-myc locus on 
8q24 (up to 10% cases) are most frequently involved in translocations (Dewald '85; Gould '88; 
Jonveaux '92; Weh '93; Zandecki '94; Lai '95; Sawyer '95; Taniwaki '95; Taberno '96). The most 
common genetic event in MM (20-40% of patients with an abnormal karyotype) seems to be a 
translocation involving the IgH locus (14q32.3) or one of the IgL loci (2p12 for k  or 22q11 for X) as 
it is for many B-lymphocyte derived tumors (Potter '92; Korsmeyer '92; Williams '93; Ye '95; 
Bergsagel '96). In 25% of IgH translocations the partner chromosomal locus is 11q13 (bcl1). Other 
infrequent partner chromosomal loci are 8q24 (c-myc), 11q23 (mll1) and 18q21 (bcl2).
7.3 Oncogenic hits associated with specific myeloma stages
7.3.1 Translocations involving the Immunoglobulin Heavy Chain (14q32)
Recently Bergsagel ('96) used a comprehensive Southern blot assay and detected translocations 
involving the IgH locus (switch region) in 19 of 21 myeloma cell lines and one of one primary tumor. 
In 4 of these cell lines the translocation was also detectable in primary tumor material indicating that 
the translocations were not an artifact of cell culture. In approximately half of the cell lines 
conventional karyotyping was not able to detect the translocations. Although IgH translocations have 
not been detected with Southern blot assays in MGUS and inactive myeloma, 14q32 structural 
abnormalities have. Recent southern blot studies show that translocations involving the IgH or IgL 
loci are a near universal event in MM (75% of MM patients and 90% of human myeloma cell lines)
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despite karyotypic data, suggesting that this abnormality is a key step in MM ontogeny (Bergsagel 
'97). In a study of 82 myeloma patients at diagnoses IgH translocations were detected with interphase 
fluorescense in situ hybridyzation in 52 patients (Avet-Loiseau '98). The translocation breakpoints are 
usually localized in the IgH switch regions (Bergsagel '96; 97). Since isotype switching involves the 
recombination of IgH switch regions it is logical to assume that IgH switch translocations are the 
result of illegitimate recombinations occurring in a B cell stage where the switching machinery is 
active. The partner chromosomal loci that were found most often were 11q13 (25% of cases), 4p16.3 
(25% of cases) and 16q23 (25% of cases) with dysregulation of the oncogenes bcl-1 (Bergsagel '96; 
Avet-Loiseau '98), fibroblast growth factor receptor 3 (Chesi '97; Avet Loiseau '98) and the basic 
zipper encoding c-maf (Chesi '98) respectively. Other infrequent translocation breakpoints found 
(Hallek '98) were in 1p13, 1q21, 3p11, 6p25, 7q11, 8q24, 12q24 and 21q22.
The t(11;14) is detected in most patients suffering from mantle cell lymphoma. In these patients 
breakpoints on 11q13 are clustered in a major translocation cluster (MTC) and breakpoints in the IgH 
locus are clustered in the JH region (Williams '93). With the t(11;14) found in myeloma breakpoints 
on 11q13 seldom involve the MTC (Williams '91; Ladanyi ' 92; Fiedler '92; Raynoud '93; Meeus 
'95) and breakpoints in the IgH locus are clustered in the switch regions (Bergsagel '96; Chesi '96). 
Unlike other genes identified in the 11q13 region, there is a close association between t(11;14) and 
enhanced expression of cyclin D1 (Seto '92; Akiyama '94). In 21 myeloma cell lines there was a 
100% correlation between the presence of t(11;14) and the overexpression of cylin D1 protein. 
(Bergsagel '96; Chesi '96). The presence o f t(1 1; 14) in myeloma is associated with an 
undifferentiated lymphoplasmacytic morphology of myeloma cells and myeloma patients with t(11;14) 
tend to develope more agressive disease and have a poorer prognosis (Weh '95; Tricot '95; Chesi 
'97). Cyclin D1 associated with CDK4, phosphorylates and inactivates pRb and thus triggers the 
progression through the G1 phase of the cell cycle (Motokura '93). Constitutive overexpression of 
cyclin D1 in myeloma therefore promotes entry of cells in cell cycle and inhibits differentiation 
resulting in an increased tumor growth fraction.
Recently the fibroblast growth factor receptor 3 (fgfr3) gene at 4p16.3 was found dysregulated by 
t(4;14)(p16;q32) in 5 of 21 myeloma cell lines and 3 of 11 (Chesi '97) and 9 of 45 primary tumors 
(Avet-Loiseau '98). Only cell lines or primary tumors with t(4;14) show a high expression of fgfr3. 
In addition cells with t(4;14) frequently (3 of 6 cell lines; 1 of 3 primary samples) show fgfr3 
mutations with an activating effect. Germline mutations in fgfr3 result in distinct dwarfing conditions 
(Shiang '94; Rousseau '94; Tavormina '95; Meyers '95) and activating mutations of the fgfr3 have 
also been found in severe dwarfism (Naski '96; Rousseau '96). The FGFR3 is involved in signal
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transduction upon FGF binding. It is postulated that the t(4;14) results in constitutive FGFR3 
expression. In combination with FGF produced by stromal cells in the bone marrow there probably is 
a continuous signal inhibiting differentiation and apoptosis and stimulating the growth of myeloma 
cells (Hallek '98).
Recently it was shown that the t(4;14) translocation breakpoints cluster directly telomeric to and 
within the 5' introns of a gene called mmset or whsc1 (Stec '98) resulting in hybrid IgH/mmset 
transcripts (Chesi '98b). A hemizygous deletion of whsc1 has been associated with the development 
of the Wolf-Hirschhorn malformation syndrome. In addition mmset is homologous with the mll1 gene 
that is translocated in acute leukemia. It is therefore likely that dysregulation of mmset also contributes 
to neoplastic formation in multiple myeloma.
The t(6;14) breakpoint cloned from myeloma cell line SK-MM1 mapped at 6p25 near irf4, a 
member of the interferon regulatory factor (IRF) family of transcription factors (Iida '96). The level of 
irf4 mRNA in SK-MM1 was significantly overexpressed as compared to the basal level of 10 other 
myeloma cell lines, suggesting that juxtapositioning of irf4 near IgH regulatory elements may have 
deregulated expression (Iida '96). Irf is a lymphoid specific gene that is rapidly induced by T an B cell 
recep tor cross-link ing  (G rossm an '96). M ice defic ien t in IRF4 have profound 
hypogammaglobulinemia and cannot mount detectable antibody responses indicating a critical role for 
IRF4 in normal plasma cell development and differentiation (Mittrucker '97). It is therefore postulated 
that IRF4 overexpression results in an inhibition of differentiation.
In BALB/c plasmacytomas and rat immunocytomas activation of c-myc by chromosome 
translocation into a switch region of the IgH locus (or by variant translocation to one of the IgL loci) is 
a universal event (Bazin '88; Potter '92; ,Muller '95). Recently t(8;14) was detected in 5 out of 9 
human cell lines using double colour FISH (Taniwaki '98). In primary human MM t(8;14) seems to 
occur in less than 5% of cases and variant translocations are rare. Rearrangments involving c-myc or 
the downstream MLVI-4 locus have been detected more frequently in MM patients using southern 
blotting (Selvanayagam '88; Palumbo '90; Bakkus '90; Ladanyi '92). Occasional DNA amplification 
of the c-myc locus has also been reported (Sumegi '85; Bakkus '90). Structural abnormalities near the 
c-myc locus were detected in 10-20% of MM patients overall. Increased expression of the c-MYC 
protein is detected frequently in MM cells (Brown '94) and cell lines (Fourney '90; Jernberg-Wiklund 
'92) and a relationship between high c-myc expression and aggressive transformation of myeloma 
cells has been suggested (Nobuyoshi '91). The elevated c-myc expression levels might be caused by 
mutations in the 5' untranslated region of the c-myc gene (Paulin '96). C-myc (8q24) appears to play
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a central role in controlling proliferation, differentiation and apoptosis (Amati '94; Henriksson '96). 
Constitutive and high expression of c-myc probably results in a stimulation of proliferation and a 
differentiation stop, effectively increasing the growth fraction of the tumor.
7.3.2 Oncogenic events associated with growth factor independence and extravasation
The proliferation, differentiation and function of hematopoietic cells is regulated by a complex 
network of hematopoietic growth factors and cell surface receptors which establish a fine tuned 
communication between stroma cells and hematopoietic precursors in the bone marrow (Clark '87; 
M etcalf '89; Sieff '90). The pathogenesis of myeloma depends on the presence of some of these 
growth factors which support the survival, proliferation and differentiation of myeloma cells in the 
bone marrow (Klein '92; '95). The cytokines involved in myeloma pathogenesis are similar to those 
normally mediating the proliferation of early plasma cells and their differentiation to mature plasma 
cells. Interleukin 6 (IL-6) is of particular importance during myeloma establishment. IL-6 supports the 
survival and expansion of myeloma cells by stimulating cell division (Kawano '88; Zhang '92; Klein 
'89; '92; '95) and preventing apoptosis (Hardin '91; Lichtenstein '95; Puthier '96; Levy '96; Demartis 
'96; Chauhan '97). IL-6 is probably produced in large amounts by bone marrow stroma cells, 
osteoblasts and osteoclast (Bataille '91; Caligaris-Cappio '91; '92) as a response to Il-1 P secretion of 
the tumor cells (Klein '89; '95). Stimulation of cells by IL-6 requires binding to the IL-6 receptor (IL- 
6R). Binding of IL-6 to IL-6R alpha chain induces the formation of a hexameric receptor complex 
composed of 2 IL-6Ra, 2 gp130 and 2 IL-6 molecules, gp 130 is phosphorylated and mediates signal 
transduction (Murakami '93). For signal transduction association with members of the Janus kinase 
(JAK) and Src kinase families (Ihle '94; Hallek '97) is critical. Subsequently, Janus kinases JAK-1, 
JAK-2 and TYK 2, which are constitutively associated with gp130 become activated (Narazaki '94; 
Lütticken '94; Stahl '94; Kumar '94) and a signalling cascade named JAK-STAT pathway is induced 
(Darnell '94; Heim '96; Ihle '96). Since the major STAT proteins (1 and 3) involved in this cascade 
are constitutively active in IL-6 responsive and non-responsive cells the JAK-STAT pathway seems of 
minor importance in myeloma pathogenesis (Grigorieva '96; Ogata '97). Alternatively JAK-2 
activation can initiate a signalling cascade named the RAS-MAPK pathway. A model for this pathway 
was constructed from studies on epidermal growth factor signalling (Schlessinger '93). Upon IL-6 
induced IL-6R activation the complex of GRB2 and SOS1 becomes attached to the activated receptor 
complex. Subsequently SOS1 induces the exchange of GDP for GTP thereby activating membrane 
bound p21 RAS (Schlessinger '93; Marshall '93). Activated p21 RAS induces the activation of other 
signalling intermediates like RAF-1 and MAPK and NF-IL-6 (Kumar '94). The importance of the 
RAS-MAPK cascade in IL-6 signalling is emphasized by results showing that IL-6 induced 
proliferation of cells can be inhibited with the use of MAPK antisense oligonucleotides (Ogata '97)
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and that the introduction of a constitutively active N-ras cDNA into the IL6 dependent myeloma cell 
line ANBL6 results in augmentation of IL6 dependent growth, significant IL6 independent growth 
and the depression of apoptosis in the absence of IL-6 (Billadeau '95).
transcrip tion facto rs IL6 target genes regulating proliferation
and survival of myeloma cells
Figure 3: Transmembrane signaling o f  IL-6 (from Hallek '98). Binding o f  IL-6 to the alpha chain o f  
the IL-6 receptor causes the formation o f  multimeric complexes composed o f  2 IL-6R alpha chains, 2 
gp130 molecules and 2 IL-6 molecules. Subsequently, tyrosine kinases (JAKs and SRC kinases, in 
particular H CK that are bound constitutively to gp130 bcome activated and phosphorylate the 
receptor. This creates specific docking sites fo r  signaling proteins as STAT1, STAT3 and SHC on 
gp130. Activation o f  SHC recruits GRB2/SOS1 to the cell membrane. SOS1, a RAS-GDP/GTP  
exchange factor activates RAS and a signaling cascade is initiated resulting in the acitvation o f  RAF-1, 
M K K  and MAPK. Finally M APKphosphorylates nuclear substrates like c-MYC, c-JUN, c-FOS etc, 
and these events enhance myeloma cell proliferation or prevent myeloma cell death.
Growth and survival of myeloma cells is generally dependent on the supply of IL-6 by bone 
marrow stromal cells. In advanced myeloma IL-6 independent growth can be observed. Several
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oncogenic events may lead to IL-6 independent growth or survival. A mutation in the IL-6R can result 
in constitutive signalling as was shown in a mouse plasmacytoma. The ability to activate the IL-6R in 
an autocrine way has been observed in several myeloma cell lines. Constitutive signalling via the Ras- 
MAPK pathway may also lead to IL-6 independent growth and survival. Activating pointmutations in 
N-ras and Ki-ras codons 12, 13 and 61 resulting in constitutive ras signalling occur in about 39% of 
newly diagnosed patients. Interestingly the frequency of ras mutations increases with disease 
progression. Mutation of N- and Ki-ras are rarely detected in solitary plasmacytoma and MGUS, but 
common in MM (9-30%) and in the majority (64-70%) of fulminant cases and patients with PCL 
(Neri '89; Tanaka '92; Portier '92; Corradini '93). Ras mutations have been associated with more 
aggressive disease and a poor clinical outcome in a phase II study (Gertz '95). Recently Nagesh et al. 
('98) found N-ras codon 61 mutations in sorted BB4 positive plasma cells from all of the 32 
investigated myeloma samples and 2 MGUS cases, suggesting that N-ras codon 61 mutations are 
universal in multiple myeloma at presentation. Overexpression of Ha-ras or N-ras oncogenes in 
Epstein-Barr virus infected human B lymphoblasts induces malignant transformation and 
plasmacytoid differentiation of these cells (Seremetis '89). In early stages p21 ras is activated via the 
paracrine secretion of IL6 by BM microenvironment. At later stages activating mutations of N-ras or 
Ki-ras replace this function, thus allowing an IL6 independent tumor expansion and dissemination 
outside the marrow.
Recently it was found that over 25% of myeloma cases have acquired a constitutive expression of 
the FGFR3 as a result of t(4;14) (Chesi '97). Fibroblast Growth Factor (FGF) is produced by stromal 
cells in the bone marrow. It inhibits differentiation and apoptosis and stimulates the growth of 
myeloma cells. In advanced myeloma activating mutations of the FGFR3 have been found (Chesi 
'97). These mutations may result in ligand independent signalling, stromal independent survival and 
extramedullary proliferation of tumor clones.
p16 and its family of cyclin dependent kinase inhibitors p15 and p18 are homozygously deleted in 
some MM patients (Tasaka '97). p16 is expressed in some MM cells and cell lines and higher 
expression correlates with a more mature phenotype tumor cells that are no longer responsive to IL-6 
proliferation / differentiation signals (Kawano '96; Urashima '97). The p16 gene is frequently 
hypermethylated in fulminant MM (Ong '97), plasma cell leukemia and cell lines (Urashima '97b). 
Since CDK inhibitors are inhibitors of cell cycle this suggests that inactivation of p16 by 
hypermethylation might be involved in decreased growth control and the development of PCL.
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7.3.3 Oncogenic events associated with increased chemoresistance and impaired cell death
FAS (also known as APO-1 or CD95) is a transmembrane protein that mediates apoptosis upon 
trimerization induced by cross-linking to FAS ligand (Suda '93; Nagata '97). Fas is normally 
expressed on the surface of activated T- and B-lymphocytes and FAS/FAS ligand induced apoptosis is 
important for eliminating autoreactive immature T cells during ontogenesis and for maintaining 
peripheral lymphocyte homeostasis (Rathmell '96; Nagata '97). Many neoplastic cells, including those 
derived from MM patients express FAS antigen on their surface (Dirks '97; Mandik '95; Wang '96), 
yet do not undergo apoptosis in response to antigen cross-linking (Shima '95; W estendorf '95; 
Landowski '97b). Loss of function mutations in the FAS antigen may be the explanation since they 
have been associated with benign lymphoproliferation, severe multisystem autoimmune disease and 
hypergammaglobulinemia in mice (Nagata '95; Watanabe-Fukunaga '92) and humans (Rieux-Laucat 
'95; Fisher '95; Le Deist '96; Drappa '96; Bettinardi '97). Fas mutations have been detected in 16 out 
of 150 (11%) cases of non-Hodgkin lymphoma. Interestingly 10 of 13 evaluable patients with Fas 
mutations showed features suggestive of autoreactive disease. The authors suggest that anergic and 
potentially self-reactive B cells that acquire Fas mutations may no longer be susceptible to apoptosis. 
Instead they may proliferate and eventually cause the production of autoantibodies. These cells will 
also be at risk of becoming tumor cells by acquiring additional oncogenic hits (Gr^nbaek '98). Fas 
mutations have been detected in 5 out of 48 (10%) BM specimens of MM patients as well. All 
mutations were located in regions known to be involved in transduction of the apoptotic signal. An 
additional 6 patients showed no detectable levels of Fas mRNA. Since cells with abberations in the 
FAS apoptotic pathway are resistant to the FAS/FAS ligand apoptotic stimulus, these abberations are 
likely to contribute to the transformation of myeloma cells (Landowski '97). Because patients with 
MM frequently have a history of autoimmune disease it is likely that a relationship between Fas 
mutations, autoimmune disease and tumor formation exists that is similar to that proposed for Fas 
mutations in non-Hodgkin lymphoma.
Expression of bcl-2 is thought to play an important role in B-cell malignancies, particularly in 
follicular lymphoma where more than 80% of patients have the t(14;18), resulting in overexpression 
of bcl-2 (Hermine '96; M eyerink '97). t( 14; 18) is an infrequent (0-15%) event in MM but 
overexpression of bcl-2 is observed in the majority of MM patients and cell lines (Pettersson '92; 
Ladanyi '92; Ong '95). Overexpression of bcl-2 can result in chemoresistance and blocks apoptosis 
(Ray '94; Schwarze '95; Tian '96). Recent work has shown the existence of several BCL-2 related 
proteins that either inhibit (BCL-Xl, MCL-1, NR-13, A1, BCL-W) or enhance (BAX, BCL-Xs, 
BAK, BAD) apoptosis (Gajewski '96; Yang '96). It is interesting that we have found a mutation in 
the bax gene in the myeloma cell line OPM1 (Meijerink '98). This mutation might impair with the
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death promoting function of bax as was shown for mutations found in cell lines HPB-ALL and Daudi 
(Meijerink '97) and thus also promote survival and increased chemoresistance of tumor cells.
Mutations in the p53 gene have been detected in 80% of myeloma cell lines. In primary samples 
however p53 mutations were infrequent. Inactivating mutations were found in 5% of smoldering MM 
patients and in 20-40% of acute plasma cell leukemia patients, suggesting the association with disease 
progression (Portier '92; Preudhomme '92; Neri '93; Willems '93; Corradini '94). The inactivation of 
the p53 gene (17p13) can be caused by a loss of both alleles or by point mutations having a dominant 
negative effect (Baker '89; Eliyaho '89; Milner '91). The p53 gene is important in the control of cell 
growth and differentiation. Recently it was found that TP53 can bind to response elements on bcl-2 
and bax genes resulting in downregulation of BCL-2 and upregulation of BAX. Therefore TP53 can 
control apoptosis of cells (Korsmeyer '95) as well. Inactivation of TP53 leads to increased 
chemoresistance, an uncontrolled growth pattern, karyotypic instability and inhibition of apoptosis 
and differentation of tumor cells at the final stages of MM.
Amplification of the murine double minute (mdm2) gene has been implicated in oncogenesis. We 
did not find evidence for gene amplification in a panel of 30 patients (results not shown). Others 
found overexpression of the MDM2 protein in MM cell lines and plasma cells from myeloma patients 
(Teoh '97). The MDM2 protein facilitates the G1 to S transition by enhancing transcription of genes 
associated with proliferation or by activation of E2F. It also abrogates tumor suppressive functions of 
wild-type TP53 by direct binding (Teoh '97). These data suggest that an overexpression of MDM2 
protein enhances cell cycle progression, inhibits apoptosis and increases chemoresistance in myeloma 
ontogeny through sequestering of TP53.
The mdr gene encodes a 170 KD glycoprotein. This glycoprotein functions as a membrane pump 
that is responsible for the resistance of tumor cells to a variety of antineoplastic drugs. The 
amplification of mdr gene expression can be detected in myeloma cells, and its expression correlates 
with resistance to doxorubicin and vincristine (Dalton '89; Epstein '89; Sonneveld '95).
3.4 Oncogenic hits with no apparent stage association
The most frequent numerical chromosomal abnormality found in myeloma patients is monosomy of 
chromosome 13. Using conventional karyotyping monosomy 13 has been identified in approximately 
30% of abnormal MM karyotypes. Monoallelic deletion of Rb has been reported in about 50-60% of
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MM patients and MM derived cell lines using southern blotting or interphase FISH. Bi-allelic deletion 
however was found in only 1 of 10 primary MM tumor samples and 1 of 22 MM cell lines (Weinberg 
'93; Corradini '94; Juge-M orineau '95; Zandecki '95b). M utations in the Retinoblastoma 
susceptibility tumor suppressor gene (Rb) located on chromosome 13q14 or abnormalities in pRb 
have been described in up to 70% of MM patients and 80% of MM-derived cell lines (Corradini '94; 
Dao '94; Juge-Morineau '95). The retinoblastoma susceptibility protein is a nuclear phosphoprotein 
involved in the regulation of cell growth and differentiation. Hypophosphorylation activates pRB. 
Activated pRB binds E2F thereby induces cell cycle arrest and differentiation. In contrast 
phosphorylation inactivates pRB. E2F is released, transactivates genes involved in initiating DNA 
synthesis and promotes entry of cells in S-phase. Bi-allelic deletion of the Rb gene (Corradini '94; 
Dao '94; Juge-Morineau '95; Zandecki '95b) or pRB phosphorylation / inactivation (Zukerberg '96; 
Urashima '96) observed in MM patients therefore promotes entry of cells in cell cycle and inhibits 
differentiation, thereby effectively increasing the growth fraction of the tumor.
3.5 Defining (viral) infections as oncogenic events
Oncogenic events promoting tumor formation are not necessarily the result of DNA mutations. It is 
now well established that a number of infections have a tumor promoting capacity as well. Recently 
Kaposi's sarcoma-associated herpesvirus (KSHV) DNA was detected in bone marrow dendritic cells 
of 15 out of 15 myeloma patients, but not in malignant plasma cells or marrow dendritic cells from 
normal individuals and patients with other malignancies. The KSHV DNA was detected in 2 out of 8 
MGUS patients. An explanation for the association of KSHV (also known as HHV-8) infection with 
myeloma may be the production of viral IL-6 by marrow dendritic cells that were infected with KSHV 
(Rettig '97). The viral IL-6 has been shown to have biological properties of human IL-6 since it 
supports the growth of human IL-6 dependent cell lines (Rettig '97). These data indicate that KSHV 
infection of marrow dendritic cells supports the growth and survival of myeloma cells and may be 
involved in transformation from MGUS to myeloma.
Another strategy to promote tumor formation is used by DNA tumorvirusses as SV40, 
papillomavirus and adenovirus (Lane '90; '92). Adenovirus serves as a paradigm and directly 
immortalizes cells. It initiates E1A, E1B 55 and E1B 19kDa protein production. E1A binds and 
inactivates RB (Huang '88; Bookstein '90), induces DNA synthesis (Stabel '85; Kaczmarek '86) and 
immortalizes cells (Ruley '83; White '92). E1B 55kDa binds and inactivates the P53 protein and thus 
prevents the induction of apoptosis and cell cycle exit (Sarnow '82). In addition E1B 19kDa is
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involved in inhibiting DNA fragmentation, cytolyses and apoptosis (Hashimoto '91; Itoh '91; White 
'92) of infected cells. The Epstein-Barr virus (EBV) that is frequently detected in human B- 
lymphocytes is known to induce immortalization via the production of latent membrane protein 1 
(LMP-1) and subsequent upregulation of bcl-2 expression (Gratama '88; Yao '89; Henderson '91; 
Gregory '91).
Since the antigenic stimulation of B-cells and production of inflammatory cytokines (like IL-6) 
promote survival and proliferation of B cells in general, infections, autoimmune diseases and chronic 
inflammatory conditions are expected to promote the induction of plasma cell clones and myeloma 
establishment. In agreement with this hypothesis is the observation that patients with a history of 
chronic inflammations are at risk of developing myeloma. From these data one could argue that even 
inflammations and especially chronic conditions can be regarded as tumor promoting or oncogenic 
events.
3.6 Summary: Quest fo r the critical oncogenic hit
Multiple myeloma is characterized by the infiltration of malignant plasma cells in the bone marrow. 
Numerous reports are concerned with the detection of DNA abnormalities and other oncogenic events 
causing this malignant disease. Some of these events have been pinpointed to specific stages in the 
disease process, others have been found in equal frequencies in all myeloma stages. Like a long-lived 
plasma cell, a myeloma plasma cell has undergone three developmentally regulated changes in the 
DNA structure of the IgH and IgL loci. It is attractive to speculate that errors in productive 
rearrangement of IgH and IgL genes, somatic hypermutation and productive IgH isotype switching 
have caused genetic changes contributing to myeloma ontogeny. In this respect it is important to note 
the recent finding that a chromosome translocation to the IgH locus, most frequently into a switch 
region, is a near universal event in myeloma cell lines (90%) and primary tumor samples (60-75%). 
The invariant result of these translocations seems to be the dysregulated expression of an oncogene by 
juxtaposing it to strong regulatory sequences of the IgH locus. Since a chromosomal translocation to 
IgH is common in MM it is expected that this in an early event in ontogeny. IgH structural 
abnormalities detected in MGUS suggest that IgH translocations may also be common in pre- 
malignant stages where disease is not evident. Viral infections seem important in early myeloma 
ontogeny as well. Especially the recent detection of Kaposi's sarcoma-associated herpesvirus (KSHV) 
DNA in bone marrow dendritic cells of 15/15 myeloma patients but rarely 2/8 MGUS patients 
suggests an critical role for these infections in malignant transformation.
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Figure 4: Prevalence o f  abnormalities in specific myeloma stages. Compiled data from chapter 7.
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3.7 Summary: Timing o f  oncogenic events
Although morphological evaluations indicate that the bulk of tumour cells in myeloma are plasma 
cells the specific B cell stages in which each individual oncogenic event took place are largely 
unknown. The constant status of the IgH sequence in myeloma plasma cells indicates that fully 
transformed cells have undergone VDJ recombination and are no longer subjected to the somatic 
hypermutation machinery. We therefore suggest that the critical oncogenic event occurred in a B cell 
stage (memory B cell, plasmablast or plasma cell) where somatic hypermutation was no longer active. 
In MGUS microheterogeneity in the IgH sequence has been detected suggesting that somatic 
hypermutation is still active. These data indicate that early oncogenic events contributing to myeloma 
ontogeny took place before somatic hypermutation was off. Finally the nearly universal presence of 
IgH switch translocations in myeloma indicates that IgH switch translocations are early oncogenic 
events that probably occur at the time of isotype switching (e.g. the memory B cell). In early studies 
differentiation markers have been used to evaluate the involvement of early B lymphocyte stages in the 
ontogeny of active myeloma. The coexpression of early B lineage or markers of other lineages with 
plasma cell markers has been observed on the malignant population (Grogan '87; Jensen '91; Omede 
'93) and the authors therefore concluded that transformation occurred in a pre-B cell stage or in 
hematopoietic stem cells. The conclusions from these studies however are controversial since 
multilineage markers have now been observed frequently on normal bone marrow plasma cells 
(Terstappen '90) and plasma cell lines (Zhang '94). Using sensitive PCR techniques (IgH-ASO PCR) 
B-cells Clonally Related to the Malignant plasma cells (BCRM) have been detected in sorted CD38 
dim, CD45 positive mature B cells (Billadeau '93), CD34 positive stem cells (Szczepek '97; Takeshita 
'94) and CD19, CD20, CD21 and CD10 positive B cell stages (Takeshita '94) and IgM positive B 
cells. In many studies the contamination of plasma cells in sorted subfractions may account for 
positive PCR signals obscuring these results (Willems '96; Kimlinger '97) and although there are 
reports of the detection of ras mutations in BCRM (Bergsagel '94) and CD19, CD10 positive, BB4 
negative cells in bone marrow and peripheral blood (Nagesh '98) there is no fundamental proof that 
BCRM have acquired oncogenic hits.
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For the eradication and detection of all malignant cells it is essential to define the critical oncogenic 
hit transforming pre-malignant cells into fully transformed cells causing disease. Since p53 point 
mutations were detected frequently in many different tumors (Baker '89; Mulligan '90; Varley '91; 
Hollstein '91) and were shown to have oncogenic effects (Prosser '90; Michalovitz '91) we 
hypothesized that a mutation in p53 might be the critical oncogenic hit in myeloma ontogeny. 
Therefore we tested myeloma tumor samples for mutations in the p53 gene. In chapter 3 we used 
single stranded conformation polymorphisms to search for p53 mutations in myeloma bone marrow 
samples. In addition we evaluated if the occurence of several myeloma cases in a family was 
associated with p53 germline mutations as is the case for Li Fraumeni syndrome (Malkin '90; 
Srivastava '90). Detecting point mutations with single stranded conformation polymorphism was 
performed by melting DNA strands to single stranded molecules. The migration of single stranded 
DNA molecules in a polyacrylamide gel during electrophoresis depends on the exact base composition 
of the DNA. A single point mutation usually results in a different migratory speed, explained by 
conformational differences in different ssDNA molecules. We detected no p53 germline mutations and 
observed sporadic mutations in myeloma bone marrow samples. We argued that we might have 
missed mutations with the newly introduced SSCP technique. We therefore optimized the conditions 
to separate fragments differing in a single DNA base using capillary electrophoresis in a polymer 
network (addendum part 1) and on line melting of DNA in a polymer network (addendum part 2). 
These systems enable fully automated analysis of p53 mutations in the future. Sequencing showed 
that mutations in the p53 gene were involved in the progression to fulminant myeloma but were not 
critical oncogenic hits in myeloma. The unavailability of ubiquitous myeloma tumormarkers directly 
responsible for malignant transformation prompted us to use the immunoglobulin heavy chain gene 
rearrangement of the malignant plasma cells as a clonality marker defining potentially malignant cells. 
In chapter 4 we compared the reproducibility and accuracy of several methods to quantitate myeloma 
tumor cells and clonally related cells. The use of real time IgH ASO-PCR and a limiting dilution assay 
for quantitation of clonal cells were validated in a multicentre study and both assays gave comparable 
results. Using the sensitive IgH ASO-PCR assay we found a low incidence (0.001-0.01%) of 
malignant cells in CD34 positive subpopulations selected from myeloma peripheral blood autografts 
(chapter 5). The malignant cells in these selections were shown to be contaminating CD34 negative 
plasma cells. We concluded that sorting subpopulations is prone to contaminations and we found no 
evidence for true CD34 positive malignant or clonally related cells in myeloma. In fact these 
experiments raise doubt over studies reporting the presence of rare malignant or clonally related cells 
in other subpopulations (CD10, CD19, CD20 etc) since contamination phenomena are probably 
inherent to sorting experiments. Since cells with the IgH rearrangement of the malignant clone are not 
necessarily malignant we developed a strategy to differentiate between malignant subpopulations and
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non-malignant clonally related cells. This strategy involves the selection of all cells with the Ig 
idiotype of the malignant clone using anti-idiotype antibodies. In chapter 6 we proved that anti- 
idiotypic antibodies can be selected from phage display libraries. These high affinity single chain 
antibodies allowed the specific staining of patient tumor cells, not myeloma cell lines, donor plasma 
cells or donor B-lymphocytes cultured in a CD40 system in flow cytometric experiments. The anti- 
idiotypic antibodies enabled flow-cytometric detection of 0.05% clonotypic plasma cells in a 
background of other bone marrow cells or a myeloma cell line with high Ig expression. In future 
experiments flow-cytometric selection of idiotype positive cells should allow us to evaluate the extent 
of genetic mutations in these cells and more importantly their capacity to induce disease. These 
experiments will discriminate true malignant subpopulations from non-malignant clonally related cells 
and enable the efficient elimination and monitoring of all malignant myeloma populations in the future. 
Finally in chapter 7 we discuss the potential role of mutations found in myeloma plasma cells in the 
ontogeny of active myeloma. This thesis states that identification of the differentiation stages at which 
oncogenic events take place is the key to understanding myeloma ontogeny and describes methods to 
do so.
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Addendum Part one: Detection of Point Mutations using Capillary Electrophoresis
Samenvatting
'Als hij zich door het water zou laten dragen, met zijn ogen naar de hemel, zou hij 
de zon nooit meer zien bewegen: dan zou hij op die drempel tussen vandaag en de 
vorige dag blijven drijven, buiten de tijd, op een eeuwig middaguur. En omdat de 
tijd voor hem bleef stilstaan, zou die ook op het Eiland stilstaan, waardoor haar
dood tot in het oneindige werd uitgesteld...'
Umberto Eco
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Multipel myeloom wordt gekarakteriseerd door de duidelijke aanwezigheid van kwaadaardige of 
maligne plasmacellen (volledig uitgerijpte antilichaam producerende B-lymfocyten) in het beenmerg. 
Klinische data wijzen erop dat de ontwikkeling van deze kwaadaardige ziekte verschillende stadia 
doorloopt. Het is waarschijnlijk dat drie tot zeven veranderingen (mutaties) in het DNA nodig zijn 
voor de ontwikkeling van deze maligniteit. Welke de cruciale DNA mutaties zijn die de ontwikkeling 
van deze kanker veroorzaken is nog onduidelijk. Sommige kanker veroorzakende abnormaliteiten 
worden alleen in bepaalde stadia van de ziekte gevonden. De prominent aanwezig tumorcel in het 
myeloom lijkt op een normale plasmacel. De myeloma plasmacel heeft net als de normale langlevende 
plasmacel in zijn wordingsgeschiedenis belangrijke DNA veranderingen ondergaan in genen die 
coderen voor immunoglobulinen of antilichamen. Het is zeer wel mogelijk dat abnormale DNA 
veranderingen een bijkomend effect zijn van de machinerie die de normale DNA veranderingen 
aanstuurt. Recentelijk is inderdaad gevonden dat in bijna alle myeloma gevallen een DNA 
abnormaliteit die we chromosoom translocatie noemen gevonden kan worden. In die translocatie 
wordt een gedeelte van het gen dat codeert voor de immunoglobuline zware keten geplaatst nabij een 
gen waardoor het immunoglobuline gen gedereguleerd wordt. Het aantonen van dit soort 
veranderingen in de meeste myeloma patiënten en mogelijk ook in een voorstadium van de ziekte duidt 
aan dat dit een van de kritische veranderingen is die samen met andere veranderingen aanleiding geeft 
tot de vorming van multipel myeloom.
Het is duidelijk dat de meeste cellen die behoren tot de maligne kloon plasmacellen zijn. Het is 
echter onbekend in welke B cel stadium de mutaties betrokken bij myeloom vorming hebben 
plaastgevonden. Kijkende naar de samenstelling van het immunoglobuline DNA dat uitermate stabiel 
en invariabel is kunnen we zien dat de belangrijkste DNA mutatie leidend tot de eigenlijke kanker heeft 
plaatsgevonden in een laat B-cel stadium, mogelijk in de memory B cel de plasmablast of zelfs de 
plasmacel. Omdat in voor-stadia van het myeloom een micro-variabiliteit in het immunoglobuline 
zware keten gen van de maligne cellen wordt gezien kunnen we stellen dat vroege veranderingen 
leidend tot monoclonal gammopathy of unknown significance (MGUS) al voor het memory B cel 
stadium gestart zijn.
In andere studies heeft men gevonden dat vroege B-lymphocyten ook tot de maligne kloon zouden 
behoren. Een belangrijk argument was de aanwezigheid van moleculen op de maligne plasmacel 
waarvan men dacht dat ze alleen op vroege B-lymfocyten voorkomen. Deze moleculen bleken echter 
ook op normale plasmacellen aanwezig. M et andere technieken (gebruikmakend van polymerase 
ketting reacties die alleen maligne of klonaal gerelateerde cellen detecteren) zijn mogelijk maligne
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cellen aangetoond in rijpe en vroege B cellen en in bloedvormende stamcellen. Deze technieken zijn 
echter zo gevoelig dat de gedetecteerde cellen misschien verontreinigende plasmacellen zijn.
D IT PROEFSCHRIFT
Voor de detectie en het uitroeien van alle kwaadaardige cellen in myeloom patiënten is het cruciaal 
om de kritische mutatie verantwoordelijk voor de transformatie van niet-maligne cellen in de tot ziekte 
leidende maligne cellen te definiëren. De detectie van translocaties van het immunoglobuline zware 
keten locus in voorstadia van het myeloom pleit tegen een directe rol voor deze DNA verandering in 
de progressie van de voorstadia (MGUS) naar het kwaadaardig myeloom. In dit proefschrift 
onderzochten we of mutaties in het p53 gen die betrokken zijn bij de ontwikkeling van andere tumoren 
de kritieke verandering in de ontwikkeling van het myeloom is. Beenmergmonsters van patiënten met 
multipel myeloom werden onderzocht op veranderingen in het p53 gen. In hoofdstuk 3 zochten we 
naar veranderingen met behulp van een techniek die we single stranded conformation polymorphism 
noemen. Hierbij wordt dubbelstrengs-DNA in enkele strengen gesmolten. De migratie-snelheid van 
enkelstrengs-DNA in een gel bleek afhankelijk van de exacte bouwstenen (basen) van het DNA. 
Hierdoor komt veranderd DNA op een andere plaats in een gel terecht. Met deze techniek vonden wij 
slechts sporadisch p53 veranderingen in tumorcellen van multipel myeloom patiënten. In de normale 
cellen van deze patiënten werden de veranderingen niet teruggevonden. Om uit de sluiten dat 
veranderingen door de nieuwe techniek werden gemist hebben we de techniek geoptimalizeerd met 
behulp van capillaire electrophorese (addendum). Ook met behulp van capillaire electrophorese en 
sequentiebepalingen werden echter niet meer veranderingen gevonden. Bewezen werd dat p53 
veranderingen geen kritische veranderingen zijn bij het ontstaan van het myeloom maar betrokken zijn 
bij de progressie van het myeloom naar aggressieve vormen. Daar geen kritische tumormerkers voor 
het myeloom beschikbaar waren hebben we in het vervolg onderzoek gebruik gemaakt van de 
immunoglobuline zware keten sequentie van de maligne plasmacellen als een klonaliteitsmerker die 
potentieel maligne cellen definieert. In hoofdstuk 4 hebben we de reproduceerbaarheid en 
betrouwbaarheid van verschillende methoden om kwaadaardige cellen en klonaal gerelateerde cellen in 
het myeloom te quantificeren met elkaar vergeleken. In een studie waarbij de data van verschillende 
centra met elkaar werden vergeleken gaven een limiting dilution assay en een nieuwe methode die 
gebruik maakt van een continue meting van het produkt gemaakt bij de polymerase kettingreactie (real­
time IgH ASO-PCR) vergelijkbare resultaten. Gebruik makend van deze IgH ASO-PCR vonden we 
een lage frequentie (0.001-0.01%) kwaadaardige cellen in bloedvormende stamcellen (CD34 selecties) 
geselecteerd uit autologe bloedtransplantaten van myeloom patiënten (hoofdstuk 5). De kwaadaardige
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cellen bleken uiteindelijk verontreinigende kwaadaardige plasmacellen. Wij concludeerden daarom dat 
het selecteren / sorteren van subpopulaties met de huidige technieken vaak resulteert in 
verontreinigingen en dat geen bewijs was geleverd voor het bestaan van kwaadaardige CD34 positieve 
stamcellen. In feite duiden deze experimenten erop dat het moeilijk is via sorterings-experimenten een 
indruk te krijgen van het bestaan van kwaadaardige vroege B cellen of zelfs kwaadaardige stamcellen 
in myeloom patiënten. Omdat cellen met de immunoglobuline zware keten sequentie van de 
kwaadaardige kloon niet perse zelf kwaadaardig zijn hebben we een strategie ontwikkeld die 
kwaadaardige cellen van niet kwaadaardige klonaal gerelateerde cellen differentieert. We selecteren 
daarbij alle cellen die het immunoglobuline eiwittype van de kwaadaardige kloon op hun membraan 
hebben met behulp van antilichamen (zgn. anti-idiotype antilichamen). In hoofdstuk 6 hebben we 
laten zien dat anti-idiotype antilichamen kunnen worden geselecteerd uit een bibliotheek van fagen 
wier mantel met antilichamen is bedekt. Met de zo geselecteerde antilichamen konden we de 
kwaadaardige plasmacellen van patiënten kleuren en op een flow-cytometer zichtbaar maken. De 
antilichamen reageerden alleen met de kwaadaardige cellen, niet met andere cellen van de patiënten, 
met andere kwaadaardige plasmacellen of met normale B-lymfocyten. M et de anti-idiotype 
antilichamen konden we 0.05% kwaadaardige plasmacellen detecteren in een achtergrond van normale 
beenmergcellen of een plasmacellijn. Deze techniek is bedoeld om potentieel kwaadaardige cellen te 
gaan sorteren. Van de gesorteerde cellen moet worden bekeken welke DNA veranderingen ze dragen 
en of ze in staat zijn om een kwaadaardige ziekte te veroorzaken. Door deze experimenten zullen we in 
staat blijken een onderscheid te maken tussen kwaadaardige B-lymfocyt subpopulaties en goedaardige 
klonaal gerelateerde cellen. Hiermee is de ontwikkeling van een efficiënte detectie-techniek en gerichte 
aanpak van kwaardaardige subpopulaties in multipel myeloom patiënten mogelijk. Tenslotte 
bediscussiëren we in hoofdstuk 7 de rol die mutaties gevonden in myeloom plasma cellen kunnen 
spelen in de ontwikkeling van het aktieve myeloom. Dit proefschrift laat zien dat het belangrijk is te 
weten in welke B cel differentiatie stadia de verschillende oncogene gebeurtenissen plaatsvinden. 
Hierdoor ontstaat een beter begrip van de ontstaanswijze van het multipel myeloom. Het proefschrift 
beschrijft methoden om deze vraagstukken op te lossen.
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Addendum Part
Detection of Point Mutations in DNA using 
Capillary Electrophoresis in a Polymer Network
By: Aldy W.H.M. Kuypers, Peter M.W. Willems, Marcel J. van der Schans, Peter C.M. Linssen, 
Hans M.C. Wessels, Chris H.M.M. de Bruijn, Frans M. Everaerts and Ewald J.B.M. Mensink.
Journal of Chromatography 1993: 621: 149-156 1
^Containing grammatical modifications
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ABSTRACT
The detection of DNA point mutations might be helpful for the diagnosis of genetic diseases and 
cancer. Single strand conformation polymorphism (SSCP) is a method to detect DNA point 
mutations. We investigated if capillary electrophoresis (CE) in a polymer network could be used for 
SSCP analyses. The p53 gene is a tumour suppressor gene known to be frequently mutated in 
malignant cells. We amplified p53 gene regions and could separate two single strand DNA fragments 
of identical length (372 bp), differing in only one nucleotide using CE. We conclude that SSCP using 
CE in a polymer network is a powerful method for the detection of point mutations in DNA 
sequences.
INTRODUCTION
Point mutations are nucleotide changes in both complementary strands of the deoxyribonucleic acid 
(DNA) molecule, the carrier of genetic information. When a mutation occurs in the germ-line DNA 
present in a gamete and interferes with the function of genes, it can result in a genetic transmissible 
disease. Cancer is a distinct type of genetic disease in which not one, but several mutations are 
required. Each mutation drives a wave of cellular multiplication associated with gradual increases in 
tumour size, disorganisation and malignancy. Three to six such mutations appear to be required to 
complete this process (Vogelstein '93). These mutations include point mutations in the DNA and 
chromosomal aberrations like translocations, deletions, amplifications and inversions. The detection 
of DNA point mutations might be helpful for the diagnosis of genetic diseases and cancer.
Point mutations can be detected by several techniques. To increase the sensitivity of these 
techniques, DNA fragments can be multiplied prior to analysis by enzymatic amplification, using the 
polymerase chain reaction (PCR) (reviewed by Mullis '90) Mutations alter the resistance of DNA 
segments to denaturation. Therefore double stranded DNA products that differ in one or more 
nucleotides can be separated on acrylamide gels cast with linear gradients of denaturants, i.e. 
denaturing gradient gel electrophoresis (DGGE) (Myers '87). Alternatively, localisation of point 
mutations in PCR amplified products is also possible by a method using chemical modification. In this 
method heteroduplexes are generated between normal and mutated single strand DNA molecules. The 
result is a nucleotide mismatch at the site of the mutation. Mismatched cytosine or thymine residues 
are sensitive to modification by hydroxylamine or osmium tetroxide ('HOT') respectively. 'HOT' 
modified DNA in heteroduplex form is sensitive to piperidine cleavage. Cleavage products of different
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lengths can be separated on a denaturing acrylamide gel (Tindall '91). A third and more simple method 
for the detection of nucleotide substitutions is the single strand conformation polymorphism (SSCP) 
technique. Point mutations give rise to conformational changes of the single stranded DNAs and lead 
to a mobility shift of the DNA fragments on neutral polyacrylamide gels. This SSCP technique is a 
convenient and efficient method for the detection of point mutations (Orita '89b).
The recent development of applications using capillary electrophoresis, a family of related 
techniques that use narrow capillaries to perform high efficiency separations of molecules (reviewed 
by Deyl '91), was a reason for us to investigate the possibility of detecting SSCP of DNA molecules 
using capillary electrophoresis (CE) in a polymer network. We studied the detection of point 
mutations in the p53 gene located on the short arm of chromosome 17 (Isobe '86). The p53 gene is 
frequently mutated in malignancies and the mutations can be used as molecular markers for pre- 
malignant or malignant cells (Nigro '89). This report presents the use of CE for the detection of small 
DNA changes. SSCP-CE may enable a fast screening of patient samples for DNA mutations in the 
future.
EXPERIMENTAL 
DNA isolation
DNA was isolated (Miller '88) from normal white blood cells derived from a pool of 30 normal 
persons, the cell line CEM which contains a p53 point mutation in one of its alleles and bone marrow 
cells of two Multiple Myeloma patients known to have a p53 point mutation. These patients and the 
cell line material were the same as used in Willems ('93).
Amplification o f  the p53 mutation clusters A and B by Polymerase Chain Reaction (PCR)
Primers used for amplification of the mutation clusters A and B of the p53 gene were synthesised 
on a 391A DNA synthesiser (Applied Biosystems, Warrington, UK). The names and the sequences 
of the primers used were: p53-i3-primer ; 5'-TTT CTT TGC TGC CGT GTT CCA and p53-AS1- 
primer; 3'-ATA AGA TGC TGA GGA GGG GC. Positions of the 5' end of the primers in the p53 
sequence are 12973 and 13344 respectively (EMBL X54156). The 100 |il PCR mixture contained 30 
pmoles of each primer, 250 ^M  dNTP's and 2,5 U Taq DNA polymerase (Life Technologies, 
Gaithersburg, MD USA). PCR was performed for 35 cycles at 95°C for 1 min, at 56°C for 1 min and 
at 72°C for 1 min in a Perkin-Elmer Cetus thermocycler. The length of the generated PCR fragment 
was checked on a 2% agarose gel.
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Preparation o f  PCR samples prior to CE analysis
The PCR products were ethanol precipitated, rinsed with 70% ethanol to lower the salt 
concentration, and dissolved in TBE (90 mM Tris-borate pH 8.3, 0.2 mM EDTA). Prior to SSCP 
analysis the samples were heated to 90°C for 3 min, snap cooled and kept on ice water for 10 min, to 
melt the double stranded DNA molecules into single stranded DNA molecules. These samples were 
electrokinetically injected onto a column filled with a polymer network.
Capillary Electrophoresis
A fused silica capillary with an internal diameter of 75 ^m and an effective length of 310 mm was 
precoated with 3-methacryloylpropylmethoxysilane. The coated capillary was mounted in an assembly 
cartridge and placed in a Bio-Rad BioFocus 3000 CE instrument (Bio-Rad, Hecules, CA, USA). 
Additional coating was performed by purging for 5 min with a 4% acrylamide (4% T, 0% C) solution. 
The acrylamide was left in the capillary for 1 h to polymerise using 8 ^  l 10% N,N,N',N '- 
tetramethylethylenediamine (TEMED) and 4 ^l 10% ammonium persulfate (APS) per ml acrylamide 
solution (Heiger '90). This prepared capillary could be used for at least 20 runs using the following 
protocol. After each run the capillary was rinsed with water for 2 min and filled again with the 
polymerised 4% linear polyacrylamide network by purging for 5 min using 8 bar pressure. The 
polyacrylamide network contained TAE buffer (40 mM Tris-acetate pH 8.3, 2 mM EDTA). Before 
electrokinetic injection of the sample the inlet end of the capillary was dipped in water to prevent 
contamination of the sample. Injections were performed at reversed polarity (cathode at the injection 
side) of 167 V/cm for 10 or 20 s and separations were performed at reversed polarity under constant 
voltage of 250 V/cm, in TAE running buffer (same concentration as above). Buffers were degassed 
by bubbling helium through the solutions for 15 min. SSCP analyses were performed using UV 
absorption at 260 nm for detection. During the run the temperature of the caroussel was kept at 15°C 
and the capillary was kept at 25 °C.
The molecular marker used was pBr322 DNA digested by the Hae III restriction enzyme (DNA 
MW marker V, Boehringer Mannheim, Germany), resulting in fragment sizes of 8, 11, 18, 21, 51, 
57, 64, 80, 89, 104, 123, 124, 184, 192, 213, 234, 267, 434, 458, 504, 540 and 587 bps.
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Fractionation
With the BioFocus 3000 Integrator program (Bio-Rad™) the peaks on the electropherogram of a 
test run were integrated. In the fractionation run samples were collected in a vial containing 10 ^l TAE 
running buffer every 15 s during 3 min starting 1 min before the first peak. To avoid contamination, 
in between every fraction a 0.01 min sampling wash step was simulated in a new vial containing 500 
^l TAE running buffer. An aliquot of 5 |il of all fractions was directly used as template in a 25 cycle 
PCR using the same conditions as described before. These PCR products were not ethanol 
precipitated before CE re-analysis.
RESULTS
Analysis o f  Single Strand Conformation Polymorphisms o f  amplified DNA fragments by Capillary 
Electrophoresis in a polymer network
DNA amplification of the point mutation clusters A and B of the p53 gene resulted in a DNA 
fragment of 372 base pairs. This corresponds to the expected size based upon the p53 sequence 
(EMBL X54156). The PCR product was tested on a conventional 2% agarose gel (data not shown) 
and on a capillary filled with a linear 4% polyacrylamide network. We compared the migration time of 
the double stranded PCR fragment (figure 1b) with the migration times of a pBr322 Hae III DNA 
restriction fragment marker (figure 1a). Peaks in the electropherograms of PCR fragments at migration 
times of about 8 to 12 min are due to DNA primers, salt, enzyme and nucleotides used in the PCR.
Figure 1c shows the electropherogram of the single stranded PCR fragments of normal white blood 
cells after denaturation of the p53 PCR product. The peaks at 24.86 and 25.71 min observed on the 
electropherogram represent the two single stranded fragments of a denatured DNA molecule. The 
difference in mobility can be explained by the complementary nucleotide sequence of both strands, 
resulting in different folding of the strands. The double stranded DNA peak at 18.18 min that is still 
present in the denatured sample is due to incomplete denaturation of the double stranded DNA and 
renaturation of both single strand fragments in the vial before loading. SSCP-CE analyses of the 
amplified p53 AB region of cell line CEM showed a double stranded DNA peak at 14.70 min and four 
additional peaks at 17.11, 17.39, 17.70 and 17.87 min (figure 2). Since SSCP-CE of a single DNA 
molecule results in the separation of two single stranded DNA molecules the presence of four or more 
peaks is suggestive for the presence of more than one DNA sequence.
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Figure 1: (a) Electropherogram o f  a pB r 322 Hae 
IIIDNA molecular weight marker with fragment 
lengths: 8-11-18-21-51-57-64-80-89-104-123­
124-184-192-213-234 267-434-458-504-540-587 
bp. (b) Electropherogram o f  a double stranded  
p53  AB am plified fragm ent (372 bp) o f  normal 
DNA. (c) Electropherogram o f  a denatured p53  
AB amplified fragment o f  normal DNA.
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Figure 2: Electropherogram o f a denatured p53  
AB am plified fragm ent o f  ce ll line CEM. 
M igration time o f  the double strand peak  is 
14.70 min. Migration time o f  the single strand  
peak 1 is 17.11, o f  peak 2 is 17.39, o f  peak  3 
is 17.70 and o f  peak 4 is 17.87 min.
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Figure 3 shows the SSCP-CE analyses of the amplified p53 AB region of Multiple Myeloma 
patients 1 and 2 known to have a point mutation in the p53 AB mutation cluster (Willems '93). The 
double stranded DNA fragments derived from the patients have the same size as the fragment derived 
from normal DNA (data not shown). Electropherograms (figure 3) show more than three peaks, 
suggestive for the presence of more than one DNA sequence.
15 20  25  30 35 40  15 20  25  30 35 40
Time (min) Time (min)
Figure 3: Electropherogram o f the p53 AB amplified fragment ofpatient 1 (a) and 2 (b) after 
denaturation.
Analysis o f  fractionated peaks by Capillary Electrophoresis in a polymer network
To prove that different peaks observed in the electropherogram of cell line CEM correspond to 
different sequences, all the fifteen collected fractions (experimental section) were re-amplified by 
PCR. All the amplified fractions showed an amplification product on agarose gel, whereas no 
amplified DNA was present in the negative control reaction without DNA template (data not shown). 
Figure 4a and 4b show CE results of re-amplified fractions 5 and 8, corresponding to peak 1 (17.11 
min in figure 2) and 2 (17.39 min in figure 2). PCR amplification of a fractionated single strand peak 
results in the generation of a double stranded PCR product. SSCP-CE analyses of a re-amplified 
single strand peak therefore shows the presence of three peaks on the electropherogram. CE analysis 
of a mixture of fraction 5 and 8 is shown in figure 4c. The fractions 5 and 8 gave rise to different 
electrophoretic patterns and therefore five peaks are observed. This indicates that the different peaks 
indeed contained different p53 sequences. CE analysis of a mixture of fraction 5 and normal DNA 
shows four peaks (three single strands). A mixture of normal DNA and fraction 8 shows only three 
peaks (figure 5a and 5b).
115
Myeloma Plasma Cells and Clonally Related B-lymphocytes
o 6(2
ecncobrosba
V
U
r
20 25
Time (min) Time (min)
10 15 20
Time (min)
Figure 4: The electropherogram o f  single strand  
peak 1 and 2 (see Fig 2) after PCR amplification 
and denaturation is shown in (a) and (b), 
respectively. The electropherogram o f  a mixture 
o f  peak 1 and 2 is shown in (c).
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Figure 5: Electropherogram o f  a mixture o f  amplified normal DNA and amplified peak 1 (a) and o f  
amplified normal DNA and amplified peak 2 (b) after denaturation.
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DISCUSSION
We decided to investigate the feasibility to detect DNA single strand conformation polymorphisms 
(SSCP) with capillary electrophoresis (CE) in a polymer network. We consistently observed three 
DNA peaks with SSCP-CE analyses of amplified normal p53 sequences. SSCP-CE analyses of 
samples containing p53 point mutations (amplified p53 of cell line CEM or myeloma patients 1 and 2) 
consistently resulted in more than three peaks. We used CE in a preparative way to prove that the 
additional peaks represent different DNA sequences. DNA was fractionated and fractions were re­
amplified and subjected to a secondary SSCP-CE analysis. Using this technique CEM-DNA obtained 
from sampling of peak 1 was shown to have its complementary sequence in peak 3 and the CEM- 
DNA from peak 2 and 4 were complementary sequences as well. By comparison of these 
electrophoretic patterns with the electrophoretic patterns of normal DNA we conclude that the DNA 
represented by peaks 1 and 3 contained the p53 point mutation (figure 5a). We conclude that the 
observation of additional peaks is indicative for the presence of DNA mutations. Definite prove for the 
presence of mutations can be obtained with DNA sequencing (Innis '88) of isolated peaks in a 
fractionated CE run.
Our results show that it is possible to separate two single stranded DNA molecules of the same 
length differing in just one nucleotide using CE in a polymer network. Compared to the detection of 
point mutations by the SSCP technique using conventional slab gels, SSCP-CE has several 
advantages. It is less laborious and the amount of sample needed for analysis is small (more than 100 
CE analyses can be done with one PCR). An important additional advantage of SSCP-CE is that the 
detection is non-radioactive and the commercially available systems are automated. UV detection of 
SSCP patterns by CE is direct and data are stored as an electropherogram which can be used for re­
evaluation and quantitation. Other systems for non-radioactive SSCP analyses exist, but are not 
automated and time-consuming due to the necessity of gel staining (Dockhorn-Dworniczak '91; 
Mohabeer '91).
A problem in this study was the fact that the PCR amplified fractions collected before and after the 
single strand peaks and used as negative controls showed PCR-product on agarose gel. Secondary CE 
analysis showed four peaks (data not shown). Because the PCR without DNA template was shown to 
be negative, contamination in the PCR could be excluded. We conclude that fractionated samples 
contained a background of DNA, even when sample collection was during base-line absorption. This 
background did not interfere with our analysis since the DNA collected from a UV peak on the 
electropherogram was strongly enriched for one sequence and that sequence was mainly amplified in
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the PCR (figure 4). Whether vigorous rinsing and cleaning steps can prevent this contamination 
remains to be studied.
It is known that the conformation of a DNA fragment in non-denaturing polyacrylamide gels 
depends on the percentage of acrylamide, the temperature and the presence or absence of glycerol. 
Therefore the use of different PCR-SSCP gel-conditions minimises false negatives with large scale 
DNA mutation screening (Orita '89b). With CE using linear polyacrylamide networks it is easy to 
purge, wash and re-fill the capillary and run different conditions in an automated way. In this study 
we used PCR fragments known to have p53 mutations so it was not necessary to use more than one 
conditions to detect all mutations. Under the used temperature and polymer network condition no false 
positive or negative SSCP results were observed in repeated runs.
We detected point mutations in fragments of 372 bp. Using the conventional slab gel SSCP point 
mutations could be detected in fragments differing in size from about 100 to 400 bp (Orita '89; '90) 
Whether point mutations in fragments beyond these size limits can be detected using CE needs to be 
studied. How the sensitivity (i.e. the minimum amount of mutated DNA that can be detected in 
relation to the amount of normal DNA) of the CE relates to the conventional slab gel SSCP analysis is 
as yet unknown. Whether the resolution of the SSCP-CE can be increased in such a way that every 
DNA mutation can be detected in a single run remains a topic for further study as well.
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Addendum Part
On-line Melting of Double-stranded DNA 
for Analysis of Single-stranded DNA 
using Capillary Electrophoresis
By: Aldy W.H.M. Kuypers, Peter C.M. Linssen, Peter M.W. Willems and Ewald J.B.M. Mensink.
Journal of Chromatography 1996: 675: 205-211
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ABSTRACT
Capillary Electrophoresis (CE) is a convenient, fast and non-radioactive method with possibilities 
for automatization. To analyse single stranded DNA molecules in a more automated way, we 
developed a heating device to melt double stranded DNA fragments in the capillary during 
electrophoresis. In this study we used this device to obtain single stranded DNA, necessary for the 
detection of point mutations in DNA using the Single Strand Conformation Polymorphism technique. 
Results show that double stranded DNA molecules can be melted on-line into single stranded DNA 
molecules, although not for 100%. In an attempt to find universal electrophoretic conditions for the 
analysis of single stranded DNA, we investigated the influence of several parameters on the yield of 
single stranded DNA molecules and on the resolution of the single stranded DNA peaks. We 
demonstrate that this heating device is a technical adjustment of CE which contributes to more 
automated analyses of DNA fragments.
INTRODUCTION
Since DNA mutations are involved in the pathogenesis of genetic diseases as well as in the 
multistep nature of cancer (Vogelstein '93), efficient and reliable detection of those mutations is 
becoming more and more important for the diagnosis of these diseases. Often point mutations are 
involved, which are single nucleotide changes in both strands of the double stranded DNA (dsDNA). 
A simple method to detect point mutations is the Single Strand Conformation Polymorphism (SSCP) 
technique (Orita '89b). The technique is based on the fact that a single stranded DNA (ssDNA) 
molecule folds itself into a conformation which depends on its sequence. A point mutation alters the 
sequence of a ssDNA molecule and therefore the conformation. Because the mobility of a ssDNA 
molecule in a non-denaturing gel depends on its conformation, mutant and wild type DNA molecules 
can be separated.
Several electrophoresis protocols can be used for SSCP analysis (Vidal-Puig '94). Recently we 
described the application of SSCP to Capillary Electrophoresis (CE) using a 4% linear polyacrylamide 
gel (Kuypers '93). SSCP using CE was shown to be a convenient and non-radioactive method for the 
detection of point mutations. Other methods for the detection of point mutations using CE are 
described, each with their own advantages and disadvantages (Khrapko '94, Bianchi '94, Gelfi '94).
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For the SSCP method it is necessary to have ssDNA. Usually this is obtained by heating and 
immediate cooling of the sample before injection. To automate the existing SSCP method and to limit 
sample handling before injection, we developed a heating device to obtain ssDNA molecules in the 
capillary during analysis. Using this heating device a very small part of the capillary (4 mm) is heated 
to 95 °C. When a dsDNA fragment migrates through the heated part of the capillary it melts into 
ssDNA during electrophoresis. Further migration of the ssDNA molecules leads to immediate cooling 
of the ssDNA molecules, because directly after the heating device the capillary is cooled again.
This device differs from the one used in the Constant Denaturant Capillary Electrophoresis method 
described by Khrapko eta l. ('94). They use a water jacket to heat a large part (10 cm) of the capillary 
to a temperature (30-40°C) where dsDNA heteroduplexes are only partially melted and dsDNA 
homoduplexes remain unmelted. Using this device a heating and annealing procedure of half an hour 
before injection is still necessary.
Since, at one electrophoretic condition, the melting of dsDNA depends on the length and the 
sequence of the DNA fragment (Baldino '89), we tested this melting procedure on several DNA 
fragments using CE in a Non Gel Sieving Buffer (NGSB). Furthermore, we investigated the 
influence of the temperature of the heating device, the salt concentration of the running buffer and the 
injected amount of PCR fragment on the yield of single stranded molecules.
To improve the separation of ssDNA molecules we tested several parameters known to have an 
influence on the migration of the single stranded molecules, for one DNA fragment. Preliminary 
results of this work were presented before.
EXPERIMENTAL
Material
DNA was isolated (Miller '88) from the cell lines CEM, MOLT-4 and SW480 and was used as 
template for amplification of the P53 gene, the N-ras gene and the Ki-ras gene respectively. A lysate 
from the Mycoplasma infected cell line CaCo2 was used to amplify the ribosomal RNA of the 
Mycoplasma.
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Polymerase Chain Reaction
Oligonucleotides used for amplification were synthesised on a 391A DNA synthesiser (Applied 
Biosystems, Warrington, UK). The sequences and positions of the oligonucleotides are listed in Table
1 and the PCR conditions for each fragment are listed in Table 2. PCR was performed in a Perkin- 
Elmer Cetus thermocycler (Perkin-Elmer, Norwalk, CT, USA). The Taq (Thermus aquaticus) DNA 
polymerase was obtained from Life Technologies (Gaithersburg, MD, USA).
Table 1: The sequences and positions o f  the oligonucleotides.
nr. sequence (5'-3') EMBL genbank 
Accession nr.
position
1 GACTGAGTACAAACTGGTGG M10055 3-22
2 TGGGCCTCACCTCTATGGT M57430 190-198
3 GGCCTGCTGAAAATGACTGA M54968 181-200
4 GTCCTGCACCAGTAATATGC L00045 226-245
5 TTTCTTTGCTGCCGTGTTCCA X54156 12973-12993
6 ATAAGATGCTGAGGAGGGGC X54156 13325-13344
7 GCGGTGTGTACAAGACCCGA M23931 1370-1389
8 GCGGTGTGTACAAA(AC)CCCGA M24658 1369-1388
9 CGCCTGAGTAGTACGT(AT)CGC U04657 517-536
10 TGCCTG(AG)GTAGTACATTCGC L24103 847-866
11 CGCCTGGGTAGTACATTCGC M24293 873-892
12 CGCCTGAGTAGTATGCTCGC M23931 872-891
Table 2: The PCR conditions used fo r each fragment.
N-ras Ki-ras P53 Mycoplasma
oligo 1 + 2 3 + 4 5 + 6 7 t/m 12
amount each oligo (pmol) 30 30 30 80
template DNA (^g) 0.5 0.5 0.25 20 |il lysate
taq (units) 2.5 2.5 2.5 2.5
dNTP's (|lM) 250 250 250 500
PCR volume (^l) 100 100 100 50
number of cycli 35 40 35 40
denaturation 30 s @ 94°C 30 s @ 94°C 60 s @ 94 °C 60 s @ 94 °C
annealing 30 s @ 55°C 30 s @ 55°C 60 s @ 56°C 60 s @ 50°C
extension 60 s @ 72°C 60 s @ 72°C 60 s @ 72°C 120 s @ 72°C
length PCR fragment (bp) 118 162 372 518
% GC 50 40.7 58.1 46.1
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Instrumentation
An uncoated fused sillica capillary, 480 mm effective length and 0.075 mm i.d. (SGE, Ringwood, 
Victoria, Australia) was mounted in a User Assembled Cartridge and placed in a BioFocus 3000 CE 
instrument (Bio-Rad, Hercules, CA, USA).
Figure 1: The modified BioFocus User Assembled Cartridge with the interrupted and diverted cooling 
flow  and the heating device with the additional heating flow.
For on-line melting the BioFocus User Assembled Cartridge was adapted (figure 1). The 
temperature range of the capillary cooling flow was extended from 15-40°C to 0-60°C by using an 
external thermostatic waterbath instead of the BioFocus 3000 capillary cooling. For local heating, this 
water-cooling flow was interrupted and diverted at 146 mm from the inlet side and at right angles to
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this interrupted flow, another water flow was applied, which can be heated to 95°C by another 
external waterbath. The length of the capillary heated is 4 mm.
CE analyses
Prior to all analyses the capillary was rinsed, using a pressure of 100 psi, with water (60 s), 1 M 
NaOH (50 s), 0.1 M HCl (20 s) and with 1xTBE (89 mM Tris-Borate, 0.2 mM EDTA, pH 8.3) (20 
s) and then filled with 1:1 diluted Non Gel Sieving Buffer (kindly provided by Bio-Rad) for 50 s. 
PCR samples were pressure (5 psi) injected without pre-treatment and separated at reversed polarity 
(cathode at the injection side) under constant current in a 1xTBE running buffer. UV absorption at 260 
nm was used for detection.
RESULTS AND DISCUSSION
Polymerase Chain Reaction
The amplification of the N-ras gene of Molt-4 DNA, the Ki-ras gene of SW480 DNA and normal 
DNA and the P53 gene of CEM DNA resulted in a PCR fragment of respectively 118 bp, 162 bp and 
372 bp (Table 2). The amplification of the ribosomal RNA of Mycoplasma infected CaCo2 lysate 
resulted in a fragment of 518 bp. Using these amplification reactions we had a broad range in length 
and GC content of the PCR fragments to test the on-line melting procedure.
On-line melting
We described the application of SSCP to CE using a 4% linear polyacrylamide gel in a coated 
capillary (Kuypers '93). Under these conditions the capillary coating decayed when heating part of the 
capillary to 95°C, resulting in a severe loss of resolution after repeated experiments. We therefore 
used a Non Gel Sieving Buffer (NGSB) in an uncoated capillary. The high temperature had no 
detectable negative effect on the resolution after repeated runs.
Figure 2 shows the electropherograms of the amplified Ki-ras gene of normal DNA without (a) and 
with on-line melting (b). With the heating device at 65°C, only the dsDNA fragment is present. With 
the heating device at 95°C, part of the dsDNA molecules are melted into ssDNA molecules. Because 
of the complementary sequence of the single strands of one DNA molecule, their folded conformation 
is different, which leads to different mobilities in the Sieving Buffer. This results in two different 
ssDNA peaks in the electropherogram. As is the case for external heating and cooling, the dsDNA 
peak is still present with on-line melting, due to incomplete denaturation. This dsDNA peak can be
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used as an internal standard because the mutant and normal dsDNA molecules have the same 
migration time. The shift of the dsDNA peak is a result of a temperature effect on the migration time 
caused by the difference of the temperature of local heating (65°C versus 95°C). Oligonucleotides, 
salt, enzyme and nucleotides used in the PCR migrate from 6 to 7.5 min (not shown in panels b).
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Figure 2: Electropherograms o f  the Ki-ras PCR  
product o f  normal DNA with (a) the heating flow  
a t 65°C and (b) the heating flow  a t 95°C. 
Conditions: pressu re injection o f  40 psi.s, 
constant running current o f  15 ¡lA and a 
temperature o f  the capillary o f  5°C.
Time (min)
Influence ofparameters on the y ie ld  o f  single stranded DNA
The UV absorbance of ssDNA molecules is different from the UV absorbance of dsDNA 
molecules. We defined the DNA melting efficiency as the ratio of the area under the curve (AUC) of 
the two ssDNA peaks and the AUC of the ssDNA plus the dsDNA peaks.
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Figure 3 shows the influence of the temperature of the heating device on the yield of ssDNA 
molecules of the Ki-ras PCR product of normal DNA. Melting of the dsDNA molecules is well 
established using a heating device at more than 85°C, which is in agreement with the calculated 
melting temperature of this PCR fragment, which is 80.5°C (Baldino '89). Since the calculated 
temperatures of the other PCR fragments are 78.9°C (N-ras), 83.3°C (Mycoplasma) and 86.1 °C 
(P53) we used a temperature of 95 °C for further analyses to be sure of melting all different dsDNA 
samples used.
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Figure 3: Influence o f  the temperature o f  the 
heating device and the injected amount o f  PCR  
product on the y ie ld  o f  single stranded molecules 
o f  the K i-ras PCR produ ct o f  norm al DNA. 
Conditions: constant running current o f  15 ¡jA  and 
a temperature o f  the capillary o f  5°C.
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The influence of the injected amount of PCR product on the yield of ssDNA molecules of the Ki­
ras PCR product of normal DNA is also shown in figure 3. Increasing the injected amount leads to a 
lower melting efficiency of dsDNA molecules probably as a result of an increased renaturation rate. 
The yield of ssDNA molecules of different PCR products with the same concentration and the same 
injected amount differs for each PCR fragment, because the length and the GC content of the PCR 
fragment influences the melting efficiency (Baldino '89). We used a pressure injection of 40 psi.s for 
further analyses since injecting low amounts of DNA caused detection problems.
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We used a 0.5x, 1x, 2x and 3xTBE running buffer to test the influence of the salt concentration of 
the running buffer on the melting efficiency. Increasing the salt concentration decreased the yield of 
single stranded molecules. This can be expected since increasing the salt concentration leads to a 
higher melting temperature and faster reannealing (Baldino '89). Decreasing the salt concentration 
even more resulted in longer migration times (data not shown). For further analyses we used a lxTBE 
running buffer.
Influence ofparameters on the resolution o f  the single stranded DNA peaks
We investigated the influence of the voltage during the run, the concentration of the Non Gel 
Sieving Buffer and the temperature of the capillary on the resolution of the ssDNA peaks to find 
universal electrophoretic conditions for SSCP analysis. In this study we defined the resolution as the 
ratio of the difference in migration times between the ssDNA peaks and the migration time of the 
dsDNA peak.
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Figure 4: Influence o f  the temperature o f  the 
capillary cooling flow  on the resolution o f  the 
single stranded peaks o f  different PCR products. 
Conditions: pressure injection o f  20 psi.s  and a 
constant current o f  15 /jA.
The running voltage had no significant influence on the resolution. For further analyses we used a 
constant current of 15 ^A. For the influence of the concentration of the NGSB we tested a 0.3x, 0.5x, 
0.6x, 0.75x and a 0.8x NGSB diluted with lxTBE. Decreasing the concentration to 0.5x had no 
influence on the resolution, but had a positive effect on the yield of ssDNA molecules. Lowering the 
NGSB concentration under 0.5x diminished mutation resolution. For further analyses we used a 1:1 
diluted NGSB (running voltage and NGSB data not shown).
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The temperature of the capillary plays an important role in the resolution of the ssDNA peaks 
(figure 4). The optimal temperature is different for different PCR products. Not the length but the 
sequence of the DNA product is the reason for this effect.
For the resolution of the single stranded molecules of the Ki-ras PCR product the optimal 
temperature of the capillary is 5°C. Figure 5 shows that using these conditions it is possible to 
separate the single stranded peaks of SW480 DNA (containing a homozygous point mutation) from 
normal DNA.
Figure 5: Electropherograms o f  (a) the Ki-ras 
PCR produ ct o f  norm al DNA and (b) a 1:1 
mixture o f  the PCR products o f  normal DNA and  
the homozygous celline SW480. Conditions: 
pressure injection o f  40 psi.s, constant current o f  
15 ¡jA  and a temperature o f  the capillary o f  5°C.
Time (min)
CONCLUSIONS
From the results we conclude that it is possible to melt dsDNA molecules into ssDNA molecules 
during analysis. The modification of the User Assembled Cartridge is simple and easy to accomplish. 
The use of a NGSB in an uncoated capillary, instead of a 4% linear PAA gel with a coated capillary, 
makes it possible to use a high temperature of the heating device, necessary to melt the dsDNA
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molecules, without a decay of the capillary. However, the resolution of the ssDNA molecules may be 
further improved by using other sieving polymers which can be used in uncoated capillaries. That 
remains a topic for further studies.
We investigated the influence of several parameters on the yield and the resolution of the ssDNA 
molecules. The outcome of the temperature of the heating device, the salt concentration of the running 
buffer, the voltage during the run and the concentration of the NGSB resulted in standard 
electrophoretic conditions for all PCR products. The optimal temperature of the capillary has to be 
determined separately for each individual PCR product. This is a disadvantage of the SSCP technique 
when used in an automated setting.
In this study we used on-line melting for the detection of point mutations using the SSCP method, 
but this melting during analysis can probably also be used for other applications like on-line 
hybridisation of a probe to a single stranded target DNA.
We feel that this on-line melting method contributes to a more automated and routine way of 
molecular diagnostics of human diseases.
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